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Abstract
The extracellular environment plays an important and crucial role in orchestrating
the behaviors of the cells in the central nervous system (CNS). In my thesis work, I
studied how the extracellular environment regulates a subset of glial cells,
Oligodendrocytes (OLs) and astrocytes. Moreover, I studied the relationship of the
astrocyte and the OL, particularly for astrocytes to promote a favorable environment for
OL maturation. The extracellular matric (ECM) is composed of a variety of factors,
including glycoproteins and secreted extracellular proteins.
In my thesis work, I focused on a subset of glycoproteins: Laminin (Ln),
Tenascin-C (TnC), Fibronectin (Fn), and Vitronectin (Vn) and their regulation of
astrocytes. As described in chapter 4 of my thesis, I concluded that the ECM
differentially regulates astrocytes and their functions through β1 integrin. Additionally, I
studied the effect of an extracellular factor, tissue inhibitor of metalloproteinase (TIMP)1 and its effect on both astrocytes and OLs. In chapter 5 of my thesis, I described how
TIMP-1 is important for astrocytic behavior and astrocytes’ ability to respond to injury
and inflammation.
Furthermore, I studied the effect of the extracellular environment on OL
maturation. First, as described in chapter 6 of my thesis, I studied the direct effect of
TIMP-1 on OL maturation and discovered a previously unreported mechanism of TIMP1 action on OL maturation. I also studied the effect of TIMP-1 on the astrocyte and how
it affected OL maturation, specifically through the factors that astrocytes secrete in the
absence of TIMP-1. As described in chapter 7 of my thesis, I found that TIMP-1
regulates the factors astrocytes secrete, specifically a Fn fragment that inhibits OL
maturation.
In general, my thesis studies focused on the effect of the extracellular
environment, particularly the ECM molecules, Ln, TnC, Fn, Vn, and the secreted factor,
TIMP-1 on the glial cells, astrocytes’ and OLs’ functions.
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Chapter 1. Multiple Sclerosis, Oligodendrocytes (OLs) and Remyelination
I.

Diagnosis and Clinical Forms of MS
Multiple Sclerosis (MS) is a chronic inflammatory demyelinating disease of the

central nervous system (CNS) characterized by lesions or plaques of demyelinated
axons that leads to significant disability. MS affects 2.5 million people worldwide, with
an age of onset between 20-50 years of age; it is the most common neurological
disability affecting young adults [7]. MS patients often present with heterogeneous
symptoms, including visual problems and muscle spams, and the vast majority of
patients will develop progressive decline in functions with difficulty speaking, swallowing,
movement, and cognitive failure. The course of any given MS patient is often unique
and unpredictable. Unfortunately, the cause of MS is unknown and there is currently no
cure.
In the majority of MS cases, autoreactive T cells drive the bouts of disease
worsening, called clinical relapses that are associated with new or evolving immunemediated pathology within the CNS [9]. Current immune-modulatory therapies, like
Interferon-β, manage the severity of relapses and their frequency, but they do not slow
the progression of the disease [10]. This suggests that even with treatment the disease
continues unabated with ongoing demyelination and only limited remyelination. Failure
to fully remyelinate white matter lesions is a cardinal feature of MS, which contributes to
interrupted axon conductance, can lead to axon degeneration, and neurodegeneration
that contributes to the progressive decline seen in most patients. Demyelination strongly
correlates with disease progression and clinical disability in MS patients [11, 12], thus
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early therapeutic strategies to promote remyelination would be expected to provide
long-term benefit for MS patients.
Although the clinical presentation of MS is often varied (Figure 1-1), the
pathological features remain consistent. The hallmark feature of MS is demyelinated
plaques. MS is also characterized by glial scarring [7, 13]. The emergence of these
plaques or lesions often have a propensity for certain areas of the CNS including: optic
nerves, periventricular white matter, brain stem, cerebellum, and spinal cord [13, 14].
There are also inflammatory cells present, such as macrophages/microglia and
lymphocytes, which surround lesions with some of these cells located within the lesion
site [13, 14]. Briefly, there are four main types of MS lesions: reactive, active
demyelinating, chronic active, and chronic inactive [15]. Reactive and active
demyelinating plaques are described by having dense infiltrates of macrophages that
contain myelin proteins, additionally these are the plaques found most predominately in
the early stages of disease [15]. Chronic active plaques tend to have an inactive core,
with little to no macrophage infiltration, but surrounded around the perimeter by active
macrophages [15]. Finally, chronic inactive plaques have little to no macrophage
infiltration in the entirety of the plaque [15].
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Figure 1-1: Clinical disease courses in different types of MS. Representative graphs of
clinical presentations of the different types of MS. Y axis depicting increasing disability; x axis
representing time. Top left panel showing disease course of RRMS. Top right panel showing
disease couse of SPMS. Bottom left panel showing disease course of PPMS. Bottom right
paenl showing disease course of PRMS. Figure from the National MS Society:
www.nationalmssociety.org/what-is-ms/types-of-ms
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The diagnosis of MS is based on several criteria: 1. Clinical 2. Imaging 3.
Diagnostic oligoclonal banding. Specifically, 1. neurologic dysfunction “disseminated in
space and time” meaning neurological disability for a period of time, 2. the presence of
gadolinium(Gd)-enhancing lesions on MRI that indicate inflammatory demyelination; Gd
is a large molecule that cannot normally pass through the blood brain barrier, therefore ,
GD positive MRIs show that there is active lesions and 3. positive oligoclonal banding
[14]. When there is still uncertainty, tests on the cerebrospinal fluid are used, to look for
increased intrathecal synthesis of immunoglobulins of restricted specificity with
moderate lymphocytic pleocytosis [14].
There are different clinical forms/courses of MS. The most common type is
relapse remitting MS (RRMS), which represents about 80% of all the MS cases. In
RRMS, symptoms present over a period of a few days then spontaneously resolve
within a few weeks that can reoccur ever few weeks, months, or even years [14]. RRMS
predominately affects young adults, with initial signs of disease in early 20s. RRMS is
more common in women with a rising ratio of 2:1. In recent studies this difference does
not reflect an underlying cause related to gender, but to decreases in the incidence of
MS in men, potentially through the decreasing levels of male smokers [16]. RRMS
generally presents with sensory disturbances including: optic neuritis, diplopia, trunk
and limb parethesia, limb weakness, clumsiness, gait ataxia, and bladder and bowel
symptoms [14]. Eventually there is cognitive impairment, depression, emotional lability,
dysarthria, dysphagia, vertigo, progressive quadriparesis, sensory loss, ataxic tremors,
pain, sexual dysfunction, spasticity, etc [14]. Approximately 70% of these cases will lead
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into secondary progressive MS (SPMS) [14]. However, although MS is life-altering
disease with severe disability, it does not generally shorten the life span of the patient.
Primary progressive MS (PPMS) is a less common, but more aggressive form of
MS. PPMS is described as gradual but progressively declining clinical course and there
is no difference in incidence between the genders. Additionally, PPMS patients
generally present with symptoms in their 40s. PPMS patients often present with upper
motor-neuron syndrome of legs and gradually worsen to quadriparesis, cognitive
decline, visual loss, brain-stem syndromes, cerebellar dysfunction, bowel and bladder
dysfunction, and sexual dysfunction [14]. Moreover, PPMS does not involve the immune
system, therefore, all current therapies remain useless, which will be discussed further
in this chapter.
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A.

B.

Figure 1-2: Plaques in the MS brain. Representative images of MS brains. A. Coronal
brain slice stained with luxol fast blue of an MS brain depicting lesioned sites. Green
arrows showing chronic MS lesions; red arrows showing shadow plaques or areas of
limited remyelination. Adapted from Franklin et al. [8] B. GD enhanced MRI of an MS
brain
depicting
lesion
sites
in
white.
Adapted
from
http://emedicine.medscape.com/article/1146199-overview
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II.

Role of Immune System in MS
In most forms of MS, the immune system drives the clinical relapses and is

thought to evoke most myelin injury. The MS immune response is driven by myelin
antigens from the CNS, specifically by T cells. It is widely accepted that among most
MS patients, there is an aberrant development of T cells that recognize “self-antigens”,
which lead to autoimmunity and destruction of the host tissues. For the purposes of this
thesis, we will broadly refer to the major classes of immune cell types (e.g. T-cell) and
not delve deeper into the nuances and specifics of these immune cell types. In the
immune system of an MS patient a variety of immune cell types are recognized to
contribute to immunopathology. For instance, patients with RRMS have been reported
to have an increased amount of myelin specific T cells, as compared to healthy patients
or even SPMS patients [13]. In addition, myelin-reactive T Cells from MS patients have
memory and an activated phenotype, where as in the healthy patient, they have a naïve
phenotype [13]. Activated T cells adhere to the luminal surface of endothelial cells and
migrate into the CNS after an insult to the blood brain barrier (BBB) [14, 17, 18].
Following the migration of these cells into the CNS, there is a significant immune
response after the T cells become reactive to self myelin and non myelin antigens,
including myelin basic protein (MBP), myelin- associated glycoprotein (MAG), myelin
oligodendrocyte glycoprotein (MOG), and proteolipid protein (PLP) [14, 19]. Antigens on
the myelin sheaths or oligodendrocytes can be recognized by these cells and cause
demyelination [14, 19]. The complexity of the immune-response and the subsets of T
cells, while important, exceed the scope of my thesis work. Other cells also can
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contribute to the damage of oligodendrocytes and myelin, including microglia and
macrophages. Activated microglia and macrophages can produce pro-inflammatory
cytokines and generate reactive oxygen species [14].
III.

Current “Disease Modifying” Therapies for MS
Initially corticosteroids were used as a treatment during MS; which was believed to

be caused by viruses, and thus resulted in the immune system targeting for MS
treatments. However, currently steroids now are only prescribed for acute relapses.
Steroids have been shown to work by limiting the amount of cytokines in the
bloodstream, suggesting a mechanism of action of steroids by inducing an antiinflammatory effect and resulting in less activation of the peripheral immune cells [20].
Current treatments for MS predominately focus on the immune system and abating
the autoreactive T cell response. Generally treatments for MS are immunomodulatory,
but are referred to as first disease-modifying therapies (DMT). The first DMT to be
approved by the Federal Food and Drug administration (FDA) for treatment of MS was
interferon (IFN)-β in 1993 and has been shown to reduce the frequency and duration of
relapses [21, 22]. IFNs are a group of proteins that play a role in regulating the body’s
immune response. IFN-β has a multifactorial influence on the immune systems leading
to an anti-inflammatory effect, including: decreased antigen presentation, upregulation
of interleukin 10 (IL-10), decreased expression of T helper-1 and -17, and reduce
infiltration of immune cells across the BBB [14, 23]. IFN-β in randomized clinical trials
was shown to decrease the amount and severity of relapses, as well as decreasing the
T2 lesion volume, which show all lesions on MRI as white, a criteria for MS diagnosis,
as compared to the placebo group [23].
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Another therapy currently used for treatment of RRMS is glatiramer acetate (GA).
GA is an active amino acid sequence that contains a large number of synthetic peptides
that may compete with myelin basic protein (MBP) for presentation on MHC class II
molecules, which leads to the inhibition of antigen-specific T cell activation [14, 23]. The
mechanism of action for GA remains elusive, however, it is believed to act on antigen
presenting cells (APC) incorporate the GA peptides and present them to lymphocytes
and thus inhibits the multiplication of lymphocytes that are capable of reacting to MBP
[23].
Natalizumab is a therapy that uses the interaction of integrins on the leukocyte to
prevent the migration into the brain [23]. Natalizumab contains immunoglobulin
monoclonal antibodies against α4 integrins and thus blocks α4 integrins, meaning the
leukocytes containing α4 chains cannot interact with blood brain barrier (BBB) and enter
into the brain [23]. It reduced the risk of sustained disability, the amount of clinical
relapses, and the enlarging of emergence of T2 lesions [23]. Although very effective, it
cannot be broadly used. Progressive multifocal leukoencephalopathy (PML) is an
opportunistic viral brain disease that is caused by reactivation of the JC virus [24].
Unfortunately, treatment with natalizumab has resulted in a group of JC-virus positive
MS patients to develop PML, which can result in fatality [24]. Because of the negative
consequences and the prevalence of the JC virus in the population, natalizumab
unfortunately cannot be widely used.
Fingolimod is the first oral therapy for treatment of MS. It is a sphingosine-1
phosphate (SIP) receptor modulator and binds to the S1P1 receptors on lymphocytes
thus leading to the internalization and its down regulation, preventing the release of
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lymphocytes from the lymphnodes [21, 23, 25]. However, fingolimod has also shown to
have a direct effect on neural cells, including the promotion of differentiation of OPCs
through S1P1 receptor activation [21, 25].
Currently there is no therapy for PPMS. The current therapies used by physicians
to treat MS are disease-modifying drugs, and treat primarily by reducing inflammation
and the amount and severity of relapses, and thus improving the quality of life of those
with RRMS; with PPMS relapses and inflammation are not a part of the disease and
therefore are not effective in treating PPMS [26]. Therefore, research into studying the
underlying cause of MS (failure to remyelinate), provides potential for therapeutics to
treat PPMS and potentially to treat the underlying cause is all MS, as well.
IV.

Oligodendrocytes (OLs), Myelin, and Remyelination

1. Demyelination and Remyelination
Demyelination is a process where by the myelination surrounding the axons in the
CNS are lost. Demyelination is a major pathological feature in MS, and destruction of
myelin in MS leads to the disability and neurological decline observed in these patients.
Demyelination in the CNS occurs as a consequence of a direct injury to the OL [7]; in
the context of MS this is due to inflammatory damage [7]. With the loss of myelin, the
axon loses both trophic support and the fidelity of the excitable signal.
Remyelination is the process of restoring myelin sheaths to unmyelinated areas of
axons and restoring saltatary conduction and functional deficits by newly matured OLs
[7, 27]; however, the newly formed myelin has shorter segments along the axon and is
thinner [7]. Limited remyelination is observed in MS. However, these areas of
remyelination or shadow plaques have limited efficiency and eventually, in part due to
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reoccurring inflammation, ultimately fail [28, 29]. This leads to chronically demyelinated
lesions [28, 29]. While OLs can participate in remyelination, most OPCs are found to
migrate to an area of injury to fix the damage, but they do not mature [27]. Potential
explanations for this failure of OPC differentiation include the pathological expression of
inhibitory signals, the lack of pro-differentiating signals, or an innate deficit in the ability
to efficiently differentiate. Additional studies have found that although OPCs are able to
migrate to areas of injury, there is also a depletion of these OPCs under chronic distress
[7]. Early life experiences, as stated in a recent paper, would suggest that depletion of
OPCs in juveniles has the effect of developing chronic demyelination when they mature
to adulthood. In this study, it was found that depletion of OPC cells during early
postnatal days (P5-7), after myelin injury, had limited remyelination in adults [30].
Therefore, understanding which cues inhibit the OPC maturation and defining how
trophic factors may be used to promote OPC differentiation in MS is an area of intense
study. Also, one factor related to the regulation of myelinating potential in MS is the role
of the extracellular environment, which will be addressed in later chapters.
2. Oligodendrocytes (OLs)
OLs are the myelinating glial cell of the CNS. One OL is able to myelinate up to
40 different axons [3]. An individual OL can extend many processes, which contact and
repeatedly circles a segment of an axon; this is known as an internode. Myelin is a
multilamellar membrane, which allows for rapid salutatory nerve conduction by acting as
an electrical insulator and physically organizes the clustering of sodium channels to the
unmyelinated regions between the internodes, called the Nodes of Ranvier [31, 32].
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OLs differentiate from migratory and mitotic precursor cells known as
oligodendrocyte progenitors cells (OPCs) [32, 33]. The mechanism(s) for OPC
differentiation into OLs is highly regulated spatially and temporally; specifically,
differentiation begins with OPCs from the subventricular zone (SVZ). OPCs are bipolar,
migratory, and proliferative, and present in the adult CNS, therefore, OPCs provide a
potential target for MS regenerative medicine to promote remyelination because not all
OPCs are terminally differentiated into OLs
OLs differentiation occurs in stages over time that can be identified by 1.
expression of specific proteins, 2. morphology, or 3. the loss of other surface
intracellular antigens [6, 32, 34] (Figure 1-3).

Specifically, Platelet-derived growth

factor alpha-receptor (PDGFR-α), NG2 proteoglycan and A2B5 are used to detect the
early stages of OL differentiation, specifically at the OPC stage [32, 34-36]. The antigen
O4 is used differentiate between early OPCs and late OPCs, OL lineage cells will
remain O4 positive even as mature, myelinating OLs. A variety of markers are used to
identify immature OLs and mature myelinating OLs. These include: galactosylceramides
(GALC) and 2’,3’-Cyclic nucleotide-3’-phophohydrolase (CNP). Where immature OLs
will express these markers, they will not express other myelin component antigens such
as MBP, proteolipid protein (PLP), myelin-associated glycoprotein (MAG) or
myelin/oligodendrocyte glycoprotein (MOG) [32, 37, 38]. OLs will become positive for
these markers once they are mature and competent to form compact myelin.
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Figure 1-3: Stages of OPC differentiation. Representative images of the stages of
Oligodendrocyte differentiation and stage-specific markers (60x Magnification). The top panels
depict the morphology of the four main stages of OPC differentiation: Early OPC, Late OPC,
Immature OL, and Mature OL. The bottom panel depicts the markers that each stage of OPC/OL
differentiation are positive or negative for. Adapted from [6].
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There are many factors that are known to promote and/or inhibit the migration
and differentiation of OPCs. These factors would ultimately affect myelination (Figure 14) [39-47]. CNS myelination is a tightly regulated process that has stage specific
requirements that are temporally regulated [39, 40, 43, 45, 46, 48]. For example,
tenascin-c, an extracellular matrix molecule (ECM), has been shown to inhibit the
migration of OPCs, specifically to retinal ganglion cell axons [49].
There are many growth factors that have been shown to be important for the
proliferation and/or differentiation of OPCs. Many of the factors that are important for the
proliferation of OPCs can also inhibit the differentiation of OPCs. Several of these
factors are described in the following section.
3. Oligodendrocyte Cell Biology
From work initially performed by Raff and Noble, it was found that there were
factors in calf serum that prevented the differentiation of OPCs into OLs [50, 51]. This
observation led to intense research into understanding the factors that both promote
and inhibit the differentiation of OPCs. Many research groups have identified a variety of
factors that influence OPC differentiation. Briefly, I will describe some of the main
factors studied with regards to OPC differentiation.
Bone morphogenic protein (BMP) has been shown to inhibit OPC differentiation
[52]. The mechanism of inhibition of differentiation is in part due to maintaining the
OPCs in the proliferative and immature phase but in part through promoting the
progenitor cells into different CNS cell type lineage [52].

14

PDGF is made by both astrocytes and neurons in the developing CNS and it is
necessary for the survival and proliferation of OPCs; it signals through PDGFR-alpha [3,
32, 53]. In addition, it keeps the OPCs in a proliferative and immature state.
Fibroblast Growth Factor (FGF)-2 is also a necessary mitogen for OPCs;
however, it is also inhibits the differentiation of OPCs into OLs [3, 32, 54]. FGF-2
promotes proliferation and specification of OPCs through the interaction with FGF
receptor 1 or2 and by activation and phosphorylation of extracellular signal-regulated
protein kinases (ERK) [3, 55].
Triiodothyronine/thyroid hormone 3 (T3) plays an important role in the
production of myelin and OPC differentiation into OLs and can actually override the
signaling from mitogens such as PDGF and FGF to remain in the proliferative state [3,
56, 57]. T3 has been demonstrated to be in important for myelination using hypothyroid
mice; hypothyroidism is a well-known cause of hypomyelination, meaning that the
presence of thyroid hormones is important for myelination [57].
Insulin- like growth factor (IGF)- I stimulates the proliferation of OPCs and
increase survival by activating the PI3K/Akt pathway through the IGF-1 receptor and
ultimately by preventing the phosphorylation and degradation of cyclin D1 and ultimately
preventing apoptosis [3, 32, 58]. It has also been shown to be important for myelin
formation and thickness; in IGF-I transgenics, there are significantly more myelinated
axons as well as increase thickness of myelin [3, 32]. In addition, IGF-1 may also target
OLs directly to promote remyelination, which has been shown using an animal model of
MS, where remyelination occurs concordant with upregulation of IGF-1 [58].
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Wnt/β-catenin is heavily researched signaling pathway with regards to OPC
differentiation and myelination due to conflicting reports about the necessity of Wnt/βcatenin. Initially it was observed that there are elevated levels of Wnt3a and Wnt7a
present in the MS lesions that sparked the initial interest in studying the Wnt/β-catenin
pathway and its influence on OPC differentiation [59]. Wnt/β-catenin signaling has been
shown to both inhibit and promote OL differentiation [60]. The canonical Wnt pathway
acts through the Frizzled receptor and leads to the nuclear localization of β-catenin.
Studies using Wnt3a have shown to inhibit the differentiation of OPCs [61]. A recent
study has found that Wnt/β-catenin signaling has differing roles depending on the stage
of OPC differentiation; activation of β-catenin in NPCs inhibits the generation of OPCs;
however, β-catenin activation is necessary for OL differentiation and myelination [62].
This phenomenon is further explored in Chapter 6 of my thesis. The canonical signaling
pathway of WNt/β-catenin is described in Figure 1-6.

16

Figure 1-4. Inhibitory and Stimulatory factors that affect OPCs differentiation into
OLs at various stages of OPC differentiation. The middle panel depicts cartoon
images of the different stages of OPC/OL differentiation: Progenitor/Early OPC, Prooligodendrocyte/Late OPC, OL/ Immature OL, Myelinating OL/ Mature OL. The top
panels details factors that inhibit OPC differentiation at the various stages of
differentiation. The bottom panel details factors that promote OPC differentiation at the
various stages of differentiation. Adapted from [3, 4]
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Figure 1-5. Pathway of canonical Wnt/β-catenin signaling (A.) Without Wnt ligand,
the β-catenin pathway is inactive state. Without Wnt ligand, β-catenin interacts with the
destruction complex, which consistens of the proteins Axin/APC/GSK3β. β-catenin
interacts with the destruction complex and is phosphorylated and binds to β-Trcp,
where it is targeted for degradation. This results in a downregulation of β-catenin
mediated gene transcription. (B.) In the presence of Wnt ligand, β-catenin signaling is
active. There is an upreglation of β-catenin mediated gene transcription, for example Cmyc. Wnt binds to its Frizzled receptor and LRP5/6 co-receptor thus activating Dvl. Dvl
then interacts and inhibits the degradation complex thus leading to free β-catenin. βcatenin is then able to translocate into the cell nucleus and stabilize with the
transcriptional complex, Lef//Tcf promoting gene transcription. Additionally, ? signify
areas where additional signals may influence β-catenin signaling. We hypothesize that
TIMP-1 is one of the other signals that mediate β-catenin. Adapted from [5].
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4. Myelin
Myelin is a multilamellar extension of the plasma membrane of OLs. Compact
myelination of axons allows for electrical insulation that promotes rapid salutatory nerve
conduction and provides fidelity of neural signaling [32, 63, 64]. OLs are also though to
provide trophic support to the axons [32, 63, 64]. Myelin is able to ensure these
functions, at least in part, due to its structure, thickness, low water content, and lipid
richness [3, 32 ]. Myelin sheath segments, or internodes, are typically 15-200um long
and separated by myelin free spaces called nodes of Ranvier [31, 32]. It is within the
nodes that sodium channels are clustered, which allow for salutatory conduction [31, 32].
The structure of myelin is composed of 40% water; the dry weight is 70% lipids and
30% protein [32, 65].
Myelin is composed primarily of distinct lipids and proteins. Myelin contains
cholesterol, phospholipids, and glycolipids at a ratio range from 4:3:2 to 4:4:2 [32, 65].
GalC is a major component of myelin and comprises 20% of the dry weight of myelin
[32, 65]. The major proteins in myelin within the CNS are PLP[66-69], MBP[67-69],
MAG[69, 70], MOG[69, 70], and CNP[68, 71]; these genes are temporally regulated to
develop myelin.
Myelination occurs from the caudal region to the rostral region in the brain and
from the rostral region to the caudal region in the spinal cord [3, 32, 72]. The timing of
myelination depends on species: in the mouse, myelination starts at birth in the spinal
cord, and is complete around p45-60, whereas, in humans, myelination begins during
the second trimester, peaks in during the first year of life, and continues until 20 years of
age [32, 73]. Recent studies have found that myelin formation is actually a lifelong
process in the CNS and is necessary for mastering new complex motor skills [74].
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McKenzie et al. found that in the healthy adult brain, myelinating OLs were continually
being formed [74]. An inability of mice to acquire new complex motor skills occurred
when myelination was blocked, suggesting an important role for myelination in the adult
CNS [74].
It is recognized that the process of myelination is very complex. Our understanding
on the specific mechanisms and signals that control myelin formation and maintenance
in health and disease is constantly emerging. Early notions suggested that axon surface
ligands, secreted molecules, and axonal activity are critical for compact myelin [60].
However, recent studies have redefined the requirement for this as OLs can myelinate
inert carbon fibers [75]. Additionally, experiments in culture have shown that OLs will
myelinate inherently without signaling from the axons, suggesting additional
mechanisms to promote myelination [60, 75]. The process of myelination requires the
formation of the membrane with the specific composition described above that allows
for the compaction and formation of the dense lamellar sheaths. The three main steps
that are required for myelination include: the migration of OLs to axons, not dendrites,
that need to be myelinated; the adhesion of the plasma membrane processes of the
OLs to the axons; the actual engulfment and wrapping of the axons to a fixed space and
number of wraps.
The reason why some axons are myelinated but not others are myelinated is not
fully understood. In general an axon must have a diameter of at least 1μm to be
myelinated [76]. Axonal signaling can influence OLs to promote myelination. Ligand
dependent axonal regulation of myelination mechanisms discovered have largely been
inhibitory including: Jagged, which inhibits Notch pathway [77]; PSA-NCAM[78]; LINGO-

20

1[79]; all of which inhibit OPC differentiation and myelination [3, 60]. In addition,
integrins have been shown to play an important role with regards to the initiation of
myelination. Specifically, pre-myelinated axons produce laminin-α 2 which interacts with
β1 integrin receptors on the immature OLs to promote the initial interaction of its
cytoplasm to the axon [3, 80]. This receptor-ligand meeting activates integrin-linked
kinase to initiate myelination (ILK) [3, 80].
There is also evidence that neuronal activity plays an important role with regards
to myelination. Specifically, using myelinating cultures and blocking action potentials
using tetrodotoxin, Na+ channel blocker, prevented the initiation of myelination [81].
Additionally, using α-scorpion toxin, which induces electrical activity, there was
increased myelination [81]. This data suggests a role of electrical activity in regulation
myelination.
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Figure 1-6: Compact Myelin. Representative electron microscopy (EM) images of
the corpus collosum of control mice (A) and mice treated with cuprizone (B). Dark
circles in A show proper myelination and the loss of myelin when fed cuprizone as
depicted in B with minimal black circles or myelin sheets. Scale bar=2um. Images
courtesy of Alex Nicaise.
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V. Animal models of CNS Demyelination
Animal models have provided tremendous benefits to an understanding of myelin
and treatment of demyelinating diseases like MS. Currently, there are a number of
widely used animal models, but three main animal models of CNS demyelination are
used to study distinct and different aspects of myelin biology and autoimmune-induced
demyelination: experimental autoimmune encephalomyelitis (EAE), Lysolecithin, and
dietary cuprizone intoxication.
1. EAE
EAE was first identified in the 1930s when researchers were trying to understand
the phenomenon of paralysis that occurred with vaccinations in children [82]. EAE is the
most commonly used animal model to study MS and has great value as a model of the
inflammatory components involved on MS. EAE is characterized by inflammation and
demyelination that is induced by injection of myelin peptides such as: MOG peptide,
residues 35-55;PLP; MBP, residues 1-37, emulsified with completes Freud’s adjuvant
as well as an injection of pertussis toxin, to allow for a permeable BBB and the
sensitization of the immune system to the self-antigens [83-86]. EAE in C57B6 mice
using MOG peptide, is a well-characterized and highly reproducible model; however, it
is monophasic, meaning there are no relapses in addition the immune component is
predominately an autoreactive T cell response that results in demyelination within the
CNS, mostly in the spinal cord [84, 85]. However, areas of demyelination in this model
are random, allowing for complications in studying this model. EAE in SJL mice develop
a relapsing and remitting form of EAE using MBP peptide or spinal cord emulsifant,
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where there are periods of acute recovery [87-89]. Additionally, EAE mimics MS by
primarily affecting the white matter, however, it is not a perfect model and lacks some of
the complexity seen in MS, such as disease progression, difficulty in studying
remyelination due to the spontaneity of lesion formation, and the regional specificity to
the spinal cord, where as MS effects the brain as well [85]. EAE has proven useful for
treating MS. It has resulted in three of the six currently approved MS therapeutics after
showing promising results in this model including: glatiramer acetate, mitoxantrone, and
natalizumab [90].
2. Toxin-Induced Demyelination
Microinjection of lysophospatidylcholine (lysolecithin) into the white matter of mice
induces demyelination, and is a good model to study remyelination [85]. This model is
very useful in studying the molecular and cellular components with regards to
remyelination. This model has a focal lesion and therefore is a useful model to study
remyelination, unlike EAE where the lesion formation is random. Unfortunately, there is
no immune component in this model of demyelination and, therefore, is a major
weakness of the model.
Cuprizone is another toxic model of demyelination used to study the
remyelination events. Cuprizone is a copper chelator, administered orally to rodents that
reproducibly evoke robust and predictable CNS demyelination, most noticeable in the
corpus callosum where there is spontaneous remyelination events [91]. The site of
injury is both reliable and consistent and provides a useful tool in studying the
remyelination events. It is also easily administered due to the oral consumption of
cuprizone through chow by the mice. Additionally, it also causes global demyelination,
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making it an easy model to study demyelination and thus remyelination. However, the
exact mechanism of demyelination is not fully understood, but results in apoptosis of
OLs [85]. Similar to lysolecithin model of demyelination, a weakness of this model is the
lack of an immune component of demyelination.
VI.

Emerging Remyelinating Therapies for MS
Current mainstream therapies have been shown to improve the quality of life for
most patients, but unfortunately most do not promote remyelination in the MS brain.
Considerable research is now focused on the discovery of such agents that may target
OLs to promote remyelination. It is known that OPCs are present in the MS lesion [27],
so targeting these stem cells to differentiate into myelinating OLs provides an interesting
therapeutic intervention. One recently identified example is in phase 3 trials: an antibody
targeting Lingo [92]. This antibody blocks the effect of LINGO-1, a protein that prevents
OLs to myelinate. Leucine-rich repeat and immunoglobulin-like domain-containing
protein (LINGO)-1 is a transmembrane protein that has been shown to inhibit OPC
differentiation through decreasing activity of Fyn kinase and ultimately increasing RhoA
signaling, a pathway involved in OPC differentiation [3, 79]. In addition, treatment of
anti-LINGO in the lysolecithin model of demyelination and cuprizone model of
demyelination induces robust remyelination, suggesting an important role of LINGO-1 in
inhibition of OPC differentiation and a potential therapeutic measure in treating MS [93].
Recently a new high throughput-screening platform has been developed using
micropillar arrays [75]. Using this array, compounds to promote remyelnation can be
screened in order to determine if they promote myelination by determining the formation
of myelin rings around the micropillars [75]. Interestingly, with the use of this new
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technology, a cluster of antimuscarnic compounds were found to promote OL
differentiation among which, benztropine and clemastine were found to cross the BBB in
animal studies [75]. Clemastine was found to also promote remyelination in vivo using a
demyelinating animal model, lysolecithin injection [75]. Interestingly, this study has lead
to advances in potential remyelination therapies for MS patients. Around the same time,
another group found similar results of anti-muscarinic components, specifically
benzatropine, promoting OPC differentiation in vitro, as well as promoting remyelination
in the EAE model [94].
Another recent study by Najm et al. identified additional compounds that promoted
OL differentiation in vitro, organotypic slice cultures, and in vivo in early postnatal
mouse pups: miconazole and clobetasol [95]. These new potential therapeutics were
identified using a stem-cell based screening platform, where OPCs derived from ES cell
lines from mouse pups were tested for enhanced OPC differentiation and myelin
formation in vitro. This study also confirmed the potential of these agents to promote
remyelination in vivo using the lysolecithin model of demyelination in adult mice, where
they found that the drugs were also able to promote remyelination in the slice culture as
compared to controls [95]. These recent studies are both promising and exciting for the
merging field of remyelinating therapies for treating MS.
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Chapter 2. Astrocytes and CNS Myelination
Historically, astrocytes had been defined as the “glue” that holds together the
CNS, however, emerging active roles of astrocytes have been discovered recently. For
the purpose of my thesis, I will be focusing on the emerging role of astrocytes promoting
myelination, however, briefly I will describe additional functions of astrocytes in the CNS.
Astrocytes are a prominent type of glial cell, and the most abundant cell type in
the CNS. Astrocytes can be identified by star-like morphology and expression of a
range of markers including: S100B [96], vimentin [97], and glial fibrillary acidic protein
(GFAP) [98, 99]. They are organized in distinct, non-overlapping domains, without
interdigitation and exhibit cell contact inhibition of proliferation [100].
Astrocytes are heterogeneous. This is not unexpected given the range of diverse
functions attributed to these cells. Grossly, astrocytes can be divided into two main
types of astrocytes that are defined by the areas of the CNS in which they are located:
Protoplasmic or, grey matter astrocytes; Fibrous or, white matter astrocytes [50]. It has
been speculated that each type has developmentally distinct origins, which will be
discussed further in the following section [50, 101]. The origins and nature of astrocyte
heterogeneity is an area of growing interesting, with limited consensus.
In the following sections I will outline the basic questions pertaining to a
fundamental understanding of astrocytes in the CNS. In particular, I will relate how the
basic understanding of astrocyte biology is expected to further the understanding in a
variety of CNS diseases. Specifically, how astrocyte dysfunction may be an underlying
etiology during injury and inflammation.
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I. Origins and Functions of Astrocytes
Developmental biology of Astrocytes
a.

During development (as depicted in Figure 2-1)
In this chapter, I will discuss astrocyte differentiation in the brain and the spinal

cord during development and adulthood astrocyte differentiation. It is important to
understand the developmental origins of astrocytes because it is believed that injury
induced

proliferation

and

differentiation

of

astrocytes

reactivates

important

developmental mechanisms.
In the developing mammalian CNS, neural progenitor cells (NPCs) generate
neurons and glial cells, originating from the embryonic germ layer, the neuroectoderm
[102]. Astrocytes are thought to progress in a step-wise fashion through four stages: (1)
a radial glial progenitor, (2) a proliferating intermediate progenitor, (3) a maturing
postnatal astrocyte, (4) an adult astrocyte [101, 103, 104]. The mechanism(s) in
regulating this switch from neuronal fate towards glial cells is not fully understood [100,
104]. Additionally, studies have also found another type of multipotent cell, NG2 cells,
that can give rise to astrocytes during development [105, 106].
There is no current consensus on the morphologically or genetically distinct
stages of astrocyte differentiation. Radial glia can actively divide and are believed to be
a common progenitor to neurons and astrocytes in different regions within the CNS
[104]. Radial glia can divide both symmetrically, producing two identical daughter cells
(radial glial or NPCs), or asymmetrically, producing two different daughter cells (NPC
and a radial glial cell) [104]. At varying times, radial glia will migrate to different regions
28

within the CNS and differentiate. Radial glia can give rise to both grey matter and white
matter astrocytes in development in the brain and in the spinal cord.
Promotion of astrocytic fate is due in part to promotion of JAK-STAT signaling
and activation of Notch signaling [100, 104]. In addition, the diversity of astrocytes is
due, in part by location and cues form neurons and not believed to have a homogenous
stepwise differentiation; however, this is a somewhat controversial topic that has been
debated among many groups [100, 101, 104].
The current views with regard to terminal differentiation of astrocytes involve
patterning, specification, migration, and local cell-cell contact [101]. Neural tube
patterning is a process that generates large diversity within cell populations, wherein,
cell-extrinsic patterning signals, when secreted factors such as sonic hedge hog (SHH)
and Wnts, are converted to cell-intrinsic differences in transcription factor expression,
creating distinct domains of transcription factor expression [101, 107, 108]. However,
cell patterning, as of yet, has not been observed in cortical astrocytes, only in the spinal
cord astrocytes.
A variety of transcription factors have been implicated in regulating astrocyte
generation. Specifically, nuclear receptor corepressor for multiple transcription factors
(N-CoR) has been shown to repress the generation of astrocytes by forming a complex
with neuregulin receptor Erb4 and binding and repressing astrocytic genes [101, 109].
Another example of a transcription factor regulation astrocytic specification is
neurogenin (ngn1-3), which have been shown to block astrocyte specification [101, 110].
There are also a variety of transcription factors that promote the generation of
astrocytes. NFIA is a member of a family of transcription factors that bind to CAATT
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boxes and control gliogensis in the embryonic spinal cord; NFIA also promotes
differentiation of astrocytes [101, 111]. Sox9 is expressed in NSCs in the spinal cord
and has been shown to be important for the generation of grey matter astrocytes [101,
112].
1. Grey Matter Astrocytes
Both grey matter and white matter astrocytes can be found in the brain and
differentiate from a common glial progenitor cell. Glial progenitor cells can differentiate
into two types of immature cells, what is commonly known as OPCs and also a form of
an immature protoplasmic astrocyte (grey matter astrocyte). OPCs are commonly
shown to differentiate into OLs; however, it is now believed that they can also give rise
to Fibrous or white matter astrocytes [51]. In a study by Raff et al., they found that when
they cultured this glial progenitor cell, later termed OPC, that not only could it give rise
to OLs, but also to fibrous astrocytes, depending on the media it was cultured in,
suggesting that extrinsic signaling to these OPCs determined the fate in which they
differentiate [51]. However, protoplasmic astrocytes could not be generated from this
cell population, suggesting a bifurcation, or additional lineage step from glial progenitor
cells into proteoplasmic astrocytes (Figure 2-1). To complicate the matter, Nishiyama’s
group found another type of multi-potent cell, NG2 cell, which was originally thought to
give rise only to OLs, however, using transgenic line of mice that expressed DsRed in
NG2-expressing cells, found that a portion of the NG2 cells differentiate into
protoplasmic astrocytes in the forebrain but not to white matter astrocytes, however,
NG2 cells can only differentiate into astrocytes during development [105, 106]. These
conflicting studies further show the importance into the study of astrogliogensis and the
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heterogeneity of this cell type.
2.

White Matter Astrocytes
During development, astrocytes in the spinal cord develop and differentiate
similarly to astrocytes in the cortex. Astrocytes originate from radial glia in the spinal
cord, [113]. Again, this data suggests a common progenitor to OLs and fibrous
astrocytes, potentially OPCs, as depicted in Figure 2-1. Essentially, during
development, the generation of spinal cord astrocytes is similar to that of cortical white
matter astrocytes, derived from radial glial cells. Neural tube patterning has been shown
to be important for astrocytic specification in the spinal cord, specifically that a basic
helix-loop-helix (bHLH) code is required for astrocytic development [108]. Three types of
ventral white matter astrocytes (VA1, VA2, VA3) have been shown to arise due to
combinational patterning of Pax6 and Nkx6.1[107]. However, it has not been
determined whether this patterning is critical for astrocytic specification in all regions of
the CNS, especially with grey matter astrocytes.

31

Radial&Glia&
OPCs&

Fibrous&Astrocytes&

Glial&
commi/ed&
Progenitor&cell&

Protoplasmic&Astrocytes&

Immature&&
protoplasmic&astrocyte&

Figure 2-1: Astrocytic differentiation during development. Adapted from [50, 51, 105, 113].
Briefly, glial progenitor cells originate from radial glial cells that divide into asymmetric daughter
cells. Glial progenitor cells can differentiate into two distinct progenitor cell populations, OPCs or
immature protoplasmic astrocytes. OPCs are able to differentiate into fibrous astrocytes and
immature protoplasmic astrocytes can differentiate into protoplasmic astrocytes.
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b. Astrocytes in the mature, adult CNS
Development of new astrocytes is not a limited process throughout a lifespan,
since astrocytes can continue to develop during adulthood. Astrocytes can arise from
resident stem cell populations within the adult CNS. Although there are man similarities
to the developmental process of astrocyte generation, astrocyte differentiation in the
adult CNS is a less understood potential mechanism of astrocyte proliferation and
resident astrocytes in the adult brain and spinal cord. I will describe the steps of
differentiation of astrocytes in adulthood.
Postnatally, astrocytes can arise from neural stem cell populations in the
subventricular zone (SVZ) [103, 104, 114, 115]. In response to injury, astrocytes can
arise from the NSCs in the SVZ [115]. Additionally, injury stimulates an expansion of
postnatal astrocytes that is not fully understood, but believed to be due to proliferation of
the astrocytes and not from migration of progenitor cells from the SVZ [103]. This data
suggests that astrocytes are also able to generate locally. These studies show multiple
mechanisms to allow for adult generation of astrocytes in the CNS.
Astrocytes additionally arise from adult stem cell population in the spinal cord and
the entire ventricular neuroaxis contains multi-potent stem cell population that can
differentiate into astrocytes, among other CNS cell types [116]. Dissociated spinal cord
cultures were used and were shown to be able to differentiate into astrocytes,
additionally discovering an adult stem cell population within the spinal cord [116].
Additionally, it was found that both protoplasmic and fibrous astrocytes can arise in the
adult spinal cord, from distinct intermediate cell types, suggesting a mechanism similar
to that seen during development [117].
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Figure 2-2: Astrocyte differentiation in the adult CNS. Adapted from [50, 51, 114, 116, 117].
Briefly, in the adult CNS, glial progenitor cells originate from an adult population of neural stem
cells. Glial progenitor cells can differentiate into two distinct progenitor cell populations, OPCs or
immature protoplasmic astrocytes. OPCs are able to differentiate into fibrous astrocytes and
immature protoplasmic astrocytes can differentiate into protoplasmic astrocytes.
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Astrocyte functions and CNS Myelin
Astrocytes fulfill essential functions that promote proper CNS development and
maintain CNS homeostasis. Key functions of astrocytes include: ion and water
homeostasis, energy metabolism, blood flow regulation, release of trophic factors, and
synaptic signaling [118]. Astrocytes are known to have 3 main functions in maintaining a
healthy CNS: 1. Synapase regulation 2. BBB maintanence 3. Trophic support for
myelination. In the following sections, as the focus of my thesis studies, I will
concentrate on how astrocyte regulation allows for he trophic support of myelination.
a. Astrocytes and Myelination
The temporal relationship between the development of astrocytes and
oligodendrocytes point to an import role for astrocytes in myelination [101]. Recent work
has determined the role of astrocytes in promoting myelination carries into adulthood,
and astrocytes may be critical determinants of remyelinating potential in the adult CNS
[119]. Work from our lab has shown that astrocytes promote remyelination in the EAE
model [46]. In this study, it was determined that the protein tissue inhibitor of
metalloproteinase (TIMP)-1 is important for remyelination [46]. TIMP-1 is predominately
produced by astrocytes in the CNS, and thus, these data suggest that TIMP-1 is
involved in the astrocytic functions necessary for timely and correct myelination
following injury [46]. In addition, TIMP-1 was shown to be important for developmental
myelination, which supports the earlier stated notion that through studying
developmental processes, we may better understand how to restore myelin in diseases
like MS [46]. Astrocytes secrete a variety of trophic factors that promote myelination and
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control OL proliferation. Examples of these factors include: PDGF [32], FGF-2 [54], LIF
[120], CNTF [121], IGF-1 [58], and BMP [3, 52, 122]. OPC cultures grown in TIMP-1KO
astrocyte conditioned media did not support OL differentiation, suggesting an important
role of TIMP-1 as an astrocytic secreted factors in promoting myelination [46].
One emerging important aspect of astrocyte biology is the plastic nature of
astrocytes and determining what controls how astrocytes function. Nash et al found that
active astrocytes are able to promote myelination, where as quiescent astrocytes do not
support it, suggesting a fundamental role of astrocytes in supporting myelination, in part
through secretion of inhibitory and trophic factors onto OLs [123]. They found that the
activity of astrocytes directly depended on the extracellular matrix (ECM) [123].
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Figure 2-3: Astrocytic functions in the healthy CNS. Astrocytes are known to promote a
healthy CNS environment through a variety of ways including secretion of trophic factors as well
as direct cell contact. This diagram depicts some of the major functions of the astrocytes and
how the astrocytes promote these functions in the healthy CNS.

Synapse forma0on and matura0on
Myelina0on
Neuronal survival

Secreted factors

Cell contact

BBB maintenance
Synapse forma0on

37

II. Reactive Astrogliosis
Under normal, healthy, basal conditions, astrocytes are though to be
homeostatically active, but after injury or inflammation astrocytes undergo major
phenotypic changes, known as “reactive gliosis” [123]. The mechanisms that control
astrogliosis are not fully understood, but it is known to be a major hallmark feature
accompanying a variety of CNS traumas. Specifically, a staple of reactive astrocytes is
the upregulation of intermediate filament proteins, in particular GFAP, as well as
vimentin and reexpression of nestin, a marker for early development [124]. Indeed, a
prominent feature of many neurological diseases and focal injuries is “reactive
astrogliosis”. Reactive astrogliosis is characterized by a significant change in astrocytic
phenotype, specifically, changes in their morphology (i.e. hypotrophy) and chronic
changes gene expression [124, 125]. Reactive astrogliosis is a CNS response to an
injury or disease that is thought to be a means of “sealing off” the injured tissue and
restricting inflammation. However, glial scarring can also lead to enhanced neuronal
death, inhibit axonal regeneration and prevent remyelination [126]. The latter effect of
astrogliosis is thought to be mediated by the production of several classes of growthinhibitory molecules including CSPGs [126].
It is now accepted that astrocytes can undergo a spectrum of activation states or
phenotypes ranging from “quiescent” to active or reactive [123]. This spectrum of
astrocyte phenotypes is an area of intense research. It has been shown that areas
farther from the injured site in the CNS, the astrocytes are activated and not reactive.
Factors known to induce activated phenotype include: transforming growth factor (TGF)alpha [127], ciliary neurotrophic factor (CNTF) [128], interleukin (IL)-6 [129], LIF [130],
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and oncostatin [130, 131]. Active astrocytes become hypertrophic and secrete a variety
of enzymes, growth factors, trophic factors, and antioxidants [123]. Active astrocytes
have been shown to support recovery after injury, like promoting remyelination, unlike
the reactive astrocytes, which inhibit remyelination and axonal regrowth [123].
A long-term effect of reactive gliosis is the formation of what is called a glial scar.
Glial scars are most often found around lesions focally, injured site, or foci of infections
[124]. The glial scar is comprised primarily of astrocytes, but may also contain microglia,
OPCs, and immune cells [124]. It is thought that the purpose of the glial scar is to
restrict spread of inflammatory cells and limit damage emanating from a focused area,
thus protecting the CNS from further immune-mediated injury, as well as encapsulating
infections and areas of tissue necrosis [123]. However, glial scars may also be
detrimental to CNS recovery and regeneration. For instance, it is well recognized that
the environment of the glial scar prevents axonal regeneration following spinal cord
injury, and reactive astrocytes circumscribe chronic myelin lesions in MS [123, 124].
Unfortunately, the mechanisms of glial scar formation are not fully understood.
Recent work provided mechanistic insight to better understand how the of glial scar
formation is controlled [132]. In this study the response to CNS injury was reported to be
associated with increased Wnts [132]. Since Wnts regulate β-catenin, Rodriguez et. al
used a β-catenin conditional knock out to eliminate β-catenin from OPCs, and they
reported reduced glial scaring in response to a spinal cord injury in the mice [132]. This
work supports the idea that a glial scar engages many CNS cells types that interacting
within the injured site to regulate the formation of the scar [132]. Interestingly, OPCs are
known to be the first cells to infiltrate areas of damage and thought to mold the
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astrocyte responses [133], therefore, these studies provide further evidence of OPCs
orchestrating CNS cellular responses in the context of the glial scar.
Reactive astrocytes undergo profound phenotypic changes associated that are
associated with changes in gene expression [123, 125]. Using laser capture
microdissection in mouse brain, has found that TIMP-1 is one of the most upregulated
genes during reactive astrogliosis; however, the significance of this increased
expression is not fully understood (Figure 2-4) [125]. The function of TIMP-1 in the
context of astrocytic function is covered in a later section of this chapter.
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Figure 2-4. Spectrum of Astrocytic phenotypes. Astrocytes undergo a spectrum of
phenotypes ranging from quiescent to reactive. In addition, phenotypic different astrocytes
secrete different factors. Recent work has tried to determine differences in secreted factors
between quiescent and reactive astrocytes, specifically quiescent astrocytes have been shown
to secrete CXCL10 and reactive astrocytes have been shown to secrete a variety of factors,
including TIMP-1. Adapted from [123, 125].
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Astrocyte functions in neurodegenerative diseases
Not only are astrocytes reactive to acute injury, but dysfunction of astrocytes is
now recognized as an underlying cause of a variety of CNS disorders. It is thought that
a better understanding of the how astrocytes develop and function may lead to a better
understanding of their role(s) in these neurodegenerative conditions. In the following
sections I will focus on the relationship between astrocytic dysfunction in a variety of
CNS disorders.
Amyloid lateral sclerosis (ALS) is an adult motor neuron disease characterized by
death of upper and lower motor neurons and gliosis. A mutation in the gene that
encodes superoxide dismutase 1 (SOD1), an enzyme that converts superoxide into
oxygen and hydrogen peroxide, is a known cause of ALS in twenty percent of inherited
cases by causing toxicity in the neural cells [134]. SOD1 mutated astrocytes when cocultured with motor neurons have been shown to induce apoptosis of the motor neurons
[134, 135]. With this mutation, astrocytic functions are impaired, specifically secretion of
toxic molecules to motor neurons [134, 135]. This suggests that astrocytes play a
fundamental role in the degeneration of motor neurons in ALS.
Alexander’s disease is a disease caused by a mutation in GFAP; it is clinically
described by macrocephaly, abnormal white matter, and developmental delay [101].
The exact mechanism that leads to the dysfunction of astrocytes in unclear, but is due
in part through aggregation of GFAP in the cytoplasm of the astrocytes, which leads to
white matter injury, suggesting a potential pathological role on oligodendrocytes and

42

their ability to myelinate [101].
MS is an autoimmune disease of the CNS that is characterized by focal areas of
demyelination. The contribution of astrocytes to demyelination is not fully understood,
but they are thought to determine whether the MS lesion/plaques are able to
remyelinate [99]. Astrocytes secrete a variety of factors that may either promote
myelination; such as, ciliary neurotrophic factor (CNTF) [136, 137], TIMP-1 [46], BDNF
[138], and leukemia inhibitory factor (LIF) [99, 122] or they may produce factors that can
block OPC differentiation such as CXCL10 [123], platelet derived growth factor (PDGF)
[139], fibroblast growth factor (FGF)-2 [139], LINGO-1 [140], and fibronectin [119].
Dysfunction of the astrocytes leads to differential protein secretion and thus determining
what factors control astrocyte activation would be expected to help resolve how
astrocytes contribute to limited remyelination in MS. It has been recognized that reactive
astrocytes surround the plaque in the MS brain, and astrocytes can exert control on
OPCS and remyelination. Together these findings suggest an important role of
astrocytes in the pathology of MS [99].
Additionally, astrocytes have recently been shown to play a fundamental role in
ischemic stroke pathology. The infarct of strokes has shown to not only have severe
neuronal death but also reactive gliosis; it is now appreciated that the astrocytes have a
primary role in stroke pathology. First, astrocytes are known to support neuronal
survival; in response to ischemic stroke, astrocytes can take up oxygen free radicals, a
major cause of ischemic brain injury [141], and protect neurons from further injury [142]..
Additionally, reactive astrocytes, particularly after stroke release a variety of cytokines
tumor necrosis factors (TNFs), interleukins (IL1,6,10), and interferons; these cytokines
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can be both harmful and supportive in response to ischemic stroke [143]. In addition,
astrocytes form glial scaring surrounding the infarct that again can be harmful and
detrimental for recovery, suggesting an important area of research in understanding
glial scar formation with regards to stroke [144]. Barres group further explored the
reactive astrocyte in a mouse model of stroke, by occluding the middle cerebral artery
(MCAO), and using micro laser capture dissection, and determined the most
upregulated genes in reactive astrocytes using this stroke model as robust model of
inducing astrogliosis [125]. From their results, TIMP-1 was one of the most upregulated
genes in response to stroke injury in reactive astrocytes [125]. In chapters 5,6, and 7 of
this thesis, I will delve further in the subsequent sections into the role of TIMP-1 in
reactive astrocytes and in particular how TIMP-1 controls astrogliosis and OPC
maturation.
III. TIMP-1 and the CNS
TIMP-1 is a member of the tissue inhibitors of metalloproteinase (TIMPS), a
family of four secreted proteins (named TIMP-1 to -4) that range in size from 21-29kDa.
TIMPs, as their name implies, inhibit matrix metalloproteinases (MMPs), a family of
extracellular proteases. TIMPs bind MMPs through a non-covalent bond between the Nterminal domain of the TIMP and the catalytic domain of the MMP in a 1:1
stoichoiometry, as depicted in Figure 2-5 [145, 146]. TIMPs are 180 amino acids that
are constructed by two functional domains: an amino-terminal (N) and a carboxyterminal (C) domain. Structurally, these two domains are folded into beta-barrels that
are held together by six disulfide bonds [147]. Although the TIMPs are somewhat
redundant, they are found to mostly have differing biological functions and have
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different affinities for the MMPs [148]. The C-terminal domain, which is less well
characterized, can mediate some protein-protein interactions, for example, TIMP-1
binds to pro-MMP-9, and TIMPs -2 and -4 bind to pro-MMP-2[146, 147, 149-152].
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Table 2-1: CNS TIMPs and what they inhibit and CNS cell source. Adapted from [153-156]

TIMP

MMPs Inhibited

ADAMs inhibited

-1

-1,-2,-3,-7,-8,-9,-11,- -10

CNS cell source
Astrocytes, Neurons

14,-15,-16,-19-,24
-2

-1,-2,-3,-7,-8,-9,-11,- -12,-17

Neurons

13,-14,-16,-24
-3

-1,-2,-3,-7,-8,-9,-13,- -10,-12,-17,-19,-28

Neurons

14,-16,
-4

-1,-2,-3,-7,-8,-9,-14,

-17,-28

--26

46

Dorsal Root Ganglia

TIMP-1
TIMP-1 was first described in 1975 as a small molecular weight serum protein,
found to inhibit human collagenase activity by fractionating serum and finding the factor
that blocked collagenase activity; it was later termed TIMP-1 [157]. Interestingly, TIMP-1
has undergone the least evolutionary changes of all the TIMPs suggesting it may have
conserved function and importance [148]. From early studies on TIMP-1, it was
recognized that TIMP-1 may have dual functions as an enzyme inhibitor and a trophic
factor. However, only recently have these separate functions become well characterized
in a variety of systems.
The most studied function of TIMP-1 is its role in regulation of MMP activity.
TIMP-1 forms a specific complex with proMMP-9, which is believed to actually activate
MMP-9 [148]. TIMP-1 is known to also interact and inhibit all MMPs except for MT1MMP and ADAM-10 [147, 148] As stated, the N-terminal domain of TIMP-1 is crucial for
its MMP inhibition; through use of NMR, it was found specifically that TIMP-1 interacts
with the catalytic domain of MMP-3 [148]. Six sections of the TIMP-1 amino acid
sequence interact with MMP-3; specifically the alpha-amino and carbonyl groups of the
N-terminal TIMP-1 portion interact with the Zn of MMP-3 to displace a water molecule
that is important for catalysis [148]. Because of TIMP-1’s ability to block MMPs, TIMPs
play important roles in tissue remodeling and homeostasis. TIMP-1 has also been
shown to be important in homeostasis in the CNS, specifically through secretion by
astrocytes [152]. MMPs are crucial for remodeling the ECM and thus TIMPs are able to
modulate remodeling and control tissue homeostasis in the CNS microenvironment. A
balance between MMPs and TIMPs is crucial for preventing pathogenic conditions in
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the CNS [152], since dysregulated MMP activities are associated with pathogenesis.
For instance, TIMP-1’s interaction with MMPs can prevent breakdown of the BBB and
maintain the integrity of the BBB [152].
All of the TIMPs have unique expression within the mammalian system. For
example, TIMP-1 is high enriched in the reproductive organs, but minimally expressed
in CNS tissue [147]. During development of the CNS, TIMP-1 was found to be
expressed within the soma of Bergmann glia in the external granular layer and in
neurons within the Purkinje cell layer in the developing cerebellum [147]. There is a
specific pattern of TIMP-1 expression during development; during embryogenesis,
TIMP-1 levels are very low, increase right before birth in the telencephalic and
mesencephalic ventricular zones and rapidly declines where it is minimally expressed
only in the cerebellum, and eventually decrease postnatally [152]. In the healthy adult
CNS, TIMP-1 is undetectable [147, 158]. Proinflammatory cytokines have been found to
induce the expression of TIMP-1 in the CNS, namely, IL-1β, tumor necrosis factor-alpha
(TNF-alpha), IFN-gamma, and IL-6, but in astrocytes, IL-1β signaling is primarily
responsible for inducing TIMP-1 expression [147].
TIMPs 2, 3 and 4 are abundantly expressed in the CNS, while TIMP-1
expression is undetectable under basal conditions [147, 159]. Interestingly, TIMP-1 is
dramatically upregulated in a variety of CNS diseases, whereas the other TIMP levels
often remain constant and unchanged [45]. The rapid and robust induction of TIMP-1 in
neurological diseases suggests a role for TIMP-1 in neuropathology [45]. Clinical and
experimental data support a positive correlation between elevated expression of TIMP-1
in the CNS and remyelination. For example, with acute demyelinating encephalomyelitis
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(ADEM), a temporary condition with complete remyelination, TIMP-1 expression is
dramatically elevated[160]; however, TIMP-1 expression is not increased in patients
with MS, which is marked by minimal remyelination [161]. The levels of the other TIMP
proteins remain unchanged under diseases conditions, suggesting a selective
responsive role for TIMP-1 to neuropathology [45].
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Table 2-2: Currently Known Functions of TIMP-1 in the CNS.

Inhibitory Functions

Trophic Function

MMP activity [155]

Tissue Remodeling [164]

Apoptosis[148, 165]

Changes in cell morphology

Glioma malignancy[148, 166]

Glioma malignancy[148, 167]

Angiogenesis [164]

Myelination [46]
Astrocyte activity [46]
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1.

TIMP-1 expression in neurodegenerative diseases
As stated, TIMP-1 levels under basal conditions in the healthy, adult CNS are

below detectable limits, however, in a variety of CNS diseases, TIMP-1 is dramatically
upregulated. In the CNS, TIMP-1 is predominately produced by astrocytes [147, 154].
TIMP-1 expression in human CNS disorders can be measured in the CSF, but studies
using post mortem brain tissues have also identified elevated TIMP-1 expression. For
example, higher levels of TIMP-1 are found in patients with AD, Parkinson’s disease,
Huntington’s disease, viral meningoencephalitis and ALS [147]. Additionally, reactive
astrocytes have also been shown to produce increasing amounts of TIMP-1 in response
to HIV-1 associated dementia (HAD), which is thought to represent an attempt to repair
and protect the CNS [152]. TIMP-1 has also been found to be induced after seizures,
which can be produced by neurons and astrocytes [154]. In general, TIMP-1 is
increased in a variety of neurological disorders and has been proposed as a biomarker
of CNS injury.
Of particular interest to our research is the observation that TIMP-1 is not
increased in select neurodegenerative diseases. In particular, the absence of elevated
TIMP-1 expression in HIV-encephalomyelitis and MS warrant further discussion for their
remarkable parallels between human disease and TIMP-KO mouse studies [46, 160,
168]. TIMP-1 levels are not elevated in MS, a neurological disorder with minimal repair.
Specifically, MMP-9 to TIMP-1 ratio in serum has been studied as a potential marker for
MS [169]. In MS, there is increased expression of MMP-9 in serum, without subsequent
expression of its inhibitor, TIMP-1, suggesting a potential pathogenic role linked to the
lack of TIMP-1. In the mouse model of MS, EAE, TIMP-1 is found to be increased in Wt
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mice, where it is expressed by astrocytes surrounding demyelinated lesions [155]. This
was initially thought to represent a protective role for TIMP-1 balancing elevated MMPs
in this condition [155]. Unlike MS, EAE is associated with significant myelin repair, again
suggesting a potential role of TIMP-1 for repair. In addition, from work previously done
in our lab, we have shown that mice lacking TIMP-1 in the EAE model have limited
remyelination as compared to Wt mice [46]. This lead to our hypothesis that TIMP-1
from astrocytes is important for remyelination, and that understanding astrocyte
dysfunction and what astrocytes make in response to inflammation and injury is
important for a variety of CNS disorders, including MS. Chronic inflammation is a
feature in HIV encephalomyelitis and MS, which is potentially important for the
regulation of TIMP-1 expression in these diseases [158]. Ghorpade et al have proposed
multiple mechanisms including loss of mRNA stabilizations and changes in transcription
factors to explain the loss or absence of TIMP-1 expression with chronic inflammation
[158]. What is interesting about this idea is that TIMP-1 is known to be induced by injury
or inflammation, yet, in chronic inflammation TIMP-1 expression is no longer induced.
The lack of TIMP-1 contributes to a neuropathology through a failure of tissue recovery
or repair. This lead to the understanding that diseases like MS, where there is chronic
inflammation could lead to the downregulation of TIMP-1 and thus the inability to repair.
This data show an importance of TIMP-1 with regards to remyelination and has
lead to interesting studies in the mechanisms. TIMP-1 has been

studied extensively

using the mouse model of MS, EAE in both knockout conditions and overexpressing
conditions. First, work done previously in our lab that TIMP-1 is necessary for
remyelination to occur in chronic EAE [46]. In chronic EAE, Wt mice are able to fully
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recover and remyelinate in the lesioned area, where as TIMP-1 KO did not have
remyenation, suggesting an important role of TIMP-1 in remyelination [46]. This was
further shown to be a direct effect of TIMP-1 onto the OLs to promote differentiation and
remyelination [46]. Additionally, over-expressing TIMP-1 by astrocytes ameliorated EAE
disease course in part through inhibition the migration of lymphocytes into the CNS
[170].
We hypothesize that TIMP-1 stimulates OPC differentiation through a receptormediated signal transduction pathway to regulate Wnt/β-catenin signaling. Additionally,
we propose that study of the trophic functions of TIMP-1 to promote OPC differentiation
is expected to identify important mechanisms controlling OPC differentiation that could
be important to foster for remyelination, which will be further described in Chapter 6.
TIMP-1 as a trophic factor
TIMP-1 has predominately been studied for its role in regulating the proteolytic
activity of MMP. Recent work has shown that is has potentially many other non MMPinhibitory effects. TIMP-1 was first discovered to have potential growth factor functions
by Gasson et al. where they found that TIMP-1 was able to stimulate the growth of
erthyroid progenitors by a mechanism of direct cell binding [171]. They also suggested
homology between TIMP-1 and a growth factor called Erythoid potentiating activity
(EPA) [172]. This was the first reported case of trophic factor functions of TIMP-1. Since
that time multiple groups, including our lab have shown trophic factor functions of TIMP1 in a variety of cellular systems, including the CNS.
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TIMP-1 expression by astrocytes is highly inducible. In the CNS, this
extracellular protein is produced predominately by astrocytes in response to infection,
inflammation, or injury [46, 147]. TIMP-1, while being made by astrocytes, is also known
to activate astrocytes; TIMP-1KO mice exhibited attenuated astrocytic responses, which
have been associated with differences in astrocytic-mediated support for OL
differentiation [46, 147]. Previous work using TIMP-1KO mice has shown that TIMP1KO mice develop worsened myelin injury when compared to wildtype (wt) in a model of
inflammatory demyelination [46], conversely transgenic mice that overexpress TIMP-1
from astrocytes are more resistant to demyelinating injury [170]. Thus, TIMP-1 may be
an important molecule involved in regulating myelination in the CNS.
Although previously believed to be working through MMP inhibition, recently we
have shown that this effect is due, in part, through trophic function. Our experiments
have determined that the primary action of TIMP-1 as a novel non-MMP mediated
signaling effect of TIMP-1 to promote oligodendrocyte progenitor cell (OPC)
differentiation. This work is presented in Chapter 6 of this thesis.
TIMP-1 receptor and its intracellular signaling pathway
The identification of a receptor for TIMP-1 has provided renewed interest in the
non-MMP-related functions of TIMP-1 and a means to explain and study its signaling
mechanism. Initial work on breast epithelial cells identified a TIMP-1 receptor, a
tetraspanin protein called CD63 [173]. Specifically, CD63, β1 integrin and TIMP-1 were
found to form a complex on the membrane of breast epithelial cells[173]. Knocking
down CD63 reduced TIMP-1 localization to on the cell membrane, suggesting this
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interaction with TIMP-1 was required for the CD63/ β1 integrin complex to form [173]
Co-immunoprecipitation of CD63 with TIMP-1 confirmed this interaction [173].
CD63 is a cell surface tetraspanin that contains four transmembrane α-helices,
two extracellular loops, and a cytoplasmic tail [173, 174]. Like other tetraspanins, CD63
interacts with cell adhesion molecules such as integrins, specifically β1-integrins,
regulating intracellular signal transduction pathways [173, 175]. β1-integrin is a member
of a larger family of cell surface glycoproteins that mediate the interaction between a
cell and the extracellular environment [176, 177]. Integrins regulate many cellular
behaviors, specifically differentiation [176, 177].

Together, the CD63- β1-integrin-

TIMP-1 complex has been confirmed in several systems [173, 174, 176, 178].
Upon TIMP-1 binding to CD63, CD63 is activated and its cofactor, β1 integrin,
then activates PI3k/Akt signaling. This PI3K/Akt pathway has been shown to be
important for many functions associated with TIMP-1, such as cell adhesion, motility,
survival, and proliferation [173, 174, 179, 180]. Several pathways have been implicated
in being regulated by TIMP-1 including MAPK and cyclic adenosine 3’,5’monophosphate (cAMP)-protein kinase a pathway [179]. Akt is phosphorylated by PI3k
at threonine 308 and serine 473 sites [181]. Akt then phosphorylates and inactivates
glycogen synthase 3β (GSK3β) at serine 9 [182, 183]. GSK3β is a serine/threonine
kinase that plays an important role in canonical Wnt signaling by phosphorylating βcatenin, along with the protein axin and another factor called adenomatous polyposis
coli (APC) [183, 184]. When GSK3β is phosphorylated, β-catenin to target it for
degradation. When GSK3β is phosphorylated, β-catenin is released and then able to
translocate into the nucleus where it promotes gene transcription by interacting with
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LEF-1/TCF factors. This pathway has been implicated in not only astrogliosis but also in
promoting OL differentiation, suggesting a potential mechanism of trophic TIMP-1 action
[62, 185-189]. This potential mechanism is the focus of Chapter 6 of this thesis. These
are the core elements downstream of β1/CD63 that I have been studying in the context
of TIMP-1 signaling in glial cell.
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Chapter 3. The Extracellular Matrix and Glial Cells
I.

ECM and the CNS
The extracellular matrix (ECM) is a complex network of both structural and trophic

support for cells and tissues that can modulate the behavior of cells [190]. The ECM
plays important roles in regulating cell migration, cell division, cell fates, differentiation
and cell survival[191, 192]. In the CNS, the ECM is defined as any secreted molecules
that are immobilized outside of a cell [191, 192].
The ECM provides a dynamic medium through which cells may interact with other
cells and respond to changes in the environment. Cell express receptor molecules, such
as integrins that recognize ECM ligands. All cell types in the CNS express receptors in
order to facilitate interactions with the ECM. These interactions mediate a multitude of
cellular behaviors, and can promote production and secretion of a large amount of
additional ECM molecules [191].
In the CNS, the ECM is composed primarily of hyaluronan and chondroitin sulfate
proteoglycans [193]. For my studies, I focused on some of the more predominately
expressed ECM molecules that have been implicated in neurological disease states
including: Laminin (Ln), Tenascin (TnC), Fibronectin (Fn), and Vitronectin (Vn) [194]. In
the adult CNS, specific ECM molecules are localized to specific regions, which will be
discussed in the following sections; however, this transition is from profuse and broad
ECM expression to more localized specific localization not truly understood [192]. In
addition, under disease conditions the make up of the ECM drastically changes.
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Laminins
Laminins (Lns) are a major component of the basal lamina, which surrounds the
brain and blood vessels throughout the CNS. Ln is also present in the ventricular zone
(VZ), and through out the developing neocortex [194]. Ln is present in the ventral
longitudinal pathway from embryonic days 8-17, suggesting an important role of Ln in
growth cone development [195].
Lns are composed of 3 separate chains, α (5 variants, ranging from 200 to
440kDa), β (four variants, ranging from 120 to 200kDa), and γ (3 variants, ranging from
120 to 200kDa), which allows for a lot of diversity (16 known isoforms) in structure and
function [196]. Ln α-chain gene is located on chromosome 18, β chain gene location
can be located on either chromosome 1 or 8, and γ chain gene is located on
chromosome 1 [197, 198]. Ln 14 and Ln 15 are found in the CNS and produced by
astrocytes [199, 200].
Ln α5 chain is present in essentially all basal lamina. Null mice for Ln α5 chain die
during development, and therefore Ln is required for embryogensis [201]. These null
mice have been found to have many developmental defects including: failure of anterior
neural tube closure[201]. This phenotype relates to the promotion of NPC migration
and differentiation by Ln[194]. Lns are important for the development of neural cells and
in directing them to correct location within the CNS[194].
Ln has been shown to also play important roles in OL physiology. Ln is important
for OL survival, as shown by blocking integrins associated with Ln interactions can
induce OL cell death [202]. Expression of Ln correlates with the onset of CNS
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myelination, and Ln expression reappears in MS lesions in areas that remyelinate [192].
When the integrin receptors to Ln are blocked (α6 β1), oligodendrocytes don’t
differentiate properly and do not form proper myelin sheaths [192]. In addition, Lndeficient mice have delayed OL differentiation and there is an accumulation of
undifferentiated OPCs in the adult mouse brain [203]. Previous studies have found that
Ln promotes the differentiation of OPCs through its activation of the Src family kinase,
Fyn [203].
Ln expression has also been shown to be important for astrocyte biology. Ln
promotes migration and differentiation of astrocytes, which was shown through deletion
of chains β2 and γ3 [204]. Interestingly, Ln is also shown to be upregulated and
secreted by reactive astrocytes in response to injury [205].
Tenascins
Tenascins (Tns) are large multimeric glycoproteins present in the ECM of the brain.
There are two main Tns in the CNS, TnC and TnR. TnC is expressed in regions of
active neurogenesis and is upregulated during embryogenesis and wound healing [194,
206]. TnC is a hexamer that can range from 220-320kDa[207]. The gene that encodes
TnC is located on chromosome 9q32-34 [208]. In addition, reactive astrocytes
predominately produce TnC [191, 206]. TnC expression is also regulated spatially and
temporally, and is only expressed during development and repair [209]. TnC has long
been shown to be important for the quiescent phenotype of astrocytes and has been
shown to prevent proliferation [210]. TnC has also been shown to play an important role
in astrocytic phenotype and myelination [123]. Interestingly, TnC induced a quiescent
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phenotype in astrocytes, accompanied by a suppression of astrocytic support for
myelination by regulating the factors that astrocytes were secreting, namely CXCL10
[123]. TnC has also been shown to have direct effects on OLs as well [211]. TnC was
shown to inhibit MBP expression in cultured OLs by preventing the activation of the
tyrosine kinase, Fyn, showing an important role of TnC on OL differentiation [211]. TnCdefcient mice also had earlier MBP expression, suggesting that TnC in part blocks the
maturation of OPCs into myelinating OLs [211].
Interestingly, TnC null mice have shown no overt developmental phenotype,
changes in lifespan, or ability to reproduce. This suggests potential redundant
developmental functions to correct for the loss of TnC with the other TnS [212].
However, more recent research done with TnC knockouts has been shown to have
subtle CNS abnormalities. A major finding using TnC knockouts has shown that TnC is
important for the migration of cells, specifically the myelinating cells of the CNS, OPCs
[213]. Specifically, OPCs migrated earlier to specific areas in the CNS such as the optic
nerve [213]. Although there is normal myelination seen in these mice, again suggesting
potential redundant and conserved mechanisms [213].
Fibronectin
Fibronectin (Fn) is a high molecular weight (HMW) glycoprotein that exists in two
identical dimer of ~250kDa each that has been shown to be produced by astrocytes,
hepatocytes, fibroblasts, endothelial cells and macrophages [119, 191, 214]. The gene
encoding Fn is located on chromosome 2q34, but due to alternative splicing can result
in up to 20 isoforms [214, 215]. The alternative splicing can occur at 3 sites: EDA, EDB,
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and IIICS [216]. Fn has two major variants in the body: (1.) Plasma fibronectin, which is
secreted into the blood as as a dimer by hepatocytes, and (2.) Cellular fibronectin,
which is made by resident cells and found in tissue [119]. Under normal basal
conditions, Fn is expressed in the adventitia of parenchymal and leptomenigeal blood
vessels of the choroid plexus [191, 217]. However, the expression of Fn is transient and
expressed during development at major migratory pathways, such as the initial
migration of cells into the external granule layer, suggesting an important role for cell
migration[218, 219]. Fn has been shown to induce the migration of OPCs to lesion sites,
but prevents OPCs to differentiate as well as preventing OLs to extend processes and
branches, thus blocking remyelination [191, 192, 220].
Fn has also been shown to being essential for development through use of
knockout mice, specifically, Fn knockouts are embryonic lethal at day 8.5 and therefore
essential for development and survival [221]. In Fn knockout mice defects are noted in
the mesodermally derived tissue, such as head and trunk deficiencies [221]. However,
many conditional Fn knockouts have been generated in order to study specific roles of
Fn in development and disease. In an inducible knockout of Fn, (knockout of Fn after
2months of age), using an ischemic stroke model, it was shown that Fn is essential for
neuron survival and reduced the infarct size [222]. More recently, conditional deletion of
Fn from astrocytes have been shown to be essential for the recruitment of OPCs after
lesion [223]. Using a toxin model of demyelination, lysolecithin, it was found that when
astrocytic Fn was conditional knocked out, there was less recruitment of OPCs to the
lesioned area; however, there were no differences in the ability to remyelinate [223].
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Figure 3-1. Functional Domains of Fibronectin. Yellow sections represent Type I
domain, where Fn can interact with Fibrin, and the extracellular matrix. Blue sections
represent the Type II domain, where Fn can interact with Collagen. Red sections
represent the Type III domain where Fn can interact with integrin receptors. Adapted
from [119].
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Vitronectin
Vitronectin (Vn) is a multifunctional 75 kDa ECM glycoprotein [224]. The gene that
encodes Vn is located on chromosome 17q11[225]. Vn plays an important role during
neurite outgrowth during CNS development. Under normal conditions, there are small
amounts of Vn expressed, specifically localized to blood vessels [191]. However, there
is much higher expression of Vn in the developing CNS, specifically from E10-18, that is
quickly downregulated in the early postnatal period [226]. The specific role of Vn in
inflammatory conditions such as MS is not known [191]. Vn has been shown to promote
microglia activation though integrin signaling, specifically αvβ5 [227]. Vn is
predominately made in the liver, and the source of Vn in the CNS is not known [228].
Vn has also been shown to not being essential for normal mouse development
using Vn knockout mice, and have no overt phenotype including normal survival and
fertility [229]. Interestingly, Vn has been shown to be important for activation of microglia,
however, there is no necessity of Vn in order for microglial activation, suggesting
potential redundancies and conserved processes [230].
Integrins
Interactions between the extracellular matrix and cells are mediated through
transmembrane cell surface adhesion receptors known as integrins. Integrins are αβ
heterodimers consisting of 18 different α subunits and 8 different β subunits to generate
potentially 24 different heterodimers (Figure 3-2) [231]. Integrins transduce signaling
from the extracellular matrix to influence cellular behavior including, proliferation,
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migration, differentiation, and cell death [232]. All cells express integrins, including the
cells of the central nervous system. Integrins have been shown to be important for man
physiological functions such as development and repair.
Integrins have been shown to be important in the CNS, as well. Specifically, mice
lacking β1 integrin in the CNS have been shown to have deficits in myelination including
decreased myelin thickness, however, there were no differences in the amount of OLs
[233]. Additionally, Barros et al. showed that β1 integrin was essential for promoting Akt
for efficient myelination, suggesting the importance of integrin signaling with regards to
correct functions in the CNS [233]. Additionally, αV integrin has been shown to be
important for the migration, proliferation, and differentiation of OPCs, specifically by
blocking αV integrins in OPC cultures [234]. In general, integrins have been shown to be
extremely important in the correct and timely development of the mammalian CNS
through interactions with their respective extracellular ligands.
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Table 3-1: ECM expression changes during development and in the adult CNS. Adapted
from [1, 2]

ECM Molecule

CNS
cell Expression in Expression
expressed
Development
Adult

Laminin

Astrocytes

Widely
expressed

Tenascin C

Astrocytes

Highly
Undetectable
expressed
in
areas of active
neurogenesis

Fibronectin

Astrocytes,
endothelial
cells,
macrophages

In areas
migratory
pathways

Vitronectin

Unknown

Highly
and Minimally
αvβ5,
α8β1,
diffusely
expressed near αIIβ3,
αvβ1,
expressed
blood vessels
αvβ3, αvβ8
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Figure 3-2. ECM and their Integrin Receptors. Integrin receptor network depicting
some of the important heterodimeric matchings of the α and β subunits and the
respective ECM molecules that interact with said integrins. Adapted form [232]
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II.

Proteolytic regulation of the ECM in the CNS
Degradation of the ECM in the CNS is an important process in development, tissue

repair, homeostasis, and remodeling that is highly regulated [235]. Among the proteins
implicated in the breakdown and turnover of the ECM, matrix metalloproteinases
(MMPS) are the major protease modifiers of ECM degradation [235].
MMPs are a family of 23 extracellular zinc-dependent proteolytic enzymes that
predominately degrade and regulate the remodeling of the ECM [227, 235]. MMPs also
have other physiological functions including: development, plasticity, cellular growth,
survival, apoptosis, migration and signaling [236]. The structure of MMPs is conserved
among the whole family: the pro-peptide domain contains a cysteine residue that binds
Zinc at its active site, which keeps MMPs in the inactive state, a catalytic domain, a
haemopexin-like domain, which is involved in anchoring to the ECM and is important for
substrate recognition, and many have a transmembrane domain (Figure 3-3) [237].
MMPs can be divided into four subfamilies including: gelatinases, collagenases,
stromelysins, and membrane type (MT)-MMPs, depending on the their substrate affinity
[237, 238]. MMPs are secreted as latent or inactive enzymes that require activation
through cleavage of the pro-peptide domain [237].
Regulation of MMPs occurs in multiple levels: transcription, activation of
zymogen, and/or inactivation by specific inhibitors [239]. Specifically, for my thesis
studies, I focused on the regulation of MMPs through their inhibitors tissue inhibitors of
metalloproteinases (TIMPs). TIMPs inhibit MMP activity by binding to the catalytic site of
MMPs, as discussed in Chapter 2.
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Figure 3-3: General structure of MMPs. Adapted from [240]. The general structure remains
consistent amongst the various MMPs including the pro-peptide domain that contains a cysteine
residue that binds zinc in the active site; catalytic domain; haemopexin-like domain, which is
involved in anchoring to the ECM and is important for substrate recognition; transmembrane
domain.

Zn2+
SP

Pro

Catalytic

Hemopexin-like
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MMPs, CNS Development, and Myelin
MMPs play crucial and beneficial roles in the development of the CNS [241, 242].
MMP protein production during development is believed to facilitate the migration of
cells through a more dynamic and fluid environment. For instance, MMP-9 null mice
have been shown to accumulate granule cells in the external granule cell layer as a
result of inappropriate cell migration [239]. Also, MMPs have been shown to facilitate
axon migration during development, by producing a dynamic and fluid ECM [239, 243,
244]. MMP inhibitors that showed reduced neurite outgrowth, where MMP-3 specifically
has been shown to be important for the migration of cells through the basement
membrane [239, 243, 244].
MMP-9 has been found to be elevated during development in areas specific for
myelination including the corpus callosum [245]. MMPs -9 and -12 also play an
important role in myelination and OL extension; null mice for these MMPs were found to
have reduced myelination and less mature OLs in the corpus callosum [239, 246].
Interestingly, MMP-9 was also shown to be essential for the process of remyelination.
MMP-9 KO mice, treated with lysolecithin were shown to have deficits in remyelination
due to a build up of NG2 proteglycan, suggesting an important role for MMP activity in
remyelination [247]. Specifically, OLs express MMP-12 during development and
differentiation and is necessary for OL process extension and myelination [248]. In
MMP-12 KO mice, OPCs had delayed differentiation and differences in morphology as
compared to wildtype [248]. In summary, MMP-9 and MMP-12 have been shown to be
important for OLs and myelination, however, in directly though regulation of the ECM.
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MMPs and the adult CNS
Some studies have investigated the presence of MMPs in the adult CNS with the
belief that MMPs are important for ECM turnover, myelin turnover, and decreased
angiogenesis in the adult CNS [249]. Studies have found that astrocytes, microglia, and
neurons produce MMP-2 and -9, while microglia produce MMP-7 [249]. Additionally,
using real-time polymerase chain reaction, MMP-2, -11, and 14 mRNA has been found
to be highly and constitutively expressed in all regions of the CNS, however, the
function of these well characterized enzymes in the CNS remains elusive [155]. Also,
MMPs have been shown to be important for synaptic plasticity, specifically in the
hippocampus, where it has been shown the MMP-3 and -9 are contribute to long-term
potentiation (LTP), the electrical manifestation of memory [250]. In MMP-9 KO
hippocampal slices, LTP is impaired, but can be restored with the application of
recombinant MMP-9 to the slice preparation [251].
MMPs have also been shown to be important under diseased conditions within the
CNS. In the adult CNS abundant and incorrect expression of MMPs can be harmful and
may result in tissue damage, suggesting a potentially pathogenic contribution of MMPs,
in diseases such as MS, which will be addressed further in the following section [236].
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Table 3-2: Important MMPs in CNS, cell source, and substrates they degrade. Adapted
from [241].
MMP

Type of MMP

Substrate Degraded

CNS Cell source

MMP-1

Collagenase

Collagens I, II, III, VII,
VIII, X, XI, gelatin,
tenascin,
aggrecan,fibronectin,
vitronectin

Astrocytes, monocytes,
macrophages, microglia

MMP-2

Gelatinase A

CollagenI, III, IV, V, VII,
X, gelatin, fibronectin,
laminin,
aggrecan,
elastin,
vitronectin,
tenascin

Astrocytes, monocytes,
macrophages,
microglia,
endothelial
cells

MMP-3

Stromelysin

Collagen II, III, IV, IX, X,
proteoglycans,
fibronectin,
laminin,
elastin,
vitronectin,
tenascin

Astrocytes, monocytes,
macrophages,
microglia,
endothelial
cells

MMP-7

Matrilysin

Casein, gelatins I, II, IV,
V,
fibronectin,
proteoglycans, Collagen
IV, aggrecan, elastin,
vitronectin
tenascin,
laminin

Microglia,
monocytes,
macrophages

MMP-9

Gelatinase B

Collagens IV, V, XI, XIV,
elastin,
aggrecan,
laminin, casein

Astrocytes, monocytes,
macrophages,
microglia,
endothelial
cells,
neurons,
neutrophils,
CCR2+CCR5+ T cells

MMP-12

Metalloelastase

Elastin,
collage
IV,
gelatin,
fibronectin,
vitronectin,
laminin,
aggracan

Macrophages,
microglia, astrocytes

MMP-14

MT-MMP

Pro-MMP-2, Collage I,
II, II, gelatin, fibronectin,
vitronectin,
laminin,
aggrecan

Monocytes
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III.

ECM and CNS myelin
The ECM in the MS lesion varies between the type/stage of lesion as well as

from the normal appearing white matter or the healthy brain. There are significant
changes in the ECM makeup in the MS brain when compared to the healthy brain [252].
The role of MMPs in demyelinating diseases are many, but 3 have been described for
MS: (1.) Breakdown of the BBB, (2.) Facilitating extravasation of brain parenchyma by
immune cells, and (3.) direct proteolysis of myelin proteins [238].
Expression of MMPs is altered in response to a demyelinating injury. For
instance, in MS, MMP-9 and -7 have been shown to be elevated in cerebral spinal fluid
(CSF) and serum in patients with MS [238, 241]. In particular, patients with higher levels
of MMP-9 in their serum were found to have higher expanded disability status scale
(EDSS) scores [253], which is a measure of increasing disability used to described MS
patients that ranges from 1 (no disability) to 10 (death due to MS). Also, increased
MMP-9 levels in serum was also shown to have a higher number of MRI Gd-TD active
lesions [169]. Additionally, MMP-3 has been shown to correlate with disease activity,
and is increased in serum during relapses in patients with RRMS [254].
In EAE MMP-2, -3,-8, -9, -10, -11, -12, -13, -14, and -25 were found to be
elevated [238, 242].

Additionally, MMP-2, -7, and -9 have also been shown to be

expressed in macrophages/microglia and lymphoctyes around perivascular cuffs [242].
It is believed that MMPs may promote migration of leukocytes into the CNS,
exacerbating the disease [241]. Interestingly, treatment with MMP inhibitors has been
shown to ameliorate the clinical course of EAE in mice and limits immune cell infiltration
into the CNS in EAE [255]. Studies on MMP-9 null mice have shown that these
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knockout mice do not develop EAE [256]. In contrast, MMP-12 null mice have a
worsened disease phenotype in EAE, suggesting a potentially important role for repair
[241, 242, 257].
MMP-2 is upregulated in a variety of diseases, specifically ones related to
inflammation and immunity, however, the precise role of MMP-2 in MS is not fully
understood [241]. MMP-2 is predominately made by monocytes, but has also been
shown to be made by astrocytes, microglia, and macrophages, and is believed to
promote immune cell migration into the CNS through disruption of the BBB [241, 258].
Additionally, there is conflicting data on the role of MMP-2 with regards to MS, some
groups have found it is upregulated in serum, others have found the opposite [258].
MMP-3 is an activator of other MMPs including MMP-1, -7, and -9 [241]. MMP-3
is also upregulated in MS, and corresponds with disease activity in RRMS, possibly
contributing to further BBB breakdown [241]. The precise role of MMP-3 is MS is not
fully appreciated, but is believed to promote remyelination. Studies using the cuprizone
model of MS have shown that during remyelination in the corpus callosum, MMP-3 was
highly expressed in astrocytes suggesting a potential benefit of MMP-3, specifically
through removing myelin debris to promote remyelination [236, 241]. Additionally, MMP3 in a known activator of microglia and plays an important role in the pathology of a
variety of neurodegenerative diseases [259].
MMP-9 is secreted by astrocytes, endothelial cells macrophages/microglia, and
circulating immune cells in the CNS [260]. MMP-9 is believed to influence the integrity of
the BBB and promote infiltration of immune cells in to the CNS [241, 261]. Patients
treated with IFN-β were shown to have reduced amounts of MMP-9 in serum samples
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that correspond with stabilization of the disease [262]. MMP-9 is involved in a variety of
inflammatory processes, specifically MS where there is increased expression of MMP-9
in serum and CSF [169, 241, 253].
MMP-12 is widely expressed in various stages of MS lesions by macrophages,
but most intensely in the active demyelinating lesions [263]. However, most studies
regarding MMP-12 are involving mouse models of MS. Specifically, in Theiler’s virus
model, MMP-12 is the highest transcriptional upregulated gene, and MMP-12 KO mice
had reduced demyelination and infiltration of immune cells in response to Theiler’s virus
infection, a viral model of CNS demyelination, suggesting a pathogenic role of MMP-12
by harming OLs [264]. However, MMP-12 has also been shown to be important for
myelin formation and OL differentiation, as described previously during CNS
development. These studies show the complex role of MMP-12 may be context
dependent with respect to studying demyelination and interpreting its possible role(s) in
MS.
Inhibitory ECM environments may play a crucial role in determining remyelination
and thus functional improvement. The plaques are the area of much interest, especially
in promoting remyelination. There are four main types of lesions or plaques: reactive,
active demyelinating lesions, chronic active and chronic inactive lesions [265]. A lot of
interest and research has been focused on the differences between the types of lesions
as well as the extracellular environment of said lesions.
ECM expression in lesions, as described in Table 3-3, is a well-studied and
interesting area of research. In the active plaques, there is little expression of TnC,
however, there is a significant increase in Vn expression, compared to healthy tissue,
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near blood vessel walls, the border of the lesion and by demyelinated axons and
reactive astrocytes [191, 228, 266]. Fn accumulation in the form of HMW aggregates
have also been detected in active lesions and shown to play an important role in
regulating OLs (see above) [119, 191, 228, 267]. In chronic inactive lesions, there is
similar expression of TnC that is seen in the normal healthy CNS [191, 238, 266]. Vn
levels are also undetectable in the chronic plaques [228, 267]. Ln is upregulated in all
active areas of demyelination [268]. Chapter 4 focuses on my thesis work with regards
to the role of the ECM, in particular the ECM changes seen in MS, in regulating
astrocytic behavior.
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Table 3-3: ECM changes in MS lesion types. Adapted from [191, 228, 266, 267, 269]

ECM

Reactive
Lesion
Expression

Active
demyelinating
lesion
expression

Chronic active Inactive lesion
lesion
expression
expression

Laminin

Upregulated

Upregulated

Upregulated

Similar
NAWM

to

Tenascin C

Downregulated

Downregulated

Downregulated

Similar
NAWM

to

Fibronectin

Upregulated

Upregulated

Upregulated

Similar
NAWM

to

Vitronecin

Upregulated

Upregulated

Undetectable

Undetectable

77

Chapter 4
Extracellular Matrix Composition Determines Astrocyte Responses
to Mechanical and Inflammatory Stimuli
Kasey M. Johnson1, Richard Milner2, Stephen J. Crocker1,3

Department of Neuroscience1, University of Connecticut Health Center, Farmington, CT
Department of Experimental Medicine2, The Scripps Research Institute, La Jolla, CA

Contact3:
crocker@uchc.edu
This article was published in a peer-reviewed journal, Neuroscience Letters
The contributions of each co-author of the publication include the following:
K.M.J., R.M. and S.J.C. designed experiments
K.M.J. performed research
K.M.J. and S.J.C. analyzed data
K.M.J., R.M. and S.J.C. wrote the manuscript

78

Abstract
Astrocytes perform critical homeostatic physiological functions in the central nervous
system (CNS) and are robustly responsive to injury, inflammation, or infection. We
hypothesized that the components of the extracellular matrix (ECM), which are known to
vary during development and in response to disease, determine astrocytic responses to
injury and inflammation. We examined the response of primary astrocyte cultures grown
on different ECM proteins to a mechanical wound (i.e. scratch). ECM substrates
selected were laminin (Ln), vitronectin (Vn), fibronectin (Fn) or Tenascin C (TnC). We
found that regrowth of the scratch wound was ECM dependent: recovery was arrested
on fibronectin (Fn), almost complete on either Vn, Ln, or TnC. To determine whether
ECM responses were also influenced by inflammation, we treated ECM plated cultures
with interleukin-1β (IL-1β). We found that IL-1β arrested astrocyte growth on Ln,
accelerated astrocyte growth on Fn and had no significant effect on astrocyte growth on
TnC or Vn. We also determined that blocking β1integrins, the major class of receptors
for all ECM proteins tested, prevented the robust response of astrocytes exposed to
TnC, Ln and Vn, and also inhibited the robust effect of IL-1β to stimulate astrocyte
growth on Fn. In addition, we evaluated downstream targets of integrin signaling,
specifically the mammalian target of rapamycin (mTOR), and determined that activation
of this pathway contributed to the response of astrocytes grown on TnC, but not on Ln,
Vn or Fn. These findings provide new insights into the role of ECM as a source of
heterogeneity

of

glial

responses

that

may

have

important

implications

for

neuropathological sequelae.
Keywords: Astrocyte, Extracellular Matrix (ECM), Integrins, mTOR
Abbreviations: ECM, extracellular matrix; Ln, Laminin; Vn, Vitronectin; Fn, Fibronectin;
TnC, Tenascin C; IL-1β. Interleukin-1β; mTOR, mamalliam target of rapamycin.
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1. Introduction
The extracellular microenvironment provides fundamental cues that guide cellular
responses. The protein composition of the extracellular matrix (ECM) exhibits regional
variation and dynamic changes related to age, injury or disease [270]. These changes in
the ECM play an important role in molding central nervous system (CNS) development
and influence cellular responses within the adult CNS [271]. For instance, tenascin C
(TnC) is a secreted ECM glycoprotein that is expressed prominently during
development and down-regulated in the mature CNS. However, TnC levels are upregulated during neuroinflammation, specifically in response to pro-inflammatory
cytokines [272]. Laminins (Ln) and fibronectins (Fn) are highly expressed during
regeneration and have been shown to promote regeneration [41]. Specific changes in
ECM protein expression, such as the accumulation of Fn or TnC in demyelinated
plaques in multiple sclerosis, have also been shown to impede remyelination in this
disease [119, 266]. Similarly, up-regulation of TnC in plaques of Alzheimer’s mouse
brain has lead to a suggested role of TnC as an integral part of the inflammatory
pathology in this disease [273]. Studies on how ECM influences the function of cells
within the CNS have revealed a prominent role for ECM regulation of astrocytic
functions [123, 274].
Astrocytes are the most abundant cell type in the CNS and provide homeostatic
and sentinel functions when they become activated in response to CNS injury,
inflammation or disease [123]. Astrocytes have a spectrum of resting and activation
states that are influenced by the extracellular environment [123]. This extracellular
influence on the activation of astrocytes likely underlies whether astrocytes contribute to
CNS pathology or promote CNS recovery [275].ECM molecules activate intracellular
signaling cascades through interactions with transmembrane protein receptors called
integrins. Integrins are members of a family of glycoproteins that regulate many cellular
behaviors, including proliferation and differentiation [177]. Integrin α and β subunits form
heterodimers that endows a range receptor diversity and specificity for ECM proteins.
Study on how different ECM molecules influence the behavior of astrocytes is expected
to enable a better understanding on the role(s) of astrocytes in pathological settings.
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Mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase and
mTOR signaling has been implicated in regulation of cell growth, proliferation, motility,
survival, as well as promoting protein synthesis, and transcriptional activation [276-278].
mTOR has two distinct complexes, mTORC1 and mTORC2, that regulate distinct signal
transduction pathways. In the CNS, mTOR has been shown to enhance protein
synthesis and promote neural cell differentiation, therefore, promoting an importance of
mTOR signaling in the health CNS. Rapamycin is an inhibitor of mTOR activation,
specifically mTORC1, and has been shown to attenuate glial cell activation [279].
Integrin signaling has been reported to engage a variety of downstream targets in the
mTOR pathway. Given that astrocytes can exhibit disparate reactions to specific ECM
proteins [280], we reasoned that activation of mTOR signaling may be one mechanism
underlying these differences
In this study, we hypothesized that the ECM substrate would impact the
response of astrocytes to a mechanical injury and an inflammatory stimulus. For these
experiments we used the canonical pro-inflammatory cytokine, interleukin-1β (IL-1β)
because it is known to activate astrocytes and is prominently produced in a variety of
neural injury settings [281]. We report that astrocytic behavior was dramatically
influenced by the ECM protein substrate and that this determined the activation and
contribution of mTOR signaling to these astrocytic responses. Together, these finding
provide new information on the regulation of astrocytes that may serve to define the
extracellular cues that contribute to astrocytic heterogeneity in responses to CNS injury
and inflammation.
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2. Material and Methods:
2.1 Primary Glial Cultures. Cultures were generated from cerebral cortices of neonatal
C57BL/6 mouse pups (P0-P3), using a neural tissue dissociation kit (Miltenyi Biotec)
[282]. Cells were plated into T175 flasks for up to 2 weeks before detachment using
trypsin (Sigma) and then re-plated onto coverglass coated with Ln (10μg/μL; Sigma
Aldrich), TnC, (100μg/μL; EMD Millipore), Fn (10μg/μL; Sigma Aldrich), or Vn (25μg/μL;
Sigma Aldrich) in 24-well plates. .The purity of each culture system was consistent with
previous reports of 90-97% GFAP+ cells [46], as verified by immunocytochemistry (ICC)
for GFAP for astrocytes (1:1000, Chemicon), and, Iba-1 for microglia (1:1000, WAKO).
2.2 Scratch Injury model. Confluent astrocyte monolayers were scratched once across
the diameter of the coverglass using a sterile P200 pipette tip to produce an injury
~600μm in diameter [283]. Cells were fixed at different time points and ICC performed.
IL-1β (10 ng/ml; Peprotech) was added to the cultures as a prototypic inflammatory
stimulus, as previously described [284]. The role of β1integrin was tested using a
function blocking antisera (Ha2/5; 5μg/mL) and compared with control, isotype-matched,
IgG (both from BD Pharmigen). Effects of mTOR were assessed using rapamycin (5 µg;
Santa Cruz Biotech) dissolved in DMSO (10 nM, Sigma). Scratch injuries were
measured perpendicular to the longitudinal axis of the scratch at a minimum of three
points spanning from the edges of the scratch using image analysis software (Northern
Eclipse software; Empix Imaging). Western blotting was performed on cultures grown in
6 well plates coated with Ln, TnC, Fn, or Vn, and scratched 4 times per well using a
sterile P200 pipette tip as described above.
2.3 Immunocytochemistry (ICC). ICC was performed as previously described [46].
Cultures were fixed in 4% paraformaldehyde, washed and then incubated with primary
fluorescent conjugated antisera for Glial Fibrillary Acidic Protein (GFAP-Cy3; 1:1000,
Sigma). 4',6-diamidino-2-phenylindole (DAPI) was added after incubation to identify
nuclei. Immunoreactivity was visualized using a fluorescent microscope (Olympus,
IX71) and image analysis software (Empix Imaging).
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2.4 Western Blot Analysis. Lysates from primary cultures grown on Ln, TnC, Fn, or Vn
were prepared as previously described [46]. Cells were scraped into PBS, after 0, 4, or
24hrs after treatment, centrifuged (6000xg), the pellet was resuspended in RIPA buffer
[Triton X-100, NaCl, Tris-HCl base, Deoxycholic Acid, SDS, H2O] and mechanically
dissociated using a motorized pellet pestle (Fisher Scientific). Each sample was
prepared with 2x loading buffer [Tris-HCl, Glycerol, SDS, H2O, BPB, DTT] and 15μg of
total protein was loaded into a graduated 5-15% acrylamide gel (Biorad). After PAGE,
protein was transferred onto PVDF membrane (Thermo Scientific). Blots were blocked
and then incubated overnight in primary antisera. Primary antisera included pAktS473
(1:1000, Cell Signaling), panAkt (1:1000, Cell Signaling) S6KpThr389 (1:1000, Cell
Signaling), p70S6Kinase (1:1000, Cell Signaling), and β-actin (1:2000, Sigma).
Secondary antisera were HRP-conjugated anti-mouse (1:10,000, Vector Labs), or HRPconjugated anti-rabbit (1:10,000, Vector Labs) for detection using ECL reagent (GE
Biosciences). Exposed films were developed and quantified relative to β-actin loading
for each sample [46].
2.5 Statistics:
Experiments were performed in quadruplicate replicates and repeated in triplicate.
Comparisons between treatments on the same substrate were made using t-tests, or
one-way ANOVA to evaluate changes over time. Inter-group comparisons for
differences on each ECM over time, or treatment were made two-way ANOVA. Data are
presented as mean±SEM. The null hypothesis for all experiments was P<0.05.
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3. Results
3.1 Astrocyte response to scratch is ECM dependent
We hypothesized that the composition of the ECM may influence the behavior of
astrocytes and their ability to recover from a scratch injury. This idea was based on
previous studies that have demonstrated the utility of the scratch assay to explore the
behavior of astrocytes [206, 284], and additional studies that explored the impact of
ECM on astrocyte phenotype [123]. We examined the response of astrocyte cultures to
a scratch injury by assessing rate and extent of recovery. Primary murine glial cultures
were grown on cover-slips that had been coated with one of the following ECM proteins
(Ln, TnC, Vn, or Fn), grown to confluence, scratched and then recovery assessed 4 or
24 hours later. Over the 24 hours incubation, astrocytes grown on Ln, TnC or Vn
exhibited significant recovery (Figure 1). In contrast, astrocytes grown on Fn exhibited
only minimal wound closure that was significantly less than all other ECM substrates
tested (P<0.0001; Figure 1B).
3.2 Astrocyte response to IL-1β is ECM dependent
Previous work suggests that exposure to IL-1β impairs the response of human
astrocytes to wound recovery [284]. To determine whether the ECM composition
influenced the effect of IL-1β, we treated cultures with IL-1β and assessed recovery on
the different substrates. Consistent with previous work, treatment with IL-1β arrested the
recovery of astrocytes grown on Ln (P>0.05 vs. 0 hr), which differed significantly from
the robust recovery seen on Ln under control conditions (P<0.001 vs. 24 hr control;
Figure 1). When treated with IL-1β, astrocytes grown on Vn. exhibited a trend of
reduced recovery but the magnitude of this effect was not statistically significant
(P<0.07 vs. 24hr control; P<0.5 vs. 0hr control). In contrast, cultures grown on TnC,
maintained their strong response in the presence of IL-1β. Most interestingly, astrocytes
on Fn exhibited a minimal growth response under control conditions, but IL-1β treatment,
induced a robust and significant recovery response (P<0.001 vs. Cntl 24 hr.).
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3.3 ECM-specific β1integrin-mediated astrocyte responses
To identify potential mediators of the astrocyte responses to ECM substrates, we
first examined β1integrins as the principal class of ECM receptors. To evaluate the
contribution of β1integrin to astrocyte wound healing responses, we used a functionblocking antibody, Ha2/5. Astrocytes grown on TnC, Ln, or Vn exhibited an impaired
scratch repair response when β1integrin was blocked, compared to IgM control-treated
cultures on the same substrates (P<0.001, TnC; P<0.005, Ln; P<0.04, Vn) (Figure 2A).
The contribution of β1integrin to astrocyte responses to Fn were difficult to assess as
astrocytes grown on Fn exhibited only a minimal wound repair response that was not
altered by treatment with Ha2/5 (Figure 2A). However, when astrocytes grown on Fn
were treated with IL-1β, which evoked a robust recovery, this IL-1β effect was
completely blocked by Ha2/5 (P<0.0001 vs. control antibody; Figure 2B). In addition,
Ha2/5 also inhibited astrocyte growth on TnC in the presence of IL-1β, (P<0.007; Figure
2B).
3.4 ECM selective activation of mTOR signaling
We next examined how the ECM affects putative downstream signaling of
integrin receptors, specifically mTOR as an effector of cellular responses [177, 276]. To
determine whether mTOR activity contributed to the astrocytic wound response on
different ECM substrates, we assayed astrocyte cultures by western blotting for
differential activation of mTOR, specifically, phosphorylation of S6 kinase (S6k; Thr389),
which is preferentially activated by mTORC1, and phosphorylation of PKB (Akt;
Ser473), which is preferentially activated by mTORC2 [181].
Analysis of S6k activation in astrocytes grown on each different ECM substrate
revealed a differential in response to scratch or IL-1β that depended on the substrate
(Figure 3, A-D). Astrocytes grown on TnC revealed significant mTORC1 activation, in
contrast, astrocytes grown on Ln, Vn, or Fn exhibited no significant change.
Interestingly, the pattern of S6k activation was affected by IL-1β treatment in astrocytes
grown on TnC (P<0.006; 4hr IL-1β vs. 4 hr control). We also found that S6k activation in
astrocytes grown on Ln, Vn or Fn was not significantly modified by IL-1β treatment.
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There were no significant differences in levels of S6kinase in response to scratch on
any substrate tested (Figure 3A-D).
We then examined whether the activity of mTORC2 was also differentially
regulated by ECM substrate, scratch injury, and inflammatory stimulation, using
phosphorylation of Akt (ser473) [276] (Figure 3, E-H) . Astrocytes grown on TnC
showed significant Akt activation over time after the scratch (P<0.02), but this effect was
absent following treatment with IL-1β. Akt was also activated in astrocytes grown on Ln
after scratch (P=0.02); however, IL-1β did not modify Akt activation. Astrocytes grown
on Vn or Fn also exhibited robust Akt activation in response to scratch injury (Vn,
P<0.04; Fn, P=0.005), and IL-1β did not significantly modify this activation. We also
looked at overall Akt levels, and saw no significant difference. There were no significant
differences in overall Akt expression in response to scratch on any substrate tested
(pan-Akt;, Figure 3,E-H).
3.5 ECM specific effects of rapamycin on astrocyte scratch wound response
To determine whether these changes in mTOR activation on different ECM
substrates functionally contributed to the differential wound responses we observed, we
next examined how the ECM affects mTOR as an effector of cellular responses [177,
276]. mTOR has two different complexes: mTORC1, which is inhibited by rapamycin;
and mTORC2, which is not inhibited by rapamycin [276]. To determine whether mTOR
activity contributed to the astrocytic wound response on ECM substrates, we treated
cultures grown on different ECM substrates with rapamycin. Analysis of scratch wound
recovery revealed that rapamycin blocked the response of astrocytes grown on TnC
(P<0.05) but had no effect on astrocytes grown on Vn, Fn or Ln (Figure 4).
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4. Discussion
In this study, we established the following hierarchical relationship towards
improved wound regrowth on ECM substrates: TnC>Vn>Ln>Fn. Previous work has
shown that the pro-inflammatory cytokine, IL-1β, can inhibit the proliferative and
migratory responses of astrocytes in an in vitro scratch wound assay [284]. We also
determined that the response of astrocytes to IL-1β was context dependent: woundhealing responses varied with the ECM substrate and ECM also impacted the response
to IL-1β. Stimulation by IL-1b, also altered the following hierarchical relationship of ECM
on wound regrowth: Fn>TnC>Ln>Vn. We also discovered that IL-1β arrested the
astrocyte wound healing response on Ln, but markedly promoted the response on Fn.
These findings complement previous observations [284, 285] on ECM effects on
astrocyte responses to other cytokines, including TNF [280]. Together, these data point
to ECM as factors influencing the heterogeneity of astrocyte responses.
As integrins are the major class of ECM receptors, we next examined the role of
β1integrins in mediating ECM dependent effects of astrocytes [41]. Interestingly,
β1integrin blockade inhibited the recovery of astrocytes grown on Ln, TnC, and Vn
suggesting an important role in astrocyte responses on these substrates. In addition,
β1integrin blockade also inhibited the recovery of astrocyte grown on Fn when
stimulated with IL-1β.
mTOR signaling has been implicated in a variety of important pathways,
including autophagy, cell proliferation, cell survival, and cytokine production by
astrocytes [41]. We found that mTOR played an important part in the ECM specific
effects as evidenced by western blot analyses and the scratch injury response of
astrocytes grown on TnC to rapamycin. These data suggest mTORC1 signaling
pathway mediated the enhanced activity of astrocytes grown on TnC; but had little effect
on astrocytes grown on Ln, Vn, or Fn, suggesting signaling through mTORC2, the
rapamycin-independent complex. These results indicate that the failure of rapamycin to
affect astrocytes grown on Ln or Vn may have been due to a specific bias toward
mTORC2 signaling. While all substrates had significant activation of pAKTs473. This
differential signaling resulting from the ECM suggests important differences in regulation
of astrocytic responsiveness. Astrocytes grown on TnC, but not Vn, Ln, or Fn exhibited
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significant S6k activation over time, suggesting ECM-dependent differential regulation of
mTORC1 signaling. Our data indicate a propensity of reactive astrocytes to respond to
specific inflammatory signals that is directly regulated by the ECM. Future studies
exploring the potential hierarchy among these ECM substrates may further define how
ECM regulated heterogeneity impacts astrocyte function and reactivity and the
production of factors that contributes to neuroinflammation and pathology [286, 287].
We propose that the disparate reactions of astrocytes on different ECM
substrates, reveals important new information about the roles of astrocytes in the CNS.
In this study, we chose the ECM substrates on account of their highly dynamic
expression levels during neurological diseases. For instance, the ECM composition in
and around demyelinated lesions in multiple sclerosis (MS) varies with the stage of the
lesion [119]: where TnC is down-regulated in active lesions; Ln, Fn and Vn are upregulated in active lesions [266]. These ECM components have been reported to impair
oligodendrocyte progenitor differentiation, and thus are considered impediments to
remyelination in MS [288]. However, the presence of reactive astrocytes in all myelin
lesions in MS suggests that differences in ECM content would also impact the role of
astrocytes in these settings. Future studies addressing this issue may reveal how ECM
regulates

astrocyte

functions

to

impact

other

neural

cell

types,

including

oligodendrocytes [46, 123] microglia or neurons [289], and expand our growing
understanding of astrocytes as active participants in neuropathology [123]
5. Conclusions
These findings complement the growing awareness that astrocyte diversity may be
strongly influenced by external stimuli, including the ECM. They also provide a new
perspective on the roles of the microenvironment as a significant factor influencing the
diversity of astrocyte functions in CNS physiology and neuropathology.
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8. Figures

Figure 4-1. Astrocytic Response to Scratch Response and IL-1β is determined by ECM
substrate. (A) Mixed glial cultures grown on cover-slips were coated with Ln, TnC, Vn, or Fn
and then scratched. Scratch widths were measured after initial scratch, 4 hours, and 24 hours.
Pictures of immunocytostaining are depicted after the initial scratch and 24 hours with or without
IL1β by staining for the astrocytic marker, GFAP and DAPI. (B) The wound recovery was
quantified to compare astrocyte wound recovery on different ECM substrates with and without
the addition of IL-1β. Data are presented as box-and-whisker plots depicting the treatment
median value and the interquartile range of outcomes for each treatment combination,
representing n=4/treatment repeated in triplicate. (**, P < 0.01; ****, P < 0.0001).
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Figure 4-2. Inhibition of Astrocyte Scratch Response to ECM substrates by β1 integrin
blockade. (A) Quantification of 24 hour wound recovery of mixed glial cultures were grow on
cover-slips coated with Ln, TnC, Vn, or Fn and stimulated with a mechanical scratch with either
with â1 integrin blocking antibody Ha2/5 or control IgM. Analysis of variance was used to
determine whether Ha2/5 affected wound injury responses on the different ECM substrates. (B)
Primary cultures were treated with Ha2/5 or Ha2/5 and IL-1β and 24 hour scratch wound
recovery measured on different ECM substrates, as indicated. Following each treatment, wound
recovery was measured following each treatment relative to initial wound diameter (at 0 hour)
and comparisons made to controls for each treatment. (*, P<0.05; **, P<0.01; ***, P<0.005; ;
****, P<0.001). (C) Representative photomicrographs of GFAP+ astrocytes from each culture
condition, as indicated, showing comparable gross morphology on each substrate with or
without Ha2/5 treatment. Scale bar = 30 µm.
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Figure 4-3. The influence of ECM substrate on mTORC activation after scratch. Time
course analysis of S6 Kinase activation (pThr389; A-D) and Akt (pS473; E-H) following scratch
wound in astrocytes grown on TnC (A,E), Ln (B,F), Vn (C,G), or Fn (D,H) with or without
treatment with IL-1β. Representative immunoblots for activated S6 Kinase (pThr389) from each
time point (as listed on the abscissa above each column) for Control (upper row) and IL-1β
(lower row) for each ECM substrate, as indicated. Representative western blots for S6kinase
from each time point show no significant change in overall levels of enzyme expression. (E-H)
Representative western blots of time course analysis for pAkt activation (pS473) after scratch
wound with or without treatment with IL-1β in primary astrocyte cultures. Immunoblotting for
pan-Akt from each time point show no significant change in overall expression Akt expression
over this time course. Quantification of western blots bands were corrected for sample loading
relative to β-actin labeling of same blots (data presented as arbitrary units, a.u.) S6 Kinase data
represent n=8/ treatment/time point.( *, P=0.006) and pAkt data represent n=8/ treatment/time
point. ( *, P<0.02, TnC, Ln; P<0.04, Vn; **, P<0.005, Fn).
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Figure 4-4. Differential Modulation of Astrocyte Scratch Responses by Rapamycin is ECM
Dependent. Astrocytes grown on different ECM substrates were scratched and treated with
either rapamycin (5 μg/mL) or vehicle. Measurements of scratch wound recovery after 24 hours
were compared with control-treated cultures on the same ECM substrate. Rapamycin was found
to only impair scratch wound recovery of astrocytes grown on TnC ( *, P < 0.005).
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Abstract
Interleukin-1β (IL-1β) is a pleotropic cytokine known to influence the central nervous
system (CNS) responses to injury or infection. IL-1β also directly induces astrocytic
expression of tissue inhibitor of metalloproteinases (TIMP)-1, a potent trophic factor and
regulator of matrix metalloproteinase activity. In this study we examined the functional
relationship between IL-1β and TIMP-1 and determined that the behavior of astrocytes
in response to IL-1β is determined by TIMP-1 expression. Using primary astrocytes from
C57Bl/6 mice, we found astrocytes from wildtype (Wt) mice exhibited a robust wound
healing response to a scratch wound that was arrested in response to IL-1β. In contrast,
TIMP-1 knockout (TIMP-1KO) astrocytes, exhibited minimal response to the scratch
wound but an accelerated response following IL-1β-treatment. We also determined that
the scratch wound effect in Wt cultures was attenuated by inhibition of Rho kinase but
amplified in the TIMP-1KO cultures. We propose that the specific induction of TIMP-1
from astrocytes in response to IL-1β reflects a previously unrecognized physiological
relationship where the directionality of astrocytic behavior is determined by the actions
of TIMP-1. These findings may provide additional insight into glial responses in the
context of neuropathology where expression of TIMP-1 may vary and astrocytic
responses may be impacted by the inflammatory milieu of the CNS.

Keywords: Astrocyte, TIMP-1, IL-1β, ROCK, MMP
Abbreviations: IL-1β: Interleukin-1β; TIMP-1: Tissue Inhibitor of Metalloproteinase-1;
ROCK: Rho Kinase; MMP: Matrix Metalloproteinase.
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1. Introduction
Astrocytes are known to promote cellular differentiation, regulate synapse
function, and promote axonal regeneration[46, 102, 290]. A prominent feature of many
neurological diseases and injuries is 'reactive astrogliosis', which is defined by
proliferation, astrocytic phenotype changes, changes in morphology and gene
expression that is believed to reflect pathological changes in astrocytic functions[124,
125]. The mechanisms regulating astrogliosis are not fully understood.
Reactive gliosis can be modeled in vitro by stimulating astrocytes with proinflammatory factors, such as interleukin 1 beta (IL-1β). IL-1β replicates features
observed with reactive gliosis in vivo, including upregulated glial fibrillary acidic protein
(GFAP) gene expression and cellular hypotrophy[291, 292]. Importantly, IL-1β induction
of reactive astrogliosis has been shown to be due to deactivation of the Rho kinase
(ROCK) signaling pathway; constitutively active ROCK was found to eliminate the
impaired astrocytic response induced by IL-1β[284]. In addition, it has been shown that
this IL-1β effect is partially due to the effect of the extracellular matrix and cross talk
between additional signaling cascades such as ERK1/2, leaving an area of interest with
regard to regulation of IL-1β effects on astrocytes[293]. Interestingly, the ROCK
pathway has been implicated in a variety of CNS diseases including stroke and
Alzheimer’s disease (AD) where ROCK inhibitors are potential therapeutic agents[294].
Astrogliosis is also a hallmark feature of these diseases, suggesting that pathological
changes in ROCK pathway regulation may affect astrocyte functions in disease.
IL-1β is also known to modify the behavioral response of astrocytes to injury[295],
in part, through altering the astrocyte secretome [296]. Tissue Inhibitor of
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Metalloproteinase (TIMP)-1 is a highly inducible secreted protein produced by
astrocytes after CNS infection, inflammation, or injury [124, 125, 147].

TIMP-1

expression is also directly regulated by IL-1β [45, 146, 297]. We have recently
determined that reactive gliosis is greatly diminished in the absence of TIMP-1 [46], and
that TIMP-1 is a potent activator of astrocytes [46]. Given the ubiquitous induction of
TIMP-1 with acute brain injuries in association with astrogliosis [147], and the pleiotropic
nature of TIMP-1 function [46], we hypothesized that TIMP-1 may impart physiological
responses to astrocytes resulting from IL-1β exposure.
Herein, we report that the astrocyte responses to IL-1β are determined by the
production of TIMP-1 as it regulates the functional effect of by modulating injury-induced
activation of ROCK pathway. These findings provide new information on the functions of
astrocytes that relate to pathology in many CNS diseases.
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2. Materials and Methods:
2.1 Primary Astrocyte Cultures. Cultures were developed from cerebral cortices of
neonatal C57BL/6 wildtype or TIMP-1 deficient (KO) mouse pups (P0-P3) using a
neural tissue dissociation kit (Miltenyi Biotec)[282, 295]. Cells were plated in T175 flasks
for 2 weeks before detachment using trypsin (Sigma) and re-plating into 24-well plates
onto laminin-coated coverglass (Ln, 10 μg/μL; Sigma Aldrich) The purity of each culture
system (GFAP+ cells) was consistent with previous reports[46, 230], as verified by
immunocytochemistry (ICC) for GFAP (1:1000, Chemicon), and, Iba-1 to identify
microglia (1:1000, WAKO).

2.2 Scratch Injury model. A scratch injury ~600μm in diameter across a confluent
astrocyte monolayer was made using a sterile P200 pipette tip[283, 295]. At varying
times after injury, cells were fixed and ICC performed. Treatments included: IL-1β (10
ng/ml; Peprotech)[284, 295]; rm-TIMP-1 (10ng/mL; R&D) or the TIMP-1 C-terminal
domain peptide (amino acids 126-184; Anaspec Inc.)[46]; GM6001 (12.5 µmol/L;
Calbiochem)[298]; ROCK-inhibitor, Y-27632 (10 µM; Fisher)[284]. Scratch injuries were
measured perpendicular to the longitudinal axis of the scratch at a minimum of three
points spanning the width of the scratch. Measurements were then used to determine
the amount of recovery relative to baseline (i.e. wound diameter at time of the scratch,
or t=0) for each sample and treatment. The average of each technical replicate was
then compared across biological replicates to assess variability, though all data points
were included in the final analyses.
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2.3 ELISA: A TIMP-1 ELISA (Duoset; R&D Systems) was performed on conditioned
media samples according to manufacturer’s protocol, as previously described[46].

2.4 Immunocytochemistry (ICC). ICC was performed as previously described[46].
Cultures were fixed in 4% paraformaldehyde, washed and incubated with primary
fluorescent conjugated antisera for Glial Fibrillary Acidic Protein (GFAP-Cy3; 1:1000,
Sigma).

4',6-diamidino-2-phenylindole

(DAPI)

was

added

after

incubation

to

counterstain nuclei. Immunoreactivity was visualized by fluorescence microscopy
(Olympus, IX71) and representative images acquired using image analysis software
(Empix Imaging).

2.5 Rho-associated Kinase (ROCK) Activity Assay: was performed according to
manufacturer’s protocol (Cell Biolabs, Inc.). Briefly, protein lysates were collected from
astrocyte cultures and placed in MYPT-1 coated wells; the level of ROCK activity was
measured by optical density to quantify Thr696 phosphorylation of MYPT-1[299].

2.6 Statistics: Experiments were performed in quadruplicate replicates and then
repeated in triplicate. Comparisons between treatments were made using t-tests, or,
where appropriate, a two-way ANOVA with Bonferroni post-hoc tests was used to
evaluate response differences between genotypes with treatments using GraphPad
Prism software (La Jolla, CA). Data are presented as mean±SEM. The null hypothesis
for all experiments was P<0.05.
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3. Results:
To understand the dynamics of TIMP-1 expression in culture and to determine
whether its expression was altered by a mechanical wound in vitro, we measured levels
of TIMP-1 in conditioned media from Wt cultures either at the time of the scratch (t0), 4
or 24 hours later. We found that production of TIMP-1 was induced over time by the
scratch wound without any additional stimulus, where TIMP-1 levels were significantly
elevated by 4 hours post injury, and subsequently returned to baseline levels by 24
hours (Figure 1). No significant changes in TIMP-1 production was found in untreated,
unscratched cultures over the same 24 hr time course (Figure 1). Consistent with
previous findings we found IL-1β induced a significant increase in TIMP-1 protein levels
in the conditioned media from Wt cultures (Figure 1). We next determined what effect
mechanical wound stress would have on induction of TIMP-1 in response to IL-1β
treatment. Interestingly, when compared with either scratched or IL-1β treatment alone,
TIMP-1 production in the scratched astrocyte cultures was delayed and significantly
lessened in scratched cultures that were also treated with IL-1β (Figure 1). These data
pointed to a previously unrecognized complexity in the relationship between IL-1β,
TIMP-1 and mechanical wound stress in astrocytes.
Our previous studies had determined that TIMP-1 can directly activate
astrocytes[46], but the functional implications of this activation had not been previously
addressed. To examine how TIMP-1 influences the behavior of primary astrocytes in
culture, we compared confluent primary Wt and TIMP-1KO astrocyte cultures and
assessed their response to a scratch wound[295]. We found significant recovery in Wt
astrocytes by 24 hours after the scratch (Figure 2), however, TIMP-1KO astrocytes
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exhibited minimal recovery (Figure 2). Since (a) IL-1β induces TIMP-1 expression, (b)
IL-1β treatment attenuated the production of TIMP-1 when the culture was scratched,
and (c) IL-1β treatment is also known to arrest scratch recovery in astrocyte
cultures[284, 295], we next examined the effect IL-1β on scratch recovery in TIMP-1KO
astrocytes. Consistent with previous work[284, 295], we found that administration of IL1β (10ng/mL) was sufficient to arrest recovery in Wt glial cells, whereas application of
IL-1β was found to increase the rate of scratch wound recovery in TIMP-1KO cultures
(Figure 2). Thus, the physiological response of astrocytes to IL-1B was inverted in the
absence of TIMP-1.
To confirm that TIMP-1 was responsible for these differences in the astrocytic
response to the scratch injury, we examined whether we could recover a "wildtype"
phenotype by introducing TIMP-1 to the TIMP-1KO astrocytes. Application of
recombinant murine (rm)-TIMP-1 protein was found to significantly improve wound
recovery (P=0.0017, Figure 3A). TIMP-1 is well-characterized as a dual function protein,
with both metalloproteinase-inhibitory function and a receptor-mediated growth factor
function. To determine what function of TIMP-1 mediated the scratch recovery, we then
applied a recombinant peptide of TIMP-1 which encompassed only the trophic factor
domain and found that it significantly improved scratch wound recovery (Figure 3B).
When we applied GM6001 (12.5uM), a non-selective broad spectrum MMP inhibitor
compound, to either TIMP-1KO cultures (Figure 3C) or Wt cultures (Figure 3D) and
measured the scratch response, we found that GM6001 did not significantly alter the
scratch wound response of either genotype (P=0.3369; Figure 3C,D). This result
indicated that deficit in scratch wound response in TIMP-1KO astrocyte cultures was a
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result of a trophic factor action of TIMP-1 and not via inhibition of MMPs.
To determine why the physiological response of astrocytes to IL-1β is inverted in
TIMP-1KO astrocytes, we examined how TIMP-1 may influence IL-1β regulation of Rho
GTPases[284]. The ROCK pathway is important for cell shape, motility, and
migration[300]. ROCK activity was measured in cell lysates from Wt and TIMP-1KO
cultures that had been either treated with IL-1β, or vehicle, and either a ROCK inhibitor
(ROCKi, Y-27632; 10 µM), or vehicle control. Basal ROCK activity in TIMP-1KO
astrocytes was significantly lower than basal levels measured in Wt cultures (P<0.01,
Figure 4A). Treatment with IL-1β increased ROCK activity in both Wt and TIMP-1 KO
cultures (Figure 4A), with the increase in IL-1β induced ROCK activity in TIMP-1 KO
cultures equal to levels in untreated Wt cultures (P>0.05).
To evaluate the functional impact of these differences in ROCK activity, we
performed the scratch assay on Wt and TIMP-1KO astrocyte cultures using ROCKi and
IL-1β (Figure 4B). Addition of ROCKi to Wt cultures dropped ROCK activity to levels
equal to basal levels in TIMP-1KO cultures (not shown), and there was a significant
decrease in the ability of the wt astrocytes to recover from the injury (Figure 4B).
Addition of IL-1β to ROCKi treated Wt cultures significantly impaired wound healing
resulting in negative recovery (i.e. wound widening). In contrast, application of the
ROCKi to TIMP-1KO astrocyte improved the scratch wound response compared to
baseline scratch response in these cultures (ANOVA, P<0.005; Figure 4B), and, there
was no measurable effect of IL-1β over that of ROCKi treatment in the knockout
cultures (Figure 4B)
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4. Discussion:
Our data confirm previous findings that ROCK activation is important for recovery
from a scratch injury in Wt astrocytes[284]. However, our data also indicate that
inhibition of ROCK in TIMP-1KO astrocytes elicited an opposite response to Wt cultures.
These data imply that the physiological impact of IL-1β on astrocytes may be
determined, in part, by the production and ability of astrocytes to express TIMP-1.
TIMP-1 is a top candidate gene upregulated in two models of astrogliosis[125], and we
have previously shown that TIMP-1 is important for astrocyte activity in vivo[46]. There
is also an emerging understanding that TIMP-1 is dynamically regulated and that
dysregulation of TIMP-1 expression by astrocytes may contribute to context under
which astrocytes respond in a variety of neurological diseases. We postulate that many
of the actions of TIMP-1 in this context are not MMP-mediated but rather through a
receptor-mediated signaling mechanism. Previous studies have reported TIMP-1
activation of PI3K and Akt signaling in non-neural cells[179], though these process have
not yet been directly confirmed in CNS cell types[178]. Future studies on the trophic
actions of TIMP-1 may provide important insights into the acute effect of inflammation
on astrocytes in disease, where a rapid elevation in TIMP-1 have been associated with
CNS repair. In contrast, elevated expression of TIMP-1 is not always observed in
several

chronic

inflammatory

neurodegenerative

diseases,

including

HIV-

encephalomyelitis and multiple sclerosis (MS)[158, 160, 169], suggesting that a reduced
propensity of astrocytes to express TIMP-1 may result from chronic inflammation and
then significantly impact how astrocytes function/respond
states.
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in these chronic disease

In this study, we wanted to further elucidate the contribution and function of
astrocytes in response to IL-1β, which has been shown to be important for the formation
of the glial scar because the mechanism that generates the astroglial phenotype of the
reactive astrocytes is still not fully understood. A better understanding of the regulation
of astrocyte reactivity could provide a beneficial insight into astroglial heterogeneity in
function and phenotype in disease. In particular, the role of TIMP-1 and the ability of
astrocytes to react to external stimulation. These previous observations have lead to our
study to understand a potential mechanism for TIMP1 regulation of astrocyte activity.
On a cellular level, our data are also consistent with primary human astrocyte cultures
from MS lesion biopsies, which have been reported to exhibit increased proliferation
and migratory capacity when compared with cultures derived from non-diseased brain
or spinal cord regions[301]. Although measurement of TIMP-1 produced in the context
of human disease-specific astrocyte cultures has not yet been reported, our findings
would suggest that the behavior of astrocytes may strongly influenced by TIMP-1
expression and this would change over time as a result of the chronic inflammation
during disease.
We have found that the astrocyte response to IL-1β is linked to the presence of
TIMP-1, and that this response is coupled to the activity of the ROCK pathway. The
ROCK pathway has been implicated in many cell functions including migration. It is
important to highlight that the cellular response to a scratch wound is complex and is
known to engage many signaling pathways related to cell proliferation, migration and
cell death [302]. For instance, cdc42, another GTPase shown to impact astrocyte
behavior in the scratch assay [283], also interacts with ROCK signaling[303]. Based on
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our scratch assay data (Figure 4), the absence of TIMP-1 dramatically influenced the
magnitude of scratch wound recovery by regulating ROCK activity in response to IL-1β.
It is possible that a mechanism for TIMP-1 regulation of astrocyte responses to IL-1β
may involve signaling molecules such as cdc42. Interestingly, another upregulated gene
in response to astrogliosis, is lipocalin 2 (lcn2)[125], which also has been previously
shown to play an important role in astrocytic reactivity is also positively regulated by
ROCK pathway signaling[304]. Previous studies have found that stimulating lcn2 can
act to polarize the function of astrocytes[305] by activating the ROCK pathway and
stimulating reactive gliosis[304]. If TIMP-1 is found to regulate lcn2 expression, future
studies may provide a plausible ROCK-mediated mechanism by which astrocytic
reactivity, astrogliosis, and wound healing may be managed TIMP-1.
Dysfunction of astrocytes is recognized as an underlying etiology of a number of
neurological diseases including: MS, AD, and amyotrophic lateral sclerosis (ALS)[46,
118, 122, 134, 135, 145, 147]. Reactive astrocytes surround MS plaques and are
thought to impair remyelination[99], which suggests an important role for astrocytes in
the pathology of MS. In AD, activated astrocytes have been shown to release proinflammatory factors that promote inflammation and foster Aβ deposition[118].
Astrocytes are thought to cause of motor neuron degeneration in ALS[134, 306]. TIMP1 has been implicated in all of these, and other, neurodegenerative diseases. Therefore,
our findings may have broad implications for understanding astrocytic functions in a
variety of neurodegenerative diseases[147].
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5. Conclusions. Astrocyte responses to IL-1β are profoundly influenced by the
production of TIMP-1 through modulation of the ROCK pathway. These findings provide
new information on how TIMP-1 may control astrocyte function and impact astrocyte
function(s) in a variety of CNS diseases.
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7. Figures

Figure 5-1: TIMP-1 induction in response to mechanical injury and inflammation. Analysis
of TIMP-1 production in primary cultures 0, 4, and 24 hrs in response to control (squares) or IL1β treatment (triangles) and scratch wound (red lines). 2-way ANOVA, P<0.0002; where ****,
P<0.0001 Cntl w/ IL-1β vs. Cntl; **P<0.01 Scratch w/ IL-1β vs. Cntl w/ IL-1β, and * P<0.05,
Scratch w/ IL-1β or Scratch vs Cntl.

107

Figure 5-2: The physiological effect of IL-1β on astrocytes is inverted in TIMP-1KO
cultures.
(A). Representative images of WT and TIMP-1KO astrocytes treated with vehicle or IL-1β. (B).
Quantitative analysis of scratch recovery (in percent) from baseline scratch wound in confluent
Wt and TIMP-1KO astrocyte cultures treated with vehicle or IL-1β (10 ng/ml).ANOVA, P<0.0001;
**, P<0.01 TIMP-1KO Cntl vs. Wt Cntl; ***, P<0.001, Wt Cntl vs TIMP-1KO Cntl or Wt IL-1β, and
P<0.002 TIMP-1KO IL-1β vs. TIMP-1KO Cntl. Scale bar = 800um.
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Figure 5-4: Diminished astrocytic Rho kinase activity in absence of TIMP-1. (A). ROCK
activity measured in Wt and TIMP-1KO astrocytes treated with either IL-1β or vehicle (control).
Two-way ANOVA; **, P=0.007 for genotype, P<0.018 for treatment effect. (B). Quantification of
scratch recovery in Wt and TIMP-1KO astrocyte cultures (in percent from baseline scratch)
when treated with either IL-1β or IL-1β and Rho kinase (ROCK) inhibitor. Two-way ANOVA, **
P<0.0009 for genotype interaction, and P<0.01 for IL-1β treatment. (C) Hypothesized IL-1β
pathway regulation of RhoK and the influence of TIMP-1 where the absence of receptormediated signaling via TIMP-1 (i.e. TIMP-1KO) modifies the physiological response of
astrocytes to IL-1β.
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Abstract
The extracellular protein tissue inhibitor of metalloproteinase (TIMP)-1 is both a matrix
metalloproteinase (MMP) inhibitor and a trophic factor for oligodendrocytes. In this report we
provide a characterization of the signaling mechanism by which TIMP-1 stimulates
oligodendrocyte progenitor cells (OPCs) differentiation into mature myelinating oligodendrocytes.
We show that trophic action of TIMP-1 to promote OPC differentiation is a function independent
of its ability to regulate MMPs. We also report that TIMP-1 trophic functions on oligodendrocytes
are mediated by β1 integrin and CD63, which together represent a putative receptor complex.
Downstream of CD63/β1 integrin, we found that TIMP-1 regulates the activity of β-catenin. This
non-canonical β-catenin regulation was counteracted by Wnts 3a and 7a to regulate OPC
differentiation. Taken together, these data support a novel function for TIMP-1 in the temporal
and spatial regulation of OPC maturation via β1/CD63-Akt-β-catenin signaling. These data
contribute to an emerging understanding on the role of TIMP-1 in CNS myelination and repair.
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Introduction
Oligodendrocyte progenitor cells (OPCs) are a population of resident stem cells within
the CNS. OPCs mediate myelination, which plays important roles in learning and brain recovery.
OPCs have been identified within demyelinated lesions in the MS brain, yet these progenitor
cells do not differentiate into myelinating OLs [27]. Multiple Sclerosis (MS) is a chronic
inflammatory demyelinating disease of the central nervous system (CNS) characterized by
lesions or plaques of demyelinated axons. Demyelination is the process where myelin is lost
from axons, usually from a direct insult to the OL in the CNS [7, 8]. Demyelination strongly
correlates with disease progression and clinical disability in MS patients [11, 12]. Thus
understanding why OPCs are arrested in MS and how we may coax OPCs to foster
remyelination in the MS brain early therapeutic strategies to promote remyelination may provide
long-term benefit in MS.
Tissue inhibitors of metalloproteinase (TIMP)-1is a recently identified trophic factor that
promotes OPC differentiation and CNS myelination [46, 146]. TIMPs are a family of secreted
proteins that are best known as regulators of matrix metalloproteinases (MMPs) protease
activity [145, 146]. Specifically, using an animal model of MS, EAE, in Wt and TIMP-1KO mice,
we showed that there was significant recovery in the chronic stages of EAE in Wt, and minimal
in TIMP-1KO, suggesting an important role for TIMP-1 in myelin biology [46]. TIMPs exhibit
other biological functions independent of their MMP inhibition. The C-terminal domain, which is
less well characterized, can mediate some protein-protein interactions [147, 152]. TIMP-1 has
been widely studied for its MMP-inhibitory functions, however, TIMP-1 has also been reported to
evoke cellular signaling mechanisms independently of MMPs. [173, 174, 179].
Recently, CD63, a tetraspanin protein, was identified as a putative receptor for TIMP-1,
providing a possible signaling mechanism for the MMP- independent effect of TIMP-1, although
a role for CD63 as receptor for TIMP-1 in the CNS has not been not been previously reported.
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CD63 interacts with cell adhesion molecules such as integrins, specifically β1-integrins,
regulating intracellular signal transduction pathways [173, 175]. β1-integrin is a member of a
larger family of cell surface glycoproteins that mediate the interaction between a cell and the
extracellular environment [176, 177]. Previous work has shown that β1-integrin is crucial for
OPC migration [220]and is also important for the activation of Akt to promote OL differentiation
for CNS myelination [233]. In transgenic mice that over-express a constitutively active Akt, the
mice have hypermyelinated axons, suggesting an important role for Akt activation in the
regulation of CNS myelination [307]. These data suggest a potential role for this β1integrins/CD63 pathway in OPCs in response to TIMP-1.
An additional target of Akt signaling is the transcription factor β-catenin through the
regulation of Glycogen synthase kinase 3β (GSK3β), a serine/threonine kinase, is a
downstream substrate of Akt that when phosphorylated becomes inactivated [126, 170]. When
GSK3β is phosphorylated by Akt, β-catenin is not degraded and then able to translocate into the
nucleus where it promotes gene transcription by interacting with LEF-1/TCF factors. Inhibition of
GSK3β can also promote β-catenin translocation into the nucleus to promote differentiation of
oligodendrocytes [187]. Though, there are conflicting data on whether β-catenin mediated
transcription promotes or inhibits OL differentiation because β-catenin can be regulated by
many different processes ( as depicted in Figure 1-5 of this thesis) [185].
In this study, we explored the mechanism by which TIMP-1 stimulates OPC
differentiation and determined that TIMP-1 regulates β-catenin signaling that requires
β1integrin/CD63 signaling. These data provide new information on how TIMP-1 may stimulate
OPC differentiation and how a loss of TIMP-1 trophic activity in patients with MS may contribute
to chronic demyelination and remyelination failure in MS.
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Materials and Methods
Primary Oligodendrocyte Precursor Cell (OPC) Cultures.
OPC cultures were developed from the cortices of neonatal Sprague-Dawley rat pups (P0-2;
Harlan). Cortices were denuded of meninges and hippocampi, and were then mechanically
minced and manually homogenized with a flame polished Pasteur pipet into a single cell
suspension in culture medium (DMEM/F12;Gibco) containing 10% fetal bovine serum (FBS;
Denville Scientific). The cell suspension was spun for 9 min (1800 rpm@ room temp/RT) and
the pellet was resuspended culture media for plating into flasks coated with poly-l-lysine (PLL
0.3mg/mL; Sigma Aldrich). Once a confluent cell monolayer formed, flasks were shaken for 1
hour (55 rpm @ 37˚C), media exchanged with fresh culture media to remove any cellular debris
and microglia and then returned to the incubator for 2-4 hours (37°C). Cultures were then
shaken overnight (255 rpm) to lift OPCs. Supernatant from shaken flasks was spun down at
1800 rpm for 10 minutes and pellet was resuspended in before mentioned media and incubated
for 3-4 hrs at 37°C in non-tissue treated petri dishes. The media was collected spun down at
1800 rpm and resuspended in media and plated onto the coated coverslips for more than 1 hr
[for PLL coating: glass coverslips were washed in sterile 1N HCl (30 min/RT), washed with
sterile water (3 time) and then incubated with poly-l-ornithine (0.05mg/mL; Sigma) 3 hrs/37°C].
Once plated onto coverglass, media was exchanged for differentiation media [Neurobasal
media (Gibco) with 2% B27 serum-free supplement (Gibco), 2mM L-glutamine (Gibco), and
10ng/mL T3 (Sigma) for up to 4 days and then OL maturation was assessed. For experimental
treatments, where indicated, OPCs were treated with specific peptides or inhibitors daily for 4
consecutive days and their impact on OL differentiation was assessed by immunocytochemistry
for markers for each stage of OL differentiation.
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Peptides, Function Blocking Antisera and Chemical Inhibitor Treatments.
Peptides. All peptides used were purchased from commercial sources. These included full
length recombinant murine (rm)TIMP-1 (10ng/mL; R&D Systems), C-terminal domain of TIMP-1
(amino acids 126-184 of TIMP-1, referred to as "TIMP-1(C)"; 100ng/mL, Anaspec), and Wnt3a
and Wnt7a (both 5ng/mL; from R&D Systems). Inhibitors used included the broad spectrum
MMP inhibitor, GM6001 (12.5 µM; selleckchem), the Akt inhibitor, MK-2206 (5µM; Selleckchem).
Function Blocking Antibodies. anti-β1 integrin (5uM; Ha2/5, BD Pharmingen) and its serotype
matched Hamster IgM2 control (Sigma), and anti-CD63 (5µM; Santa Cruz) its serotype matched
IgG control (Santa Cruz).

Analysis of OPC Differentiation.
The number of mature OL was evaluated by immunocytochemistry using stage-specific markers
CNPase and myelin basic protein (MBP) to establish efficiency of differentiation. The number of
cells per field (20x magnification) in 4 fields per coverslip using n=4 samples per treatment
group will be used for analysis, in triplicate. Using higher magnification (i.e. 40-63x) parameters
of process length and square area (μm2) of processes and Sholl analysis was used to determine
the complexity of individual cells by counting the number of independent processes that cross a
concentric circle twice the soma diameter [308].

Immunochemistry.
Immunochemistry was performed as previously described [46]. Cultures were fixed in 4%
paraformaldehyde, washed and then incubated with primary fluorescent conjugated antisera for
MBP (1:500; Millipore, Billerica, MA), A2B5 (1:500; Millipore, Billerica, MA), Olig2(1:500,
Millipore), CNPase (1:500; Sigma-Aldrich), BIII tubulin (1:500;abcam). 4',6-diamidino-2phenylindole (DAPI) was added after incubation to identify nuclei. Immunoreactivity was
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visualized using a fluorescent microscope (Olympus, IX71) and image analysis software (Empix
Imaging).

Lysoletchin and Cerebellar Slice cultures
P7 TIMP-1 KO mouse pup cerebellum were used for slice cultures, in accordance with
establish animal protocol, according to previously established protocols [309]. Demyelination
was induced by addition of .5mg/ml lyphosphatidylcholine (lysolecithin, Sigma), to the medium
for 18 hours, and then normal medium was replaced into the culture. Cultures were maintained
for up to 12 days after demyelination induction and were processed for immunolabeling.

Western Blot Analysis.
Lysates from OPC cultures grown on poly-ornithine were prepared as previously described [46].
Cells were scraped into PBS, after 0, 4, or 24hrs after treatment, centrifuged (6000xg), the pellet
was resuspended in RIPA buffer [Triton X-100, NaCl, Tris-HCl base, Deoxycholic Acid, SDS,
H2O] and mechanically dissociated using a motorized pellet pestle (Fisher Scientific). Each
sample was prepared with 2x loading buffer [Tris-HCl, Glycerol, SDS, H2O, BPB, DTT] and
100μg of total protein was loaded into a 5-15% gradient acrylamide gel (Biorad). After PAGE,
protein was transferred onto PVDF membrane (Thermo Scientific). Blots were blocked and then
incubated overnight in primary antisera. Primary antisera for Active β-catenin (1:1000, Cell
Signaling) and β-actin (1:2000, Sigma). Secondary antisera were HRP-conjugated anti-mouse
(1:10,000, Vector Labs), or HRP-conjugated anti-rabbit (1:10,000, Vector Labs) for detection
using ECL reagent (GE Biosciences). Exposed films were developed and quantified relative to
β-actin loading for each sample [46].

Image Analysis. All immunostaining was visualized using fluorescent non-overlapping Alexafluorophore-conjugated secondary antisera directed against the species of the primary
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antibodies (1:500; Invitrogen, Carlsbad, CA). For computer assisted image analysis of
immunolabeling we used Northern Eclipse software (Empix Imaging, Cheektowaga, NY) on an
Olympus IX71 inverted microscope. All comparative analyses were made using coded samples
prepared with the same reagents and processed at the same time.

Statistics. Experiments were performed as quadruplicate technical replicates and repeated
three times with biological. Comparisons between treatments were made using student t test to
evaluate changes between treatments or one-way ANOVA to evaluate changes at different
differentiation stages. Data are presented as mean±SEM. The null hypothesis for all
experiments was P<0.05.
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Results
TIMP-1 promotes OPC differentiation via its trophic factor domain
We had previously determined that TIMP-1 is a potent trophic factor for OPC differentiation [46].
To define the mechanism of action by which TIMP-1 fosters OL maturation, we tested the
functional contribution the well-characterized N-terminal MMP-inhibitory domain or TIMP-1 and
its trophic factor domain. To test the possibility that TIMP-1 acts via MMP inhibition to promote
OPC differentiation, we treated OPCs daily for 4 days with full length recombinant murine (rm)TIMP-1, or the broad spectrum MMP-inhibitor, GM6001, and then quantified the proportion of
mature OLs relative to maturation in control-treated cultures. Whereas we found that GM6001
completely blocked OPC differentiation, we found that administration of full length recombinant
murine (rm)TIMP-1 significantly increased the number of CNPase+/Olig2+ OLs in culture
(Figure 1). To test the trophic action of TIMP-1 separately from its MMP inhibitory function, we
treated OPCs daily with TIMP-1(C) and measured OL maturation after 4 days. Consistent with
the trophic effect of rmTIMP-1 (full length), we found that TIMP-1(C) also significantly increased
the number of CNPase+/Olig2+ OLs when compared with control-treated cultures (Figure 1).
Importantly, there was no significant difference between the proportion of mature OLs in OPC
cultures treated with either rmTIMP-1 or TIMP-1 (C) (Figure 1). These results suggested that
the trophic function of TIMP-1 was sufficient to promote OPC differentiation and the MMPinhibitory actions of TIMP-1 in the assay did not explain the increased OL maturation in
response to treatment with rmTIMP-1.

The trophic function of TIMP-1 is receptor-mediated
In breast epithelial cells, CD63, a member of the tetraspanin family, was found to be a
cell surface receptor for TIMP-1 [173]. Several previous studies have implicated a putative role
TIMP-1 trophic signaling in the CNS the implied a receptor-mediated mechanism, although one
has not been previously characterized for the CNS. To address this absence in our knowledge,
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we next sought to characterize the potential for CD63 as a receptor for the effects of TIMP-1 on
glial cells.
We tested several commercially available antibodies against CD63 and identified one
that served as a function-blocking antibody for CD63. From this, we administered the αCD63
antisera daily, in conjunction with rmTIMP-1, to OPC cultures and assessed the OL maturation.
Co-application of αCD63 antisera to OPCs cultures treated with rmTIMP-1 significantly
diminished the number of Olig2+/MBP+ OLs when compared with rmTIMP-1 and serotype
matched IgG control antisera (Figure 2). These results indicated that rmTIMP-1 may require
the CD63 signaling complex to initiate its trophic actions on OPCs in cultures. To fully evaluate
the CD63 receptor complex, we next tested the requirement of β1 integrin for TIMP-1 trophic
signaling. It had been previously determined that (a) OPCs express β1-integrin [220] and (b) β1integrin is required for CD63 signaling to form a TIMP-1 receptor complex [173]. To test whether
rmTIMP-1 requires β1-integrin, we administered the well-characterized Ha2/5, β1-integrin
function-blocking antibody to OPCs cultures treated with rmTIMP-1. Blocking β1-integrin using
Ha2/5 was found to significantly reduced the number of Olig2+/MBP+ OLs in response to
rmTIMP-1 treatment when compared with a serotype-matched antibody control (Figure 2).
Together, these data suggest the CD63/β1-integrin receptor complex participate in the trophic
signaling of TIMP-1 on OPCs to promote their maturation.

TIMP-1 promotes OL maturation in Cerebellar slice cultures
We next tested whether the findings of rm-TIMP-1, would be recapitulated in an
organotypic slice culture of demyelination. To this end, we applied lysoletchin to cerebellar slice
culture of TIMP-1 KO mice. We found that application rm-TIMP-1 (10ng/mL) was sufficient to
promote remyelination following lysoletchin-induced demyelination in this slice culture system
(Figure 3). Cultures treated with rm-TIMP-1 when compared with controls treated cultures
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exhibited significantly more MBP expression 12 days after lysoletchin treatment. Importantly,
this effect was blocked when treated with rm-TIMP-1 and the β1-integrin integrin blocker, Ha2/5
(Figure 3). This suggested that the increased MBP expression was mediated through a TIMP-1
receptor mediated signaling pathway involving β1-integrin.

TIMP-1 activates Akt to promote OPC differentiation
Previous work had determined that TIMP-1 can activate protein kinase B, or Akt,
downstream of the CD63/β1 integrin receptor complex [174]. Akt has also been shown to have
importance for promoting OPC differentiation and CNS myelination [307]. To determine whether
TIMP-1 activated Akt signaling and whether this was required for the trophic action of TIMP-1 on
OPC maturation, we applied the Akt specific inhibitor, MK2206, to OPC cultures treated with
rmTIMP-1. Analysis of Olig2+/MBP+ OLs following treatment determined that MK2206
significantly attenuated the trophic effect of TIMP-1 (Figure 4). To confirm that this effect was
not mediated through cell death, we determined that there was no difference between the
amounts of Olig2 positive cells between all treatment groups (Figure 4). Thus, inhibition of Akt
prevents the trophic action of TIMP-1 on OPCs, which suggested that PKB/Akt may be
downstream effector, or at the very least a regulator, TIMP-1 activation of the CD63/β1 integrin
receptor complex.

TIMP-1 induces β-catenin activation in OPCs
β-catenin is a transcriptional regulator that can be controlled by Akt activity. β-catenin is
constitutively held in the cytoplasm where it is targeted for degradation by the proteasome, until
activation of Akt releases β-catenin which then translocates to the nucleus where it promote the
transcription of target genes. β-catenin signaling has been implicated as a control signal over
OPC maturation to myelination OLs [62, 187]. Since we had determined that Akt was activated
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by TIMP-1, we next sought to determine whether this activation had any impact on the
regulation of β-catenin within OPCs. We determined that rm-TIMP-1 promoted the translocation
of β-catenin into the nucleus as compared to control treated OPCs, suggesting that TIMP-1
mediates β-catenin [310]. Additionally, we found that rm-TIMP-1 significantly increased active
β-catenin in OPCs 24 hrs after treatment (Figure 4).

Canonical Wnt signaling physiological antagonizes trophic actions of TIMP-1
Wnt3a and Wnt7a are known regulators of β-catenin signaling also recognized for
impairing OPC differentiation [311, 312]. The elevated expression of both Wtn3a and Wnt7a in
demyelinated lesions of patients with MS also points a potentially important pathological role for
β-catenin regulation in the failure of remyelination in MS [59, 311, 313]. Elevated expression of
Wnt/β-catenin regulated genes are found in the lesions of patients with MS, suggesting
dysfunction of the Wnt/β-catenin leads to the lack of remyelination seen in MS [311]. To test
whether the dual regulation of β-catenin by TIMP-1 and Wnts was competitive, we tested the
physiological impact of Wnts with rmTIMP-1 on OPC differentiation. Consistent with previously
published work, we found that Wnt3a significantly impaired the differentiation of OPCs to latter
stages of maturity (CNPase+ or MBP+) stages when compared with control or rmTIMP-1
treated cultures [39, 312]. When OPCs were treated with rmTIMP-1 in combination with Wnt3a
we observed attenuated OPC differentiation (Figure 5). We tested the effect of Wnt7a on OPC
differentiation and found that differentiation of OPCs to an mature stages (CNPase+ or MBP+)
was not negatively affected. However, when Wnt7a was applied in combination with rm-TIMP-1,
a significant block in the trophic actions of rmTIMP-1 on maturation was observed (Figure 5).
These data may point to a possible physiological antagonism resulting from convergence on the
same pathway.
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Discussion
The results of this study on the influence of TIMP-1 on OPC differentiation may have
implications for demyelinating diseases like multiple sclerosis. Multiple Sclerosis (MS) is a
chronic demyelinating disease of the central nervous system (CNS) characterized by chronic
white matter lesions exhibiting limited remyelination. Current immune-modulatory treatments
that target the chronic autoimmunity associated with MS include treatment with β-Interferon,
glateramir acetate and fingolimod. While these immunotherapies serve to manage the severity
of relapses and their frequency, accumulating evidence suggest that do not reverse the
demyelination or halt the progressive decline of function in MS patients. Therapeutic strategies
to promote remyelination are now viewed for their potential to provide long-term benefits in MS
by promoting brain lesion repair. In MS, it has been established that OPCs are recruited to
demyelinated lesions but they fail to fully remyelinate [27, 314, 315], implying that OPCs in
myelin lesions represent an endogenous regenerative response that fails as a result of a deficit
in the environment [7]. We hypothesize that TIMP-1 is a factor missing from the myelin lesion
environment in MS. Since we have shown that TIMP-1 promotes the maturation of OPCs, we
studied the trophic functions of TIMP-1 to promote OPC differentiation through a previously
unidentified and important mechanisms controlling OPC differentiation that could be important to
foster remyelination in MS.
β-catenin is a transcriptional regulator that can either induce or repress gene expression.
Future studies to understand how non-canonical β-catenin regulation by TIMP-1 when
compared with canonical regulation by Wnts may serve to refine our understanding on
functional roles of specific transcriptional targets of β-catenin. For instance, cyclin D1, a cofactor involved in regulating cyclin dependent kinase activities and cell cycle progression, is
transcriptionally induced by β-catenin activity. In this context, activated β-catenin, in conjunction
with insulin-growth factor (IGF)-1, promotes cyclin D1 that has been shown to induce OPC
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proliferation and enhance survival [316]. Additionally, c-myc, another target of β-catenin activity
mediated transcription, has been shown to be important for OPC differentiation [317].
Specifically, c-myc activity was shown to be the switch between OPCs to remain in a
proliferative and immature stage, to a mature OL [317]. Future studies to identify additional
downstream targets of the TIMP-1-Akt-β-catenin signaling may shed light on the complex
processes involved β-catenin regulation of OPC fate [59]. A recent study found that through
non-canonical β-catenin signaling, through the Wnt effector transcription factor 7-like 2 (TF7L2)
activation, there was a promotion of OPC differentiation [318], suggesting that there may be
convergent roles of β-catenin depending on the interaction with differing transcription factors,
which could be related to different factors, such as TIMP-1. Potentially, the TIMP-1 interaction
with the β-catenin signaling pathway may result in differentiation gene regulation as compared
to Wnt/β-catenin, thus leading differential outcomes of OPC differentiation.
β1-integrin has been shown to not only be important for the migration of OPCs, but also
and more pertinently, in myelin development. With use of β1-integrin KO mice, it was shown that
they had deficient myelination, but there was no different in the development of OPCs into OLs,
specifically the myelin outgrowth process [233]. Even further, this deficiency was shown to be
mediated by the inability to activate Akt to promote myelination [194]. However, this process has
only been studied during development and would be an interesting phenomenon to study in a
diseased model, such as EAE or lysolethcin. Interestingly, β1-integrin was has also been shown
to be crucial for the migration of OPCs [220] and therefore, dysfunction of the TIMP-1/CD63:β1integrin complex and lack of remyelination could have a two problem two fold.
If TIMP-1 is a regulator of β-catenin, how might this pathway be implicated in multiple
sclerosis? TIMP-1 is a highly inducible extracellular protein produced in the CNS predominately
by astrocytes in response to infection, inflammation, or injury and is known to activate
astrocytes [46, 147]. Previous work using TIMP-1KO mice has shown that TIMP-1KO mice
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develop worsened myelin injury as compared to wildtype (Wt) in a model of inflammatory
demyelination [46], whereas transgenic TIMP-1 overexpressing mice are more resistant to this
form of myelin injury [170]. There exists a striking correlation between these animal studies
where both clinical and experimental data support a positive correlation between elevated
expression of TIMP-1 in the CNS and remyelination. For example, with acute demyelinating
encephalomyelitis (ADEM), a temporary condition with complete remyelination, TIMP-1
expression is dramatically elevated [160]; however, TIMP-1 expression is not increased in
patients with MS, which is marked by minimal remyelination [161]. The levels of the other TIMP
proteins remain unchanged under diseases conditions, suggesting a specific role for TIMP-1 in
CNS myelin pathology [45]. Because of the lack of TIMP in the lesions, and the increased
expression of Wnts, the sub sequential gene regulation from β-catenin can result in the
impairment of OPC differentiation.
Many interesting questions remain to further elucidate how the TIMP-1 mediated
activation of β-catenin pathway interacts with the Wnt signaling. More specifically, can TIMP-1
modulate the activity of Wnt? A recent study on non-canonical Wnt signaling demonstrated that
WNts regulate transcription factor 7-like 2 (tf7l2) signaling to increase differentiation of and
enhance myelination [318]. This was previously unknown role non-canonical wnt signaling
mechanism that can regulate OPC differentiation [318]. This data also suggests that modulation
of the Wnt/β-catenin mechanism can have differing effects depending on downstream factors.
This may shed light on why there are seemingly conflicting outcomes in studies examining Wnt
signaling and OL/myelin.
Our experiments add to a potential TIMP-1 mechanism of cross regulation of β-catenin
signaling. To resolve how TIMP-1 vs Wnts both regulate β-catenin but have opposing effects on
OL maturation, comparisons of differential gene regulation by Wnt/β-catenin transcription versus
TIMP-/β-catenin mediated signaling would be warranted. Specifically, a comparative analysis of
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OPCs treated with rm-TIMP-1 in the presence and absence of Wnts could serve to identify
important differences that lead to key downstream regulators that promote OL differentiation
and ultimately, remyelination. Also, there may be cross talk between the regulation of β-catenin
by Akt activation since both Wnt and TIMP-1 can work through his proximal kinase. It is possible
that differential activation of Akt, or downstream targets may also be differentially affect by
TIMP-1 or Wnt. Ultimately results from studies on differential regulation of OPC differentiation
via β-catenin I would help resolve the outstanding questions.
Work from our lab has shown that this phenotype may be accountable for a novel nonMMP mediated signaling effect of TIMP-1 in the CNS in response to myelin injury [46].
Specifically, we have identified TIMP-1 as a trophic factor for OLs [46], and we have recently
determined that TIMP-1 is a novel trophic factor for oligodendrocyte (OL) differentiation. Our
experiments have determined that the primary action of TIMP-1 to promote oligodendrocyte
progenitor cell (OPC) differentiation was independent of MMP inhibition, but rather through a
novel signaling function. We hypothesize that TIMP-1 stimulates OPC differentiation through a
receptor-mediated

signal

transduction

pathway

to

regulate

β-catenin-mediated

gene

transcription.
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Figure 6-1: TIMP-1 induces OPC differentiation through a previously unreported MMPindependent mechanism. (A.) Representative images of CNP/Olig2+ oligodendrocytes (OL)
following treatments as indicated (Vehicle, rm-TIMP-1, TIMP-1 (C), and GM6001). B. Graphical
analysis of the percent of Olig2 positive cells that are also positive for CNPase to measure the
amount of OLs (Immature and Mature) in each treatment group. Data are presented as mean
SEMin each treatment, represent n=4/treatment repeated in triplicate. (**, P < 0.02). Scale bar=
100μm.
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Figure 6-2: CD63/β1 integrin mediates the trophic function of TIMP-1 on OPCs. (A-B; D-E.)
Representative images of differentiated OLs with the following treatments, as indicated
identified by Olig2 (green) and MBP (red) immunostaining. C, F. Graphical analysis of the
percent of MBP+/Olig2+ cells in each treatment group. Data represent mean +/- SEM of OLs in
each treatment, n=4/treatment repeated in triplicate. (**, P < 0.02;***,P<.005). Scale bar=
100μm.

Johnson and Crocker, Figure 1

128

A.

B.

Control

+rm-TIMP-1

C.

rm-TIMP-1
+ Ha2/5

BIII Tubulin/
MBP

200

*

150
100
50

tr
on
C

rm
-T
IM
rm
P-T
1
IM
P1
+H
a2
/5

0
ol

(M.F.I)

Mean Fluorescence Intensity

D.

Johnson and Crocker, Figure 3

Figure 6-3: TIMP-1 increased MBP expression in organotypic slice cultures from TIMP-1KO
mice. Representative images from (A.) control, (B.) rm-TIMP-1, (C.) rm-TIMP-1 and Ha2/5
treated TIMP-1 KO cerebellar slice cultures 12 days after lysoletchin induced demyelination
Organtoypic slices were stained with MBP (red), βII tubulin (green), and DAPI (blue) Scale bar=
100μm. (D.) Analysis of the mean fluorescence immunoreactivity of MBP in TIMP-1 KO slices,
n=5. (*,P =0.012). Scale bar= 100μm.
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Figure 6-5: Canonical Wnt signaling physiological antagonizes trophic actions of TIMP-1 (A.
Representative images of OLs treated wither rm-TIMP-1, in combination with Wnt3a or Wnt7a.
OL lineage cells stained with Olig2 (green) and MBP (red) to identify mature OLs. (B.) Analysis
of Olig2+/CNPase+ cells in each treatment group. Data are presented as mean +/- SEMof OLs
in each treatment, n=4/treatment repeated in triplicate. (C.) Analysis of the Olig2+/MBP+ OL
cells in each treatment group. Data represent mean +/- SEM in each treatment, representing
n=4/treatment repeated in triplicate. (*,P<0.05, **,P<0.01).
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Abstract
The extracellular environment of demyelinated lesions in multiple sclerosis (MS) patients
contributes to the limited remyelination observed in this disease. We had previously determined
that astrocytic support of oligodendrocyte maturation is mediated via production of secreted
factors regulated by tissue inhibitor of metalloproteinase-1 (TIMP-1). A comparative proteomic
analysis of the astrocyte secretome identified a novel fragment of the first type III domain of
fibronectin (Fn) which we have determined has functional homology with Anastellin and is
negatively regulated by TIMP-1. This short homolog of Anastellin impairs OPC maturation.
Anastellin fosters formation of high molecular weight Fn observed in MS lesions. These results
provide a new mechanism through which astrocytes contribute to the non-permissive
environment of a demyelinated lesion in the MS brain.
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Introduction
Astrocytes are dynamic cells unique to the central nervous system that provide critical
homeostatic functions that adapt and respond to alterations in the extracellular environment. In
the injured or inflamed CNS, astrocytes are often used to identify sites of pathology. In
demyelinating diseases, such as multiple sclerosis (MS), astrocytes are considered important
physiological regulators of remyelinating potential of oligodendrocytes [123]. We had previously
determined that astrocytic production of tissue inhibitor of metalloproteinases-1 (TIMP-1), is
closely linked to astrocytic support of oligodendrocytes; we had determined that TIMP-1
regulation of the astrocyte secretome contributes to oligodendrocyte progenitor cell (OPC)
differentiation [46].
To explore the astrocyte secretome and its impact on OPCs, we performed a
comparative proteomic analysis of the astrocyte secretome. We were able to discern the
differences related to astrocytic regulation by TIMP-1. Herein, we report on the identification of a
previously unrecognized posttranslational regulation of cellular fibronectin by TIMP-1.
Interestingly, fibronectin (Fn) regulation of OPCs had been previously found reported [119].
Recent research has shown that Fn produced by astrocytes is increased at the demyelinating
stages of MS [119]. Further, astrocytic Fn in these areas formed aggregates, believed to be the
result of inefficient clearing of Fn following injury that prevented remyelination in an
experimental model of demyelination by inhibiting the differentiation of OPCs [119]. We show
that TIMP-1 regulates astrocytic Fn production, in part, through a post-translational mechanism
and generation of Anastellin.
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Results
We had previously determined that conditioned media from primary TIMP-1KO astrocyte
cultures failed to support the maturation of A2B5 OPCs, which was in contrast to conditioned
media from wildtype (Wt) cultures that promoted OL differentiation [46]. We hypothesized that
the failure of TIMP-1 KO ACM may have been accountable to the presence of an inhibitor of
differentiation or the lack of a promoter of OPC differentiation [46]. To address these
possibilities, proteins from serum-free ACM from TIMP-1KO and Wt primary astrocyte cultures
was separated for analysis using an automated protein fractionation in 2D system [319]. Post
separation analysis of protein abundance peaks using proteome lab software revealed unique
differences from both Wt and TIMP-1KO ACM (Figure 1A). Mass spectrometry of 6 unique
peaks from each genotype when compared with the mass spec of time constant matched
samples provided a short list of potential candidates (Figure 1B). Among these uniquely
expressed peptides was a proteolytic fragment of fibronectin (Fn).
To determine whether Fn levels were directly transcriptionally regulated by TIMP-1 we
assessed the expression of Fn in Wt and TIMP-1KO primary astrocyte cultures by quantitative
PCR. To our surprise, we found no differences in Fn mRNA expression between Wt and TIMP1KO cultures, nor was Fn mRNA expression altered by application of recombinant murine
TIMP-1 to TIMP-1KO cultures (Figure 1D). Thus, Fn was not transcriptionally regulated by
TIMP-1. However, we found that TIMP-1 regulates the post-translational level of extracellular Fn
from astrocytes (Figure 1D), where we saw significantly increased amount of Fn in our TIMP1KO cultures as compared to out Wt. Interestingly, this finding is consistent with human control
and MS patients astrocytes (Figure 1E). Clinical and experimental data support a positive
correlation between elevated expression of TIMP-1 in the CNS and remyelination. For example,
with acute demyelinating encephalomyelitis (ADEM), a temporary condition with complete
remyelination, TIMP-1 expression is dramatically elevated[160]; however, TIMP-1 expression is
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not increased in patients with MS, which is marked by minimal remyelination[161]. To evaluate
whether there is a cellular deficit in TIMP-1 expression from astrocytes in MS, we cultured
astrocytes from human autopsy samples and assayed TIMP-1 and Fn expression. Consistent
with previous studies, MS astrocytes produced higher levels of Fn than control astrocyte
cultures [119]. Interestingly, there was also a significant difference in the production of TIMP-1
relative to Fn in MS when compared with control samples. We found that human astrocytes
from MS had a higher Fn to TIMP-1 ratio as compared to Control astrocytes, suggesting a
pathological feature of TIMP-1 expression and Fn levels, in MS. Also, this too was found only to
affect the protein level of Fn, not transcriptionally regulated. Thus, reduced expression of TIMP1 by astrocytes in MS may contribute to the elevated production of Fn and accumulation of high
MW Fn in this disease.
We next determined if Fn was sufficient to impair OPC differentiation by adding
exogenous Fn (0-10 μg/mL) to our culture system (Figure 2A) to determine whether Fn
contributed to reduced OPC differentiation. We found that 10μg of Fn was sufficient to block
differentiation of OPCs into OL, by significantly decreased the amount of MBP+ cells in our
culture. We next determined if Fn was the factor in our TIMP-1KO ACM preventing the
differentiation of OPCs. We immunodepleted TIMP-1KO ACM with polyclonal antisera against
Fn, or an IgM2 control antisera, and tested whether this affected the number of amount of
differentiating OPCs grown in this media (Figure 2B). Analysis of MBP+ mature OLs in cultures
treated with either native TIMP-1KO ACM or TIMP-1KO ACM treated with control IgM verified
our previous findings that this media supported spurious differentiation. However, when anti-Fn
antisera was added to the TIMP-1KO ACM, OL differentiation was increased to levels
comparable with Wt ACM (Figure 2B).
Anastellin, a proteolytic product of Fn breakdown, is known to be present in blood and its
best-described function is as an antagonist of angiogenesis where it facilitates the formation of
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high molecular weight aggregates of Fn [320]. Our determination that a Fn breakdown product
was more abundant in TIMP-1KO ACM suggested a connection with Anastellin and Fn. Several
recent studies have determined that astrocytes from MS cases produce copious amounts of
higher molecular weight Fn, which impedes OPC differentiation. We tested if anastellin, in part,
affected the differentiation by mediating the potency of Fn. We applied Anastellin either alone or
in combination with Fn, and found that in combination with a sub-impairment level of Fn, OPC
differentiation was significantly impaired (Figure 3A,B,C). Additionally, we confirmed this finding
using our synthesized Fn proteolytic peptide found in the TIMP-1KO ACM, small homolog of
anastellin we refer to as "shanestallin" (Figure 3D,E). Shanestallin did not significantly impair
OPC differentiation when applied to OPC cultures alone. However, when applied in combination
with a concentration of Fn that was also insufficient to affect OPC maturation, we found a
significant impairment to OPC differentiation (Figure 3). Thus, the presence of a proteolytic
fragment of Fn in TIMP-1 ACM can synergistically affect Fn-mediated impaired differentiation of
OPCs in culture.
Anastellin is known to block sphigosine-1-phophate (S1P)-1 signaling [321]. S1P-1
signaling is also a therapeutic target for treatment of patients with MS [322]. Since the S1P1
agonist, fingolimod (pFTY720), has been shown to directly stimulate OPC differentation [28], we
next determined whether Anastellin could be a natural inhibitor of S1P signaling on
oligodendrocytes. Application of pFTY720 to primary OPC cultures stimulated maturation of
Olig2+/MBP+ OLs, whereas coincident treatment with recombinant Anastellin blocked the
FTY720-induced increase in OPC maturation (Figure 4). Taken together, these data suggest
that Anastellin, or an Anastellin-like peptide from Fn could be a naturally occurring, astrocytederived regulator of OPC differentiation.
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Discussion
Failure of remyelination underlies the chronic demyelination in MS, which can lead to
neurodegeneration and progressive clinical disability [29]. The presence of OPCs within
demyelinated lesions in MS proffers potential for OL differentiation and remyelination [27].
However, this observation also points to disease-related perturbations in the lesion
microenvironment in MS as a primary cause of diminished remyelination in this disease.
Accumulating evidence also points to astrocytes as mediators of the MS lesion environment
[119, 223].
Previous work in our lab determined that lack of TIMP-1 impairs differentiation of OPCs
and remyelination [46]. We took this observation farther to understand what factor regulated by
TIMP-1 could be impairing OPC differentiation utilizing proteomic techniques, identifying an
anastellin-like peptide, shanestallin. We determined that both anastellin and shanestallin, in
combination with Fn, were able to block OPC differentiation. Previously, anastellin has been
shown to promote Fn aggregation [320] and HMW Fn aggregates are found in MS lesions [119].
We hypothesize that TIMP-1 mediates the proteolysis of Fn, which leads to Fn breakdown
products such as shanestallin (or Anastellin), which may promote the formation or HMW
aggregates reported within the MS lesion [119]. Our work confirms that there is a negative effect
of Fn on OPC and extends our understanding by showing that Anastellin-like peptides can
exacerbate OPC differentiation by enhancing the effect of Fn, but also potentially acting on
OPCs directly. On this latter point, our data suggest that Anastellin may antagonize S1P1
signaling and diminish the efficacy of FTY720 to promote OPC differentiation. Given the
previously defined presence of HMW Fn in MS lesions, identification of Anastellin or Anastellinlike peptides may represent a potential additional deleterious mechanism by which Fn may
endogenously limit OPC fate in MS lesions. By extension, identification of Anastellin and
addressing the means by which it is generated may also represent an approach to further
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enhance the efficacy of an already approved therapy for treatment of MS (Fingolimod) [21, 25,
28, 322]. We found that anastellin blocked the trophic effect of Fingolimod on OPCs.
TIMP-1 is a highly inducible protein in response to many CNS disorders, however, there
is not change in expression in MS patients [160]. Our study provides a potential mechanism for
the lack of remyelination seen in MS, as well as the lack of TIMP-1 induction. Briefly, we found
that the astrocyte secretome is important to foster a permissive environment to promote OPC
differentiation and that this was mediated by TIMP-1 expression. We found that TIMP-1
regulates Fn post-translationally, through proteolytic breakdown into peptides from the first type
III Fn domain, shanestallin, an anastellin like peptide. Therefore, TIMP-1 regulation of the
astrocyte proteome may be an important facet governing the extracellular microenvironment
that contributes to the chronic nature of myelin lesions in MS.

139

Materials and Methods
Primary Mixed Glial Cultures.
Animal protocols were performed in compliance with the University of Connecticut Health
Center Institutional Animal Care and Use Committees (IACUC). Primary mixed glial cultures
were prepared, as previously described. [323] Briefly, cortices of mouse pups (postnatal day 03) were obtained from wild-type C57BL/6 mice or TIMP-1 knockout (TIMP-1 KO) mice of the
same genetic background, stripped of meninges, separated from the cerebellum, and
hippocampi removed. The cortices were dissociated using a neural tissue dissociation kit
according to the manufacturer’s protocol (Miltenyi Biotec, Auburn, CA) and cultured in
Dulbecco’s Modified Eagle Medium (DMEM) culture medium (Gibco/Life Technologies,
Carlsbad, CA). Media containing non-adherent cells was removed the following day and
replaced with fresh media. For experiments analyzing the effects of replacing TIMP-1 protein to
TIMP-1 KO cultures, recombinant murine TIMP-1 (rmTIMP-1, R&D Systems, Minneapolis, MN;
10ng/mL) was added 24 hours prior to harvesting of protein/RNA.

Isolation of Rat Oligodendrocyte Progenitor Cells (OPCs).
Rat OPC cultures were generated, as previously described. [324] Cortices were obtained from
rat pups (postnatal day 0-2), stripped of meninges, and had hippocampi removed. Cortices were
mechanically minced, then manually homogenized with a flame polished pasteur pipet. The
cellular suspension was spun at 1800 rpm for 9 min at room temperature and the pellet was
resuspended and plated on poly-l-lysine (0.3mg/mL; Sigma Aldrich) coated flasks with
DMEM/F12 mixed cell culture medium (F12 media, Gibco). When a confluent monolayer of cells
was formed, flasks were placed in an incubated shaker at 55 rpm for one hour. Media was
changed to fresh F12 media to remove cell debris and microglia contained in media from first
shake. Cultures were allowed to sit in a 37°C incubator for 2-4 hours, followed by shaking at 255
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rpm overnight to lift OPCs. During shaking of flasks, glass coverslips were washed in sterile 1N
HCl for 30 min at room temperature, followed by coating with poly-l-ornithine (0.05mg/mL;
Sigma) for 3 hours. Supernatant from shaken flasks was spun down at 1800 rpm for 10 min and
pellet was resuspended in F12 media and incubated for 3-4 hours. OPCs contained in F12
media were plated on poly-l-ornithine coated coverslips and cultured in either differentiation
media (get the contents) or Fn depleted astrocyte conditioned media (ACM) for 4 days; method
of depletion is explained below.

Human Astrocyte Cultures.
Adult human astrocytes were isolated from post-mortem subcortical white matter of healthy
subjects and patients with multiple sclerosis, as described previously [325]. Astrocyte cultures
used were at least 97% pure. The cells were plated in 10 cm dishes (1.0 × 106/dish) or 8-well
chamber slides (10 000/well).

Immunodepletion of Fibronectin.
Mixed glial cultures were grown as described above. ACM was collected in a 15mL conical tube,
and antisera against Fn was applied to the media (1:100; ab23750, Abcam) and then incubated
at room temperature for 30 min to bind Fn in media and functionally deplete media of Fn.
Following depletion, Fn was added to OPC cultures for analysis of Fn effects on OPC
differentiation. A species matched IgG control (normal rabbit IgG; Santa Cruz Biotechnology,
Dallas, TX) was added to media, obtained from the same mixed glial cultures, to serve as a
control for the immunodepletion.

Function blocking Peptides.
Peptides used were purchased from commercial sources or synthesized by Peptide 2.0. These
include full length fibronectin (1-10 μg/mL; Sigma Aldrich), Anastellin (1-10μg/mL; R&D
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Systems) ,small homolog of Anastellin (1-10μg/mL; synthesized by Peptide 2.0 Inc.; Sequence:
MTTNEGVMYRIGDQWDKQHDLGHMMRCTCVGNGRHHHHHH), FTY720

(5μg/mL; Echelon

Bioscience.)

Protein-Fractionation Two Dimensional (PF-2D) Proteomic Analysis.
Confluent monolayers of wild-type and TIMP-1 KO primary mixed glial cultures were grown for
24 hours in media free of serum and collected. The media was dialyzed in varying
concentrations of phosphate buffers to remove the salt from the media. The conditioned media
was then run through a size filtration column to separate out the proteins by their molecular
weight and collected. Eluted proteins were run through protein fractionation 2-dimensional
(PF2D), where the proteins were then further separated by a gradient of isoelectric point and
then hydrophobicity, as previously described (Beckman Coulter, Pasadena, CA). [319] Identities
of proteins differentially produced in TIMP-1 KO and wild-type mixed glial cultures were
determined by mass spectrometry (MS/MS).

Western Blot.
Western blot analysis was performed, as previously described. [46] Briefly, cells from mixed glial
cultures were collected and protein was digested using a lysis buffer containing Triton X-100
(Sigma Aldrich, St. Louis, MO) and supplemented with protease and phosphatase inhibitors
(Roche Diagnostics, Indianapolis, IN). A PierceTM bicinchoninic acid (BCA) assay (Thermo
Scientific, Waltham, MA) was used to determine protein concentration. Protein was loaded onto
a precast Mini-PROTEAN TGX SDS polyacrylamide gel (4-15%; Bio-Rad, Hercules, CA) and
electrophoresed at 200v for 30 minutes. Protein was transferred to a PVDF membrane by
electrophoresis for 2 hours at 100v. Membrane was blocked in a blotting buffer containing NaCl,
Tris-HCl, and Tween-20 (Sigma) supplemented with 5% non-fat dry milk for 1 hour. Membrane
was exposed to primary antisera in blotting buffer supplemented with 2% milk overnight at 4°C.
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The primary antibody used to identify Fn protein levels was ab6584 (anti-rabbit, Abcam).
Following wash with blotting buffer, membrane was exposed to secondary antibody against
rabbit, conjugated with horseradish peroxidase (1:10,000; Vector Laboratories, Burlingame, CA),
in blotting buffer for 1 hour. Following wash, membrane was exposed to Amersham ECL Prime
Western Blotting Detection Reagent (GE Healthcare Life Sciences, Pittsburgh, PA) and
developed onto CL-XPosureTM UV film (Thermo Scientific). Relative band density of protein
was determined using ImageJ Software (NIH) (Tan and Ng, 2008). Fn protein levels were
compared to a beta-actin loading control.

Immunocytochemistry.
OPCs plated on poly-l-ornithine coated OPCs, after 4 days of differentiation, were fixed with 4%
paraformaldehyde (Sigma) at room temperature for 20 min. Cells were blocked with PBS
containing 0.3% Tween X-100 (PBS-T) and normal goat serum (5%, Sigma) for 1 hour at room
temperature. Cells were then incubated overnight at 4°C with PBS-T containing 2% NGS and
antisera against Olig-2 (1:500,Millipore) A2B5 (which stains for OPCs) (1:200, Invitrogen), or
MBP (which stains for myelinating oligodendrocytes) (1:500, Millipore). The following day the
cells were exposed to Alexa-fluorophore-conjugated secondary antisera (1:500; Invitrogen). and
counterstained DAPI (Sigma) for 1 hour at room temperature. Coverslips were mounted with
Fluoromount G (Southern Biotech, Birmingham, AL) and visualized using an inverted Olympus
IX71 microscope outfitted with digital image capture software.

Antibodies.
Anti-Fibronectin antibody (Biotin) (ab6584) (Abcam, Cambridge, UK; rabbit, 1:5000), AntiFibronectin antibody (ab23750) (Abcam; rabbit, 1:100-immunodepletion), Anti-Myelin Basic
Protein antibody [12] (MBP) (Milipore; rat monoclonal, 1:500), Mouse anti-A2B5 (Invitrogen,
Carlsbad, CA; 3ug/mL), 4',6-diamidino-2-phenylindole (DAPI) (Invitrogen, 1:1000), Mouse anti-
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glial fibrillary acidic protein (GFAP) (Millipore, 1:500), Beta-actin (Sigma Aldrich, St. Louis, MO;
mouse, 1:10,000). All immunostaining was visualized using Alexa-fluorophore-conjugated
secondary antisera (1:500; Invitrogen).

Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR).
RNA was harvested from primary mixed glial cultures using TRIzol reagent according to
manufacturer’s protocol (Invitrogen). Following DNase treatment using a TURBO DNase kit (Life
Technologies, Carlsbad, CA), RNA was reverse transcribed into complementary DNA (cDNA)
using an iScript cDNA synthesis kit (Bio-Rad). Both procedures were performed according to
the manufacturer’s protocol. The PCR reaction was carried out, according to manufacturer’s
protocol (Bio-Rad), using Sso FastTMEvaGreen® Supermix. The reaction included primer
sequences specific to Fn (Integrated DNA Technologies-IDT, Coralville, IA), constructed
according to a previous experiment (forward 5’-AGA CCA TAC CTG CCG AAT GTA G-3,
reverse 5-GAG AGC TTC CTG TCC TGT AGA G-3) (Morita et al., 2007). Primers for the
housekeeping gene GAPDH were used as an internal control for RNA loading, and used to
determine the relative gene expression of Fn, in each RNA sample (forward 5’-ACC ACC ATG
GAG AAG GC-3’, reverse 5’-GGC ATG GAC TGT GGT CAT GA-3’) (IDT). qRT-PCR was run
using a CFX Connect Real-Time PCR Detection System (Bio-Rad). The comparative cycle
threshold analysis (∆∆CT) was used to determine the relative mRNA expression as previously
described (Schmittgen and Livark, 2001).
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FIGURE
7-2.
Fibronectin
mediated
dysregulation
of
Oligodendrocyte differentiation in
TIMP-1KO astrocyte conditioned
media. (A.) Analysis of OPC
differentiation in primary cultures
treated
with
increasing
concentrations of recombinant
Fibronectin,
Representative
images of OL-lineage cells were
stained with MBP (red) and
Olig2 (green) and quantification
of
MBP+Olig2+
cells
per
treatment normalized to control
revealed a significant impairment
of differentiation with increased
Fn. (*, P<0.05, ***, P<0.001).
(B.)
Fibronectin
immunodepletion in TIMP-1KO
astrocyte conditioned media
(ACM)
restores
OPC
differentiation to Wt levels.
Representative images of WT
ACM, TIMP-1KO ACM, TIMP1KO ACM with αFn, and TIMP1KO ACM with IgG control
treated OLs stained with MBP
(red) and DAPI (Blue), as
indicated. Analysis of MBP+
(green), nucleated (DAPI+, blue)
cells per treatment revealed a
significant effect of blocking Fn
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Figure 7-3. Characterization of Anastellin and a murine small homolog of Anastellin
(shanastellin) for its inhibitory effects on oligodendrocyte differentiation and cooperative
inhibition with Fn. (A.) Representative images of Control, Anastellin, Fn or Anastellin with Fn
treated OPCs revealed a potent effect of Anastellin on the arresting of OPC differentiation as
indicated by immunostaining for MBP (red) and Olig2 (green) (B). Analysis of MBP+Olig2+ cells
treated with vehicle or Anastellin normalized to control (C.) Analysis of MBP+Olig2+ cells
treated with Fn or Anastellin and Fn normalized to control (*,P<0.05). (D.) Analysis of
MBP+Olig2+ cells treated with vehicle or small homolog of anastellin, as indicated normalized to
control (E.) Analysis of MBP+Olig2+ cells treated with Fn, and small homolog of anastellin with
Fn, as indicated normalized to control (*,P<0.05).
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Figure 7-4. Anastellin inhibits S1P1 regulation of OPC maturation. (A,B) Representative images
of PFTY72-treated and Anastellin (“Ana”) treated OPC cultures and immunostained for MBP
(red) and DAPI (Blue) to identify OL lineage cells. (C) Quantification of mature oligodendrocyte
(MBP+) in each treatment determined that pFTY720 enhanced OPC differentiation and this was
impaired by co-administration with Anastellin normalized to control **, P<0.01.
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Fn Cleavage
Anastellin as Regulator of OPC Differentiation?

Partial Sequence of Fn (Mouse) UniProtKB/SwisProt: P11276.4
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Figure 7-5. Representative schematic of Fibronectin Functional Domains and Amino Acid
Sequences of Anastellin and novel Anastellin like peptide. Blue arrow indicates the location of
the Fn fragments, anastellin and shanestallin within the 1st type III domain. Additionally, partial
sequence of mouse Fn showing the sequence localization of anastellin and shanestallin
peptides. Blue highlighting depicts the sequence of anastellin, while green highlighting shows
the sequence of the Fn fragment shanestallin found in the TIMP-1 KO ACM. The first green
highlighted portion depicts the sequence of Shanestalin. Red highlighting represents the Fn
fragments present in the Wt ACM.
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Chapter 8: Discussion and Future Directions
The extracellular matrix has only been recently appreciated as a major
orchestrator of brain function. More specifically, the ECM is now appreciated to play
major roles in promoting glial cell functions, including proliferation, differentiation, and
activity level. In my thesis, I explored how extracellular proteins, specifically how the
ECM molecules, Ln, TnC, Fn, Vn and the secreted molecule, TIMP-1 impacted glial
cells in the CNS. My data found that these extracellular factors exerted dramatic effects
and influenced their ability to differentiate, promote myelination, and recover from
inflammation and injury.
My thesis work can broadly be applied to a variety of CNS disorders where there
are major changes in the ECM environment that can influence the behavior of the glial
cells, such as astrocytes and OLs, and in turn can result in a worsened outcome.
I.

ECM and astrocytes
Astrocytes are not passive or static cells of the CNS; rather, they are dynamic

and active. Data I generated for my thesis highlighted the concept that astrocytes do not
only secrete proteins that comprise the ECM, but are also directly regulated by the ECM
[295]. For my thesis, I focused on how the effects of the ECM on astrocyte influenced
their behavior and signaling. For these studies, I used an in vitro scratch wound model,
a valuable cell culture model to study cell behavior, specifically ability to recover from an
injury [206]. In addition, it is a reliable and reproducible model to mimic astrocytic injury.
However, there are some limitations of the model, specifically, to its relation in the
context of glial scaring. Most prominently is that it only models astrocyte responses,
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whereas, glial scaring involves many cell types in the CNS, like microglia and OPCs[132,
144, 275, 326, 327]. In my thesis studies, I also used IL-1β to mimic an inflammatory
stimulus in the context of a CNS insult as well. The purpose of these studies was to
determine if ECM regulates astrocytes behavior in the context of repair and recovery,
and in the broad terms, how this may be associated with astrogliosis and glial scaring in
the CNS in association with CNS diseases and pathology.
Extracellular Matrix Composition Determines Astrocyte Responses to Mechanical and
Inflammatory Stimuli:
The ECM is always changing and represents a primary means by which cells
respond to the environment. I studied the impact of ECM on astrocyte function, as
described in Chapter 4 [295]. I focused on four ECM molecules that have been
implicated in MS pathology: Ln, TnC, Fn, Vn. These ECM components have also been
shown to have altered expression in a variety of CNS disorders [13, 119, 191, 228, 252,
266, 267, 269]. I studied the astrocytic behavior or “reactivity” by using an in vitro
scratch injury to model glial scaring, a hallmark of many CNS diseases, and how the
ECM affected how the astrocytes responded. I found that in fact, the ECM did modulate
astrocytes behavior, specifically their ability to react and recover from a mechanical
injury (in vitro scratch) and inflammatory stimuli (IL-1β). Interestingly, I found that this
behavior was mediated through integrin signaling, specifically β1-integrin, however, the
molecules activated different signaling cascades. In summary, what this portion of my
thesis concluded was that the ECM has strong regulation of astrocytes behavior,
specifically in response to injury (mechanical and inflammatory). Specifically, the ECM
substrates influenced the astrocytes ability to recovery from a scratch injury, as well as,
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from injury and inflammation [295]. In addition, these effects were mediated through
differential integrin signaling, depending on the ECM substrate [295]. These data
emphasize that astrocytes are a heterogeneous population of cells that are differentially
activated and thus behave differently depending on their surroundings.
There is a growing understanding that astrocyte dysfunction underlies a variety of
CNS diseases. My work may contribute to this and could have broad implications for
CNS dysfunction. Specifically, my work contributes to the thinking on the hallmark
features CNS of astrogliosis or glial scaring in CNS diseases. Interpreted differently, my
work also contributes to the growing area of research about the heterogeneity of
astrocytes and how understanding astrocytic behaviors may help to understanding the
underlying cause and pathology of many CNS disorders, including MS. Dysfunction of
the astrocytes, which may be due in part to the changing extracellular environment
could enhance the non-permissive environment for OLs and neurons seen in MS. A
better understanding of how astrocytes will behave in response to changing ECM could
lead to a better understanding of the lesioned environment and how astrocytes might
influence the other CNS cells.
Because of the broad area of study in this portion of my thesis, there are a lot of
interesting avenues of research that could stem from these findings and to further the
goal of understanding astrocytic behavior in response to the ECM. Firstly, astrocytes
are known as a source of ECM [119, 328, 329]. Changes in the expression of ECM from
astrocytes may promote or make the environment inhibitory for other CNS cells, such as
OPCs. Knowing what controls differential secretion of factors from astrocytes in
response to not only the ECM, but the ECM after injury or inflammation could provide a
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deeper understanding about intracellular communication, astrogliosis, and the
environment of the glial scar. Specifically, we have been collaborating with Dr. Tony
Vella (UCHC Immunology) to apply a proteomics technique called PF2D, which is able
to fractionate and compare secreted proteins from our astrocytic cultures. Peaks are
compared between the different groups and samples can be sent for mass spectrometry
to identify the differential production of proteins in the samples between the groups. This
technique was used to identify Fn in TIMP-1 astrocyte samples as described in Chapter
7 of my thesis. In future studies, we could compare the secreted proteins from
astrocytes that are grown on Ln to those grown on Fn (we see recovery in astrocytes on
Ln and minimal growth on Fn) and additionally compare the proteome of cells when
grown on on these ECM substrates and in response to injury. Understanding the
differential production of secreted proteins, we can further study those proteins impact
on both astrocytes and also OL maturation. For instance, different proteins promote a
reactive effect on the astrocytes or if they inhibit recovery, these could be measured
using astrocyte scratch assays. Additionally, we could apply candidate proteins to OL
cultures and determine if they impact the ability of OLs to grow, survive, differentiate,
and potentially myelinate in vitro.
An ultimate goal of this line of study would be to examine the impact of the ECM
molecules in the CNS environment in vivo. As previously described, not all ECM KO
mice are viable; we would have to use conditional KO mice, preferably a tamoxifen
inducible lines of ECM KO to have control over the timing of gene expression. Using a
model for glial scaring and brain trauma, such as a needle poke into the cortex of a
mouse, the glial response could then be monitored to see whether altering a specific
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ECM molecule differentially affected astrogliotic responses by measuring markers, such
as GFAP immunoreactivity. This approach could be applied to knockout for Ln [330],
TnC [331], Fn [332], and Vn [333] whether there were differences between the different
ECM to compare the glial scaring between the inducible KOs. This would further
elucidate the impact of the ECM molecules on astrocytes behavior in vivo and would
also show the impact of the astrocytes behavior onto the other CNS cells, such as
neurons and OLs.
TIMP-1 Couples RhoK Activation to IL-1β-induced Astrocyte Responses:
Another aspect of my thesis studies was my examination of the role of TIMP-1
and its impact on astrocyte behavior. Previous work reported by our lab had shown that
TIMP-1 stimulates the astrocytes’ reactivity [46]. In my studies, we wanted to better
understand the mechanism of this control and if TIMP-1 impacted astrocytic behavior.
Using the in vitro model for glial scaring, the scratch injury model, we were able to
determine that TIMP-1 does in fact have an effect on astrocytes ability to react/recover
from an injury. More specifically, without TIMP-1, astrocytes cannot recover from an
injury, however, with an inflammatory stimulation (IL-1β), we see the opposite effect,
significant recovery. This observation revealed an inverse relationship in TIMP-1 KO
astrocytes compared to Wt astrocytes by regulating Rho-kinase activity. With the lack of
TIMP-1, rho-kinase activity is dysregulated and the IL-1β effect is inverted, again
suggesting that TIMP-1 directly regulates astrocytes behavior and function through a
previously unreported mechanism of rho kinase activity, and that TIMP-1 couples these
effects of mechanical and inflammatory stimulation.
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Dysfunction of astrocytes is now appreciated as an underlying causing to many
neurodegenerative diseases, where astrocytes are shown to prevent repair and
recovery in the CNS [290]. We hypothesized that TIMP-1 is a component of this
dysfunction. TIMP-1 has been shown to be elevated in response to many CNS diseases
and is one of the top most upregulated genes during astrogliosis [125]. My study
(Chapter 5) examined how rho kinase (ROCK) activity, which has been studied in many
CNS disorders, is regulated by TIMP-1. It is important to note that ROCK inhibitors have
been suggested as potential therapeutics for certain CNS diseases [300]. Minte is the
first study to link TIMP-1 to rho-kinase regulation, as we determined that there was a
direct effect on astrocytic function. Further study into the implications of this
dysregulated pathway and how it effects astrogliosis and glial scaring could lead to a
better understanding of the underlying cause of many CNS diseases. In the context of
MS, where there is limited remyelination and a lack of TIMP-1 induction, further study of
how the rho-kinase pathway is implicated in remyelination could lead to potential
unappreciated mechanisms and understanding the role of the rho-kinase in the context
of astrogliosis and glial scaring. As well as understanding how astrocytes behave
differently with the lack of TIMP-1 with inappropriate rho-kinase activity and how this
may affect other CNS cells such as OL, which have limited remyelination potential in
MS. Essentially, further understanding of the lesioned environment, in the context of the
astrocyte and its functions could lead to a better understanding of the underlying causes
of many CNS disorders, including MS.
My thesis work on TIMP-1 regulation of rho Kinase activity in astrocytes was an
interesting and significant conclusion in in the context of astrogliosis, and this work
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helps expand the understanding of the mechanisms regulating glial scaring. Briefly, it
would be interesting to study this mechanism in vivo. By using the cortical stab model to
study astrogliosis, we could study the differences in the glial scarring between Wt and
TIMP-1 KO mice by measuring GFAP immunoreactivity. Additionally, I would cross a
mouse with constitutively active rho-kinase [334] with a TIMP-1KO mouse to determine
if active rho kinase rescued the ability of astrocytes to react/recover. We would measure
this both in vivo and in vitro. Studying in vivo, we would compare the astroglial response
after cortical stab between TIMP-1KO, constitutively active rho-kinase, and TIMP1KO/constitutively active rho-kinase and measure the GFAP immunoreactivity.
Additionally, we would make astrocytic cultures from all of the above mentioned mouse
lines and perform the in vitro scratch wound and measure recovery. We would
determine if constitutively activating rho-kinase could rescue the TIMP-1KO phenotype
that we see, and also if it remedied the inverse IL-1β affect.
II.

ECM and OLs
Another portion of my thesis studies focused on how the extracellular
environment affects OLs and their ability to differentiate and ultimately myelinate. In
particular, it is known that astrocytes can influence the extracellular environment
through secretion of proteins, including extracellular matrix molecules and trophic
factors. However, astrocytes can be harmful and promote and inhibitory and negative
environment for OL differentiation [123]. In the second portion of my thesis, I focused on
the extracellular environment and how it affected OLs. I focused on how the CNS
microenvironment, in the context of the MS lesion, could promote or inhibit OPC
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differentiation into myelinatings OLs, and what in this environment could negatively be
impacting the OLs inability to differentiate.

TIMP-1 regulates Oligodendrocyte Differentiation by non-canonical of β-catenin
Signaling
We have previously shown that TIMP-1 acts as a trophic factor for OPC
differentiation [46]. For my thesis, we further wanted to determine the mechanism of
action on how TIMP-1 promoted OPC differentiation. Through our unpublished gene
array data, we found that some of the top candidate genes of TIMP-1 regulation were
also β-catenin mediated genes, such as cyclin D1. Previous studies have reported a
receptor-mediated complex that TIMP-1 interacts with CD63: β1-integrin [173]. This lead
us to hypothesize that TIMP-1 mediates β-catenin signaling leading to OPC
differentiation through a previously unreported receptor complex that was MMPinhibition independent.
The potential implications of TIMP-1 regulation of β-catenin signaling are quite
complicated and interesting. Wnt/ β-catenin signaling has long been an area of interest
with respect to MS and OPC differentiation, leading to conflicting results [59]. In MS, it
has been found that there is both an upregulation of Wnts, as well as dysregulated
signaling through the Wnt/ β-catenin signaling pathway [59, 311, 313]. My data would
suggest a potential role for TIMP-1 in this process. Additionally, certain Wnt ligands
have been shown to have various and differing effects on OPC differentiation, such as
Wnt3a, which has been shown to inhibit OPC differentiation in culture [39, 312]. If β-
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catenin is a master pathway regulator of OPC differentiation then a better understanding
of mediators that both promote and inhibit β-catenin signaling may lead to a better
understanding of OL maturation, and the potential to elucidate the way remyelination is
limited in this disease.
An interesting and significant conclusion that came from my work is the potential
parallel regulation of β-catenin by TIMP-1 that is independent of the canonical Wnt/ βcatenin signaling. A recent study has found that non-canonical β-catenin signaling does
in fact lead to increased OPC differentiation [318]. To our knowledge, there have been
very few studies that have examined the potential of non-canonical regulation of βcatenin to promote OPC differentiation, showing an important niche for our work by
placing TIMP-1 in the process of OPC differentiation and identifying a novel mechanism
by which TIMP-1 functions as a trophic factor.
Unfortunately, studying Wnts and β-catenin signaling in vivo remains challenging
because this signaling mechanism is essential for embryogenesis. Therefore, utilizing
the culture system has answered many questions with regards to OPC differentiation,
and further use of cerebellar slice cultures to measure remeylination is also essential.
We would like to confirm all of our recent findings in our OPC cultures of the receptormediated complex being essential for the TIMP-1 trophic effect in the slice culture
model to in fact look at the process of remyelination of neurites. In addition, this system
would better elucidate the role of TIMP-1 in the context of remyelination, as opposed to
additional effects TIMP-1 may have with regards to the immune system that may be
seen in the EAE model.
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Currently, Joel Levine (SUNY) has a line of inducible β-catenin KO mice in OL
lineage cells in the CNS [132]. It would be interesting cross these mice with our TIMP-1
KO mice and make cerebellar slice cultures of the double KO and the β-catenin KO.
Using lysolecithin on the slice cultures, we could then measure remyelination at various
time points. We would hypothesize that in the absence of β-catenin, that there will
minimal remyelination, similar to that seen in just TIMP-1 KO mice. Additionally, we
would want to cross the β-catenin KO mice with the TIMP-1 overexpressing mouse and
perform EAE. We hypothesize that the lack of β-catenin will in fact inhibit the beneficial
effect of TIMP-1 of promoting remyelination after EAE, thus confirming our hypothesized
pathway and TIMP-1 regulation of β-catenin.
In addition to the hypothesized pathway of TIMP-1’s mechanism of action
mediating β-catenin signaling, previous work has shown that TIMP-1 does in fact
regulate Wnts and Wnt signaling in mesenchymal stem cells via miRNA expression[335].
We would also want to further understand the regulation by TIMP-1 of Wnt ligand
production and its context with OPC differentiation, as well as the differential gene
expression of β-catenin-mediated signaling with regards to Wnt/ β-catenin and TIMP-1/
β-catenin. Firstly, using an ELISA, we can measure the production of Wnts in media and
serum in Wt and TIMP-1 KO mice to compare differences in the production of certain
Wnt ligands that have been previously reported to play a role in MS pathology such as
Wnt 3a, Wnt 5a, Wnt 7a, and Wnt 9a [59]. We would measure this at both basal
conditions as well as in injury or diseased conditions. Second, using gene array
comparisons of OPC cell culture, we would compare gene expression of OL cultures
treated with or without rm-TIMP-1, and with or without Wnt3a to look for differential gene
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regulation between TIMP-1 mediated gene transcription and Wnt mediated gene
transcritption to further elucidate the differential regulation of β-catenin and how this can
lead to both promoting OPC differentiation and inhibition OPC differentiation.
In summary, the field of β-catenin signaling to promote/inhibit OPC differentiation
is quite complex. However, work from my thesis has provided additional understanding
of how TIMP-1 mediates this signaling, differently from Wnt canonical signaling, to
promote OPC differentiation.
Identification of a TIMP-1 Regulated Novel Anastellin-like Peptide that Impairs
Oligodendrocyte Differentiation
ECM molecules have long been studied for the changes seen in MS lesions.
Specifically, Fn has been shown to be upregulated in MS lesions by astrocytes and
inhibit remyelination. The mechanism of this Fn upregulation was previously unknown.
In my work (Chapter 7), we identified a previously unreported regulation of Fn
production by TIMP-1. More specifically, we identified a” small homolog of Anastellin”
(shanestallin), a Fn breakdown product, present in media from our TIMP-1 KO
astrocytes that was not present in our Wt cultures. I also determined that shanestallin
could inhibit OPC differentiation. Additionally, anastellin has been shown to promote Fn
aggregation, and is known to be present in MS lesions, suggesting a previously
unrecognized mechanism for how Fn and high molecular weight Fn aggregation occurs
in MS. The model for our current understanding on this is that without TIMP-1, there is
Fn breakdown that leads to the build up of shanestallin, this both directly inhibits
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remyelination, and potentially facilitates the aggregation of Fn to further impair
remyelination and modify the ECM.
MS is a multifactorial disease, meaning that it does not have one known cause,
but has been shown to have both immune and brain dysfunction. Currently, all major
MS therapies do not slow down disease course, but do improve quality of living by
limiting the amount and severity of relapses. Unfortunately, there is currently no
treatment for SPMS or PPMS. An underlying cause of the MS is the failure of
remyelination, which leads to the progressive decline. Currently, MS therapies do not
target remyelination, and promotion of remyelnation is now being stressed as a major
target of research. Therefore, understanding what in the environment of the lesion is
preventing remyelnation has major implications for understanding the disease etiology.
In MS, there is a lack of TIMP-1, which has previously been shown to be important for
myelin and remyelination. In my work, we have now discovered a small peptide,
shanestallin, that is regulated by TIMP-1 and shown to inhibit the differentiation of OPCs.
In the context of MS, it is possible that there is a build up of this small peptide in the
lesion that is preventing OPCs from differentiating into myelinating OLs because there is
a lack of TIMP-1. In MS, it has been shown that there is an imbalance of MMPs, such
as MMP-3. We hypothesize that this is MMP-3 mediated for two reasons. (1.) In our
gene array data, we found that MMP-3 is not only regulated by TIMP-1 through its
protease activity, but it is also transcriptionally regulated. (2.) Fn is a target of MMP-3
degradation [336]. Specifically we hypothesize that without TIMP-1 to inhibit MMP-3,
there is increased breakdown of the ECM molecule Fn into protolytic products such as
shanestallin and anastellin, which leads to inhibition of OPC differentiation through, in

161

part, direct effect onto the OPCs, but also in promoting the aggregation of Fn and thus
inhibiting OPC differentiation. This is a previously unknown mechanism of action in the
context of astrocytic influence of the environment of the MS lesion leading to a poor
environment for remyelination, specifically through regulating Fn and its breakdown
products: anastellin and shanestallin.
In the future, it would be interesting to look directly at the aggregation of Fn in
vitro using the deoxycholate assay to determine if shanestallin does in fact trigger Fn
aggregation. In addition, if there was increased aggregation of Fn by shanestallin, and if
the

aggregation,

it

would

be

important

to

determine

whether

this

has

a

pathophysiological role inhibiting remyelination. One could look at the role of aggregates
on remyelination in two ways. (1.) By determining if the aggregates block OPC
differentiation in vitro. (2.) Using the lysoletchin slice culture model to determine if the
aggregates can block remyelination in intact tissue. One caveat of this is that there is no
way to look directly at shanestallin. To develop new less cumbersome assays to identify
Anastellin or Shanestallin, one could extend these experiments to look at shanestallin in
the context of a biomarker in MS patients. Since we observed shanestallin in astrocyte
conditioned media, we know that is secreted. To assay this in MS patients, one could
look at the serum of MS patients for shanestallin to determine if there is an elevated
presence of it in the serum of MS patients. GFAP, an astrocyte specific protein, has
already been identified in blood and serum and thought to be a potential biomarker for
acute brain injuries [337]. Therefore, it is plausible and possible to identify astrocytic
proteins in our blood to be used as a potential biomarker for CNS diseases.
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Our lab has previously shown that TIMP-1 KO have limited remyelination as
compared to Wt in chronic EAE [46]. We want to look at differences in Fn aggregation
in Wt compared to TIMP-1 KO mice in EAE. We hypothesize that there would be more
Fn aggregation in the KO compared to wt mice after EAE and this could, in part, lead to
some of the pathology seen in TIMP-1 KO mice and their inability to remyelinate after
EAE. In conjunction, we also want to make a double KO of Fn and TIMP-1KO and
compare remyelination in the chronic phase of the double KO to the Fn KO and the
TIMP-1KO. The hypothesis to be tested would be that deleting Fn from TIMP-1 KO
would remedy the lack of remyelination seen in our TIMP-1 KO mice. This would
suggest the pathogenic role of Fn aggregation due to lack of TIMP-1 in the CNS that fits
with observations in MS. This can be brought out further because of the Fn aggregates
seen in MS lesions and the lack of TIMP-1 in MS patients.
Lastly, it would be interesting to further elucidate the role of MMP-3 in the context
of its regulation by TIMP-1 and the mechanism of remyelination and Fn aggregation.
One could cross MMP-3 KO and TIMP-1 KO mice and perform EAE. One might expect
this to alter the inability to remyelinate seen in TIMP-1KO and improve remyelination
after injury in adult TIMP-1 KO mice. We would also look at the Fn aggregation in this
context to determine if there was decreased aggregation with the lack of MMP-3 to
determine if MMP-3 has a pathogenic feature in the Fn aggregation.

163

References:
[1]
[2]

[3]
[4]
[5]

[6]
[7]
[8]
[9]

[10]

[11]
[12]
[13]
[14]
[15]

E. Ruoslahti, Fibronectin in cell adhesion and invasion, Cancer metastasis
reviews 3 (1984) 43-51.
J.D. Lathia, B. Patton, D.M. Eckley, T. Magnus, M.R. Mughal, T. Sasaki, M.A.
Caldwell, M.S. Rao, M.P. Mattson, C. ffrench-Constant, Patterns of laminins and
integrins in the embryonic ventricular zone of the CNS, The Journal of
comparative neurology 505 (2007) 630-643.
S. Mitew, C.M. Hay, H. Peckham, J. Xiao, M. Koenning, B. Emery, Mechanisms
regulating the development of oligodendrocytes and central nervous system
myelin, Neuroscience 276 (2014) 29-47.
S.C. Zhang, Defining glial cells during CNS development, Nature reviews.
Neuroscience 2 (2001) 840-843.
J. Luo, J. Chen, Z.L. Deng, X. Luo, W.X. Song, K.A. Sharff, N. Tang, R.C.
Haydon, H.H. Luu, T.C. He, Wnt signaling and human diseases: what are the
therapeutic implications?, Laboratory investigation; a journal of technical
methods and pathology 87 (2007) 97-103.
M. Schumacher, R. Hussain, N. Gago, J.P. Oudinet, C. Mattern, A.M. Ghoumari,
Progesterone synthesis in the nervous system: implications for myelination and
myelin repair, Frontiers in neuroscience 6 (2012) 10.
R.J. Franklin, C. Ffrench-Constant, Remyelination in the CNS: from biology to
therapy, Nature reviews. Neuroscience 9 (2008) 839-855.
R.J. Franklin, Remyelination of the demyelinated CNS: the case for and against
transplantation of central, peripheral and olfactory glia, Brain research bulletin 57
(2002) 827-832.
R. Ulrich, W. Baumgartner, I. Gerhauser, F. Seeliger, V. Haist, U. Deschl, S.
Alldinger, MMP-12, MMP-3, and TIMP-1 are markedly upregulated in chronic
demyelinating theiler murine encephalomyelitis, Journal of neuropathology and
experimental neurology 65 (2006) 783-793.
A. Shirani, Y. Zhao, M.E. Karim, C. Evans, E. Kingwell, M.L. van der Kop, J.
Oger, P. Gustafson, J. Petkau, H. Tremlett, Association between use of
interferon beta and progression of disability in patients with relapsing-remitting
multiple sclerosis, JAMA : the journal of the American Medical Association 308
(2012) 247-256.
M. Rodriguez, B.W. Scheithauer, G. Forbes, P.J. Kelly, Oligodendrocyte injury is
an early event in lesions of multiple sclerosis, Mayo Clinic proceedings 68 (1993)
627-636.
M. Rodriguez, Effectors of demyelination and remyelination in the CNS:
implications for multiple sclerosis, Brain pathology 17 (2007) 219-229.
E.M. Frohman, M.K. Racke, C.S. Raine, Multiple sclerosis--the plaque and its
pathogenesis, The New England journal of medicine 354 (2006) 942-955.
J.H. Noseworthy, C. Lucchinetti, M. Rodriguez, B.G. Weinshenker, Multiple
sclerosis, The New England journal of medicine 343 (2000) 938-952.
J.M. Frischer, S.D. Weigand, Y. Guo, N. Kale, J.E. Parisi, I. Pirko, J. Mandrekar,
S. Bramow, I. Metz, W. Bruck, H. Lassmann, C.F. Lucchinetti, Clinical and

164

[16]

[17]
[18]
[19]
[20]
[21]
[22]

[23]

[24]

[25]
[26]
[27]

[28]
[29]

pathological insights into the dynamic nature of the white matter multiple
sclerosis plaque, Annals of neurology (2015).
S.M. Orton, B.M. Herrera, I.M. Yee, W. Valdar, S.V. Ramagopalan, A.D.
Sadovnick, G.C. Ebers, G. Canadian Collaborative Study, Sex ratio of multiple
sclerosis in Canada: a longitudinal study, The Lancet. Neurology 5 (2006) 932936.
R.M. Ransohoff, P. Kivisakk, G. Kidd, Three or more routes for leukocyte
migration into the central nervous system, Nature reviews. Immunology 3 (2003)
569-581.
E.S. Huseby, B. Sather, P.G. Huseby, J. Goverman, Age-dependent T cell
tolerance and autoimmunity to myelin basic protein, Immunity 14 (2001) 471-481.
J. Goverman, Autoimmune T cell responses in the central nervous system,
Nature reviews. Immunology 9 (2009) 393-407.
K.P. Wandinger, K. Wessel, P. Trillenberg, N. Heindl, H. Kirchner, Effect of highdose methylprednisolone administration on immune functions in multiple
sclerosis patients, Acta neurologica Scandinavica 97 (1998) 359-365.
J. Chun, H.P. Hartung, Mechanism of action of oral fingolimod (FTY720) in
multiple sclerosis, Clinical neuropharmacology 33 (2010) 91-101.
G. Comi, M. Filippi, F. Barkhof, L. Durelli, G. Edan, O. Fernandez, H. Hartung, P.
Seeldrayers, P.S. Sorensen, M. Rovaris, V. Martinelli, O.R. Hommes, G. Early
Treatment of Multiple Sclerosis Study, Effect of early interferon treatment on
conversion to definite multiple sclerosis: a randomised study, Lancet 357 (2001)
1576-1582.
W. Castro-Borrero, D. Graves, T.C. Frohman, A.B. Flores, P. Hardeman, D.
Logan, M. Orchard, B. Greenberg, E.M. Frohman, Current and emerging
therapies in multiple sclerosis: a systematic review, Therapeutic advances in
neurological disorders 5 (2012) 205-220.
D.B. Clifford, A. De Luca, D.M. Simpson, G. Arendt, G. Giovannoni, A. Nath,
Natalizumab-associated progressive multifocal leukoencephalopathy in patients
with multiple sclerosis: lessons from 28 cases, The Lancet. Neurology 9 (2010)
438-446.
V. Brinkmann, A. Billich, T. Baumruker, P. Heining, R. Schmouder, G. Francis, S.
Aradhye, P. Burtin, Fingolimod (FTY720): discovery and development of an oral
drug to treat multiple sclerosis, Nature reviews. Drug discovery 9 (2010) 883-897.
S.M. Leary, A.J. Thompson, Primary progressive multiple sclerosis : current and
future treatment options, CNS drugs 19 (2005) 369-376.
A. Chang, A. Nishiyama, J. Peterson, J. Prineas, B.D. Trapp, NG2-positive
oligodendrocyte progenitor cells in adult human brain and multiple sclerosis
lesions, The Journal of neuroscience : the official journal of the Society for
Neuroscience 20 (2000) 6404-6412.
C.W. Lee, J.W. Choi, J. Chun, Neurological S1P signaling as an emerging
mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis, Archives
of pharmacal research 33 (2010) 1567-1574.
R.J. Franklin, Why does remyelination fail in multiple sclerosis?, Nature reviews.
Neuroscience 3 (2002) 705-714.

165

[30]

[31]
[32]
[33]

[34]
[35]
[36]
[37]
[38]
[39]
[40]

[41]

[42]
[43]

[44]

A.V. Caprariello, C.E. Batt, I. Zippe, R.R. Romito-DiGiacomo, M. Karl, R.H. Miller,
Apoptosis of Oligodendrocytes during Early Development Delays Myelination and
Impairs Subsequent Responses to Demyelination, The Journal of neuroscience :
the official journal of the Society for Neuroscience 35 (2015) 14031-14041.
R.P. Bunge, Glial cells and the central myelin sheath, Physiological reviews 48
(1968) 197-251.
N. Baumann, D. Pham-Dinh, Biology of oligodendrocyte and myelin in the
mammalian central nervous system, Physiological reviews 81 (2001) 871-927.
R. Curtis, J. Cohen, J. Fok-Seang, M.R. Hanley, N.A. Gregson, R. Reynolds, G.P.
Wilkin, Development of macroglial cells in rat cerebellum. I. Use of antibodies to
follow early in vivo development and migration of oligodendrocytes, Journal of
neurocytology 17 (1988) 43-54.
S.E. Pfeiffer, A.E. Warrington, R. Bansal, The oligodendrocyte and its many
cellular processes, Trends in cell biology 3 (1993) 191-197.
N. Spassky, C. Olivier, E. Perez-Villegas, C. Goujet-Zalc, S. Martinez, J. Thomas,
B. Zalc, Single or multiple oligodendroglial lineages: a controversy, Glia 29
(2000) 143-148.
W.D. Richardson, H.K. Smith, T. Sun, N.P. Pringle, A. Hall, R. Woodruff,
Oligodendrocyte lineage and the motor neuron connection, Glia 29 (2000) 136142.
A. Meyer-Franke, B. Barres, Axon myelination. Myelination without myelinassociated glycoprotein, Current biology : CB 4 (1994) 847-850.
S.K. Solly, J.L. Thomas, M. Monge, C. Demerens, C. Lubetzki, M.V. Gardinier,
J.M. Matthieu, B. Zalc, Myelin/oligodendrocyte glycoprotein (MOG) expression is
associated with myelin deposition, Glia 18 (1996) 39-48.
K. Feigenson, M. Reid, J. See, I.E. Crenshaw, J.B. Grinspan, Canonical Wnt
signalling requires the BMP pathway to inhibit oligodendrocyte maturation, ASN
neuro 3 (2011) e00061.
Y. Wang, X. Cheng, Q. He, Y. Zheng, D.H. Kim, S.R. Whittemore, Q.L. Cao,
Astrocytes from the contused spinal cord inhibit oligodendrocyte differentiation of
adult oligodendrocyte precursor cells by increasing the expression of bone
morphogenetic proteins, The Journal of neuroscience : the official journal of the
Society for Neuroscience 31 (2011) 6053-6058.
C. Zhao, S.P. Fancy, R.J. Franklin, C. ffrench-Constant, Up-regulation of
oligodendrocyte precursor cell alphaV integrin and its extracellular ligands during
central nervous system remyelination, Journal of neuroscience research 87
(2009) 3447-3455.
I. Gadea, J. Mensa, [Potential of anidulafungin in combined therapy],
Enfermedades infecciosas y microbiologia clinica 26 Suppl 14 (2008) 51-55.
R.H. Woodruff, M. Fruttiger, W.D. Richardson, R.J. Franklin, Platelet-derived
growth factor regulates oligodendrocyte progenitor numbers in adult CNS and
their response following CNS demyelination, Molecular and cellular
neurosciences 25 (2004) 252-262.
A.C. Vana, C.F. Lucchinetti, T.Q. Le, R.C. Armstrong, Myelin transcription factor
1 (Myt1) expression in demyelinated lesions of rodent and human CNS, Glia 55
(2007) 687-697.

166

[45]

[46]

[47]

[48]

[49]

[50]

[51]
[52]

[53]
[54]
[55]

[56]

S.J. Crocker, J.K. Whitmire, R.F. Frausto, P. Chertboonmuang, P.D. Soloway,
J.L. Whitton, I.L. Campbell, Persistent macrophage/microglial activation and
myelin disruption after experimental autoimmune encephalomyelitis in tissue
inhibitor of metalloproteinase-1-deficient mice, The American journal of pathology
169 (2006) 2104-2116.
C.S. Moore, R. Milner, A. Nishiyama, R.F. Frausto, D.R. Serwanski, R.R.
Pagarigan, J.L. Whitton, R.H. Miller, S.J. Crocker, Astrocytic tissue inhibitor of
metalloproteinase-1 (TIMP-1) promotes oligodendrocyte differentiation and
enhances CNS myelination, The Journal of neuroscience : the official journal of
the Society for Neuroscience 31 (2011) 6247-6254.
A. Gadea, S. Schinelli, V. Gallo, Endothelin-1 regulates astrocyte proliferation
and reactive gliosis via a JNK/c-Jun signaling pathway, The Journal of
neuroscience : the official journal of the Society for Neuroscience 28 (2008)
2394-2408.
A.C. Vana, N.C. Flint, N.E. Harwood, T.Q. Le, M. Fruttiger, R.C. Armstrong,
Platelet-derived growth factor promotes repair of chronically demyelinated white
matter, Journal of neuropathology and experimental neurology 66 (2007) 975988.
U. Bartsch, A. Faissner, J. Trotter, U. Dorries, S. Bartsch, H. Mohajeri, M.
Schachner, Tenascin demarcates the boundary between the myelinated and
nonmyelinated part of retinal ganglion cell axons in the developing and adult
mouse, The Journal of neuroscience : the official journal of the Society for
Neuroscience 14 (1994) 4756-4768.
M.C. Raff, E.R. Abney, J. Cohen, R. Lindsay, M. Noble, Two types of astrocytes
in cultures of developing rat white matter: differences in morphology, surface
gangliosides, and growth characteristics, The Journal of neuroscience : the
official journal of the Society for Neuroscience 3 (1983) 1289-1300.
M.C. Raff, R.H. Miller, M. Noble, A glial progenitor cell that develops in vitro into
an astrocyte or an oligodendrocyte depending on culture medium, Nature 303
(1983) 390-396.
P.C. Mabie, M.F. Mehler, J.A. Kessler, Multiple roles of bone morphogenetic
protein signaling in the regulation of cortical cell number and phenotype, The
Journal of neuroscience : the official journal of the Society for Neuroscience 19
(1999) 7077-7088.
J.B. Grinspan, B. Franceschini, Platelet-derived growth factor is a survival factor
for PSA-NCAM+ oligodendrocyte pre-progenitor cells, Journal of neuroscience
research 41 (1995) 540-551.
K. Yoshida, F.H. Gage, Fibroblast growth factors stimulate nerve growth factor
synthesis and secretion by astrocytes, Brain research 538 (1991) 118-126.
M. Furusho, Y. Kaga, A. Ishii, J.M. Hebert, R. Bansal, Fibroblast growth factor
signaling is required for the generation of oligodendrocyte progenitors from the
embryonic forebrain, The Journal of neuroscience : the official journal of the
Society for Neuroscience 31 (2011) 5055-5066.
B.A. Barres, M.A. Lazar, M.C. Raff, A novel role for thyroid hormone,
glucocorticoids and retinoic acid in timing oligodendrocyte development,
Development 120 (1994) 1097-1108.

167

[57]
[58]

[59]
[60]
[61]
[62]

[63]
[64]
[65]
[66]
[67]
[68]

[69]
[70]
[71]
[72]

J.C. Dugas, A. Ibrahim, B.A. Barres, The T3-induced gene KLF9 regulates
oligodendrocyte differentiation and myelin regeneration, Molecular and cellular
neurosciences 50 (2012) 45-57.
D. Chesik, J. De Keyser, L. Glazenburg, N. Wilczak, Insulin-like growth factor
binding proteins: regulation in chronic active plaques in multiple sclerosis and
functional analysis of glial cells, The European journal of neuroscience 24 (2006)
1645-1652.
F. Guo, J. Lang, J. Sohn, E. Hammond, M. Chang, D. Pleasure, Canonical Wnt
signaling in the oligodendroglial lineage-puzzles remain, Glia 63 (2015) 16711693.
B. Emery, Regulation of oligodendrocyte differentiation and myelination, Science
330 (2010) 779-782.
T. Shimizu, T. Kagawa, T. Wada, Y. Muroyama, S. Takada, K. Ikenaka, Wnt
signaling controls the timing of oligodendrocyte development in the spinal cord,
Developmental biology 282 (2005) 397-410.
Z.M. Dai, S. Sun, C. Wang, H. Huang, X. Hu, Z. Zhang, Q.R. Lu, M. Qiu, Stagespecific regulation of oligodendrocyte development by Wnt/beta-catenin signaling,
The Journal of neuroscience : the official journal of the Society for Neuroscience
34 (2014) 8467-8473.
M.B. Bunge, R.P. Bunge, G.D. Pappas, Electron microscopic demonstration of
connections between glia and myelin sheaths in the developing mammalian
central nervous system, The Journal of cell biology 12 (1962) 448-453.
A. Peters, Observations on the Connexions between Myelin Sheaths and Glial
Cells in the Optic Nerves of Young Rats, Journal of anatomy 98 (1964) 125-134.
P. Morell, A.H. Ousley, Metabolic turnover of myelin glycerophospholipids,
Neurochemical research 19 (1994) 967-974.
J. Folch, M. Lees, Proteolipides, a new type of tissue lipoproteins; their isolation
from brain, The Journal of biological chemistry 191 (1951) 807-817.
M. Dubois-Dalcq, T. Behar, L. Hudson, R.A. Lazzarini, Emergence of three
myelin proteins in oligodendrocytes cultured without neurons, The Journal of cell
biology 102 (1986) 384-392.
F. Peyron, S. Timsit, J.L. Thomas, T. Kagawa, K. Ikenaka, B. Zalc, In situ
expression of PLP/DM-20, MBP, and CNP during embryonic and postnatal
development of the jimpy mutant and of transgenic mice overexpressing PLP,
Journal of neuroscience research 50 (1997) 190-201.
M. Monge, D. Kadiiski, C.M. Jacque, B. Zalc, Oligodendroglial expression and
deposition of four major myelin constituents in the myelin sheath during
development. An in vivo study, Developmental neuroscience 8 (1986) 222-235.
R.H. Quarles, Glycoproteins of myelin sheaths, Journal of molecular
neuroscience : MN 8 (1997) 1-12.
T.J. Sprinkle, M.R. Wells, F.A. Garver, D.B. Smith, Studies on the Wolfgram high
molecular weight CNS myelin proteins: relationship to 2',3'-cyclic nucleotide 3'phosphodiesterase, Journal of neurochemistry 35 (1980) 1200-1208.
B.A. Brody, H.C. Kinney, A.S. Kloman, F.H. Gilles, Sequence of central nervous
system myelination in human infancy. I. An autopsy study of myelination, Journal
of neuropathology and experimental neurology 46 (1987) 283-301.

168

[73]

[74]
[75]

[76]
[77]
[78]

[79]

[80]

[81]

[82]
[83]
[84]
[85]
[86]

T.L. Kemper, A.R. Lecours, M.J. Gates, P.I. Yakovlev, Retardation of the myeloand cytoarchitectonic maturation of the brain in the congenital rubella syndrome,
Research publications - Association for Research in Nervous and Mental
Disease 51 (1973) 23-62.
I.A. McKenzie, D. Ohayon, H. Li, J.P. de Faria, B. Emery, K. Tohyama, W.D.
Richardson, Motor skill learning requires active central myelination, Science 346
(2014) 318-322.
F. Mei, S.P. Fancy, Y.A. Shen, J. Niu, C. Zhao, B. Presley, E. Miao, S. Lee, S.R.
Mayoral, S.A. Redmond, A. Etxeberria, L. Xiao, R.J. Franklin, A. Green, S.L.
Hauser, J.R. Chan, Micropillar arrays as a high-throughput screening platform for
therapeutics in multiple sclerosis, Nature medicine 20 (2014) 954-960.
D.L. Sherman, P.J. Brophy, Mechanisms of axon ensheathment and myelin
growth, Nature reviews. Neuroscience 6 (2005) 683-690.
S. Wang, A.D. Sdrulla, G. diSibio, G. Bush, D. Nofziger, C. Hicks, G. Weinmaster,
B.A. Barres, Notch receptor activation inhibits oligodendrocyte differentiation,
Neuron 21 (1998) 63-75.
L. Decker, V. Avellana-Adalid, B. Nait-Oumesmar, P. Durbec, A. Baron-Van
Evercooren, Oligodendrocyte precursor migration and differentiation: combined
effects of PSA residues, growth factors, and substrates, Molecular and cellular
neurosciences 16 (2000) 422-439.
S. Mi, R.H. Miller, X. Lee, M.L. Scott, S. Shulag-Morskaya, Z. Shao, J. Chang, G.
Thill, M. Levesque, M. Zhang, C. Hession, D. Sah, B. Trapp, Z. He, V. Jung, J.M.
McCoy, R.B. Pepinsky, LINGO-1 negatively regulates myelination by
oligodendrocytes, Nature neuroscience 8 (2005) 745-751.
H. Colognato, W. Baron, V. Avellana-Adalid, J.B. Relvas, A. Baron-Van
Evercooren, E. Georges-Labouesse, C. ffrench-Constant, CNS integrins switch
growth factor signalling to promote target-dependent survival, Nature cell biology
4 (2002) 833-841.
C. Demerens, B. Stankoff, M. Logak, P. Anglade, B. Allinquant, F. Couraud, B.
Zalc, C. Lubetzki, Induction of myelination in the central nervous system by
electrical activity, Proceedings of the National Academy of Sciences of the United
States of America 93 (1996) 9887-9892.
T.M. Rivers, D.H. Sprunt, G.P. Berry, Observations on Attempts to Produce
Acute Disseminated Encephalomyelitis in Monkeys, The Journal of experimental
medicine 58 (1933) 39-53.
R. Gold, H.P. Hartung, K.V. Toyka, Animal models for autoimmune demyelinating
disorders of the nervous system, Molecular medicine today 6 (2000) 88-91.
M. Thorne, C.S. Moore, G.S. Robertson, Lack of TIMP-1 increases severity of
experimental autoimmune encephalomyelitis: Effects of darbepoetin alfa on
TIMP-1 null and wild-type mice, Journal of neuroimmunology 211 (2009) 92-100.
R.M. Ransohoff, Animal models of multiple sclerosis: the good, the bad and the
bottom line, Nature neuroscience 15 (2012) 1074-1077.
C.S. Constantinescu, N. Farooqi, K. O'Brien, B. Gran, Experimental autoimmune
encephalomyelitis (EAE) as a model for multiple sclerosis (MS), British journal of
pharmacology 164 (2011) 1079-1106.

169

[87]

A.M. Brown, D.E. McFarlin, Relapsing experimental allergic encephalomyelitis in
the SJL/J mouse, Laboratory investigation; a journal of technical methods and
pathology 45 (1981) 278-284.
[88] F.D. Lublin, P.H. Maurer, R.G. Berry, D. Tippett, Delayed, relapsing experimental
allergic encephalomyelitis in mice, Journal of immunology 126 (1981) 819-822.
[89] S. Zamvil, P. Nelson, J. Trotter, D. Mitchell, R. Knobler, R. Fritz, L. Steinman, Tcell clones specific for myelin basic protein induce chronic relapsing paralysis
and demyelination, Nature 317 (1985) 355-358.
[90] L. Steinman, S.S. Zamvil, How to successfully apply animal studies in
experimental allergic encephalomyelitis to research on multiple sclerosis, Annals
of neurology 60 (2006) 12-21.
[91] G.K. Matsushima, P. Morell, The neurotoxicant, cuprizone, as a model to study
demyelination and remyelination in the central nervous system, Brain pathology
11 (2001) 107-116.
[92] H. Ledford, Drug that boosts nerve signals offers hope for multiple sclerosis,
Nature 520 (2015) 417.
[93] S. Mi, R.H. Miller, W. Tang, X. Lee, B. Hu, W. Wu, Y. Zhang, C.B. Shields, Y.
Zhang, S. Miklasz, D. Shea, J. Mason, R.J. Franklin, B. Ji, Z. Shao, A. Chedotal,
F. Bernard, A. Roulois, J. Xu, V. Jung, B. Pepinsky, Promotion of central nervous
system remyelination by induced differentiation of oligodendrocyte precursor
cells, Annals of neurology 65 (2009) 304-315.
[94] V.A. Deshmukh, V. Tardif, C.A. Lyssiotis, C.C. Green, B. Kerman, H.J. Kim, K.
Padmanabhan, J.G. Swoboda, I. Ahmad, T. Kondo, F.H. Gage, A.N.
Theofilopoulos, B.R. Lawson, P.G. Schultz, L.L. Lairson, A regenerative
approach to the treatment of multiple sclerosis, Nature 502 (2013) 327-332.
[95] F.J. Najm, M. Madhavan, A. Zaremba, E. Shick, R.T. Karl, D.C. Factor, T.E.
Miller, Z.S. Nevin, C. Kantor, A. Sargent, K.L. Quick, D.M. Schlatzer, H. Tang, R.
Papoian, K.R. Brimacombe, M. Shen, M.B. Boxer, A. Jadhav, A.P. Robinson, J.R.
Podojil, S.D. Miller, R.H. Miller, P.J. Tesar, Drug-based modulation of
endogenous stem cells promotes functional remyelination in vivo, Nature 522
(2015) 216-220.
[96] K. Kojima, H. Wekerle, H. Lassmann, T. Berger, C. Linington, Induction of
experimental autoimmune encephalomyelitis by CD4+ T cells specific for an
astrocyte protein, S100 beta, Journal of neural transmission. Supplementum 49
(1997) 43-51.
[97] M. Osborn, M. Ludwig-Festl, K. Weber, A. Bignami, D. Dahl, K. Bayreuther,
Expression of glial and vimentin type intermediate filaments in cultures derived
from human glial material, Differentiation; research in biological diversity 19
(1981) 161-167.
[98] A. Bignami, L.F. Eng, D. Dahl, C.T. Uyeda, Localization of the glial fibrillary acidic
protein in astrocytes by immunofluorescence, Brain research 43 (1972) 429-435.
[99] S.C. Barnett, C. Linington, Myelination: do astrocytes play a role?, The
Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry
19 (2013) 442-450.
[100] M.R. Freeman, Specification and morphogenesis of astrocytes, Science 330
(2010) 774-778.

170

[101] A.V. Molofsky, R. Krencik, E.M. Ullian, H.H. Tsai, B. Deneen, W.D. Richardson,
B.A. Barres, D.H. Rowitch, Astrocytes and disease: a neurodevelopmental
perspective, Genes & development 26 (2012) 891-907.
[102] N.J. Allen, B.A. Barres, Neuroscience: Glia - more than just brain glue, Nature
457 (2009) 675-677.
[103] W.P. Ge, A. Miyawaki, F.H. Gage, Y.N. Jan, L.Y. Jan, Local generation of glia is
a major astrocyte source in postnatal cortex, Nature 484 (2012) 376-380.
[104] F.M. Vaccarino, D.M. Fagel, Y. Ganat, M.E. Maragnoli, L.R. Ment, Y. Ohkubo,
M.L. Schwartz, J. Silbereis, K.M. Smith, Astroglial cells in development,
regeneration, and repair, The Neuroscientist : a review journal bringing
neurobiology, neurology and psychiatry 13 (2007) 173-185.
[105] X. Zhu, D.E. Bergles, A. Nishiyama, NG2 cells generate both oligodendrocytes
and gray matter astrocytes, Development 135 (2008) 145-157.
[106] X. Zhu, R.A. Hill, D. Dietrich, M. Komitova, R. Suzuki, A. Nishiyama, Agedependent fate and lineage restriction of single NG2 cells, Development 138
(2011) 745-753.
[107] C. Hochstim, B. Deneen, A. Lukaszewicz, Q. Zhou, D.J. Anderson, Identification
of positionally distinct astrocyte subtypes whose identities are specified by a
homeodomain code, Cell 133 (2008) 510-522.
[108] Y. Muroyama, Y. Fujiwara, S.H. Orkin, D.H. Rowitch, Specification of astrocytes
by bHLH protein SCL in a restricted region of the neural tube, Nature 438 (2005)
360-363.
[109] N. Gaiano, G. Fishell, The role of notch in promoting glial and neural stem cell
fates, Annual review of neuroscience 25 (2002) 471-490.
[110] L. Roybon, T. Hjalt, N.S. Christophersen, J.Y. Li, P. Brundin, Effects on
differentiation of embryonic ventral midbrain progenitors by Lmx1a, Msx1, Ngn2,
and Pitx3, The Journal of neuroscience : the official journal of the Society for
Neuroscience 28 (2008) 3644-3656.
[111] B. Deneen, R. Ho, A. Lukaszewicz, C.J. Hochstim, R.M. Gronostajski, D.J.
Anderson, The transcription factor NFIA controls the onset of gliogenesis in the
developing spinal cord, Neuron 52 (2006) 953-968.
[112] C.C. Stolt, P. Lommes, E. Sock, M.C. Chaboissier, A. Schedl, M. Wegner, The
Sox9 transcription factor determines glial fate choice in the developing spinal
cord, Genes & development 17 (2003) 1677-1689.
[113] M. Hirano, J.E. Goldman, Gliogenesis in rat spinal cord: evidence for origin of
astrocytes and oligodendrocytes from radial precursors, Journal of neuroscience
research 21 (1988) 155-167.
[114] S. Weiss, B.A. Reynolds, A.L. Vescovi, C. Morshead, C.G. Craig, D. van der
Kooy, Is there a neural stem cell in the mammalian forebrain?, Trends in
neurosciences 19 (1996) 387-393.
[115] C.B. Johansson, S. Momma, D.L. Clarke, M. Risling, U. Lendahl, J. Frisen,
Identification of a neural stem cell in the adult mammalian central nervous
system, Cell 96 (1999) 25-34.
[116] S. Weiss, C. Dunne, J. Hewson, C. Wohl, M. Wheatley, A.C. Peterson, B.A.
Reynolds, Multipotent CNS stem cells are present in the adult mammalian spinal

171

[117]
[118]

[119]

[120]
[121]
[122]
[123]

[124]
[125]
[126]

[127]

[128]

[129]

cord and ventricular neuroaxis, The Journal of neuroscience : the official journal
of the Society for Neuroscience 16 (1996) 7599-7609.
M.M. Bullon, T. Alvarez-Gago, B. Fernandez-Ruiz, C. Aguirre, Glial fibrillary
acidic protein (GFAP) in spinal cord of postnatal rat. An immunoperoxidase study
in semithin sections, Brain research 316 (1984) 129-133.
V. Parpura, M.T. Heneka, V. Montana, S.H. Oliet, A. Schousboe, P.G. Haydon,
R.F. Stout, Jr., D.C. Spray, A. Reichenbach, T. Pannicke, M. Pekny, M. Pekna, R.
Zorec, A. Verkhratsky, Glial cells in (patho)physiology, Journal of neurochemistry
121 (2012) 4-27.
J.M. Stoffels, J.C. de Jonge, M. Stancic, A. Nomden, M.E. van Strien, D. Ma, Z.
Siskova, O. Maier, C. Ffrench-Constant, R.J. Franklin, D. Hoekstra, C. Zhao, W.
Baron, Fibronectin aggregation in multiple sclerosis lesions impairs remyelination,
Brain : a journal of neurology 136 (2013) 116-131.
M. Mayer, K. Bhakoo, M. Noble, Ciliary neurotrophic factor and leukemia
inhibitory factor promote the generation, maturation and survival of
oligodendrocytes in vitro, Development 120 (1994) 143-153.
J.S. Rudge, D. Morrissey, R.M. Lindsay, E.M. Pasnikowski, Regulation of ciliary
neurotrophic factor in cultured rat hippocampal astrocytes, The European journal
of neuroscience 6 (1994) 218-229.
C.S. Moore, S.L. Abdullah, A. Brown, A. Arulpragasam, S.J. Crocker, How
factors secreted from astrocytes impact myelin repair, Journal of neuroscience
research 89 (2011) 13-21.
B. Nash, C.E. Thomson, C. Linington, A.T. Arthur, J.D. McClure, M.W. McBride,
S.C. Barnett, Functional duality of astrocytes in myelination, The Journal of
neuroscience : the official journal of the Society for Neuroscience 31 (2011)
13028-13038.
M. Pekny, M. Nilsson, Astrocyte activation and reactive gliosis, Glia 50 (2005)
427-434.
J.L. Zamanian, L. Xu, L.C. Foo, N. Nouri, L. Zhou, R.G. Giffard, B.A. Barres,
Genomic analysis of reactive astrogliosis, The Journal of neuroscience : the
official journal of the Society for Neuroscience 32 (2012) 6391-6410.
A. Buffo, I. Rite, P. Tripathi, A. Lepier, D. Colak, A.P. Horn, T. Mori, M. Gotz,
Origin and progeny of reactive gliosis: A source of multipotent cells in the injured
brain, Proceedings of the National Academy of Sciences of the United States of
America 105 (2008) 3581-3586.
A.G. Rabchevsky, J.M. Weinitz, M. Coulpier, C. Fages, M. Tinel, M.P. Junier, A
role for transforming growth factor alpha as an inducer of astrogliosis, The
Journal of neuroscience : the official journal of the Society for Neuroscience 18
(1998) 10541-10552.
C.G. Winter, Y. Saotome, S.W. Levison, D. Hirsh, A role for ciliary neurotrophic
factor as an inducer of reactive gliosis, the glial response to central nervous
system injury, Proceedings of the National Academy of Sciences of the United
States of America 92 (1995) 5865-5869.
K.W. Selmaj, M. Farooq, W.T. Norton, C.S. Raine, C.F. Brosnan, Proliferation of
astrocytes in vitro in response to cytokines. A primary role for tumor necrosis
factor, Journal of immunology 144 (1990) 129-135.

172

[130] J.L. Jankowsky, P.H. Patterson, Differential regulation of cytokine expression
following pilocarpine-induced seizure, Experimental neurology 159 (1999) 333346.
[131] M. Pekny, U. Wilhelmsson, M. Pekna, The dual role of astrocyte activation and
reactive gliosis, Neuroscience letters 565 (2014) 30-38.
[132] J.P. Rodriguez, M. Coulter, J. Miotke, R.L. Meyer, K. Takemaru, J.M. Levine,
Abrogation of beta-catenin signaling in oligodendrocyte precursor cells reduces
glial scarring and promotes axon regeneration after CNS injury, The Journal of
neuroscience : the official journal of the Society for Neuroscience 34 (2014)
10285-10297.
[133] F. Biname, D. Sakry, L. Dimou, V. Jolivel, J. Trotter, NG2 regulates directional
migration of oligodendrocyte precursor cells via Rho GTPases and polarity
complex proteins, The Journal of neuroscience : the official journal of the Society
for Neuroscience 33 (2013) 10858-10874.
[134] J. Lasiene, K. Yamanaka, Glial cells in amyotrophic lateral sclerosis, Neurology
research international 2011 (2011) 718987.
[135] M. Nagai, D.B. Re, T. Nagata, A. Chalazonitis, T.M. Jessell, H. Wichterle, S.
Przedborski, Astrocytes expressing ALS-linked mutated SOD1 release factors
selectively toxic to motor neurons, Nature neuroscience 10 (2007) 615-622.
[136] B. Stankoff, M.S. Aigrot, F. Noel, A. Wattilliaux, B. Zalc, C. Lubetzki, Ciliary
neurotrophic factor (CNTF) enhances myelin formation: a novel role for CNTF
and CNTF-related molecules, The Journal of neuroscience : the official journal of
the Society for Neuroscience 22 (2002) 9221-9227.
[137] M. Sendtner, P. Carroll, B. Holtmann, R.A. Hughes, H. Thoenen, Ciliary
neurotrophic factor, Journal of neurobiology 25 (1994) 1436-1453.
[138] J. Xiao, A.W. Wong, M.M. Willingham, M. van den Buuse, T.J. Kilpatrick, S.S.
Murray, Brain-derived neurotrophic factor promotes central nervous system
myelination via a direct effect upon oligodendrocytes, Neuro-Signals 18 (2010)
186-202.
[139] O. Bogler, D. Wren, S.C. Barnett, H. Land, M. Noble, Cooperation between two
growth factors promotes extended self-renewal and inhibits differentiation of
oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells, Proceedings of the
National Academy of Sciences of the United States of America 87 (1990) 63686372.
[140] J. Satoh, H. Tabunoki, T. Yamamura, K. Arima, H. Konno, TROY and LINGO-1
expression in astrocytes and macrophages/microglia in multiple sclerosis lesions,
Neuropathology and applied neurobiology 33 (2007) 99-107.
[141] P.H. Chan, Role of oxidants in ischemic brain damage, Stroke; a journal of
cerebral circulation 27 (1996) 1124-1129.
[142] S. Desagher, J. Glowinski, J. Premont, Astrocytes protect neurons from
hydrogen peroxide toxicity, The Journal of neuroscience : the official journal of
the Society for Neuroscience 16 (1996) 2553-2562.
[143] G.Z. Feuerstein, X. Wang, F.C. Barone, The role of cytokines in the
neuropathology of stroke and neurotrauma, Neuroimmunomodulation 5 (1998)
143-159.

173

[144] L. Huang, Z.B. Wu, Q. Zhuge, W. Zheng, B. Shao, B. Wang, F. Sun, K. Jin, Glial
scar formation occurs in the human brain after ischemic stroke, International
journal of medical sciences 11 (2014) 344-348.
[145] L.A. Cunningham, M. Wetzel, G.A. Rosenberg, Multiple roles for MMPs and
TIMPs in cerebral ischemia, Glia 50 (2005) 329-339.
[146] S.J. Crocker, R. Milner, N. Pham-Mitchell, I.L. Campbell, Cell and agonistspecific regulation of genes for matrix metalloproteinases and their tissue
inhibitors by primary glial cells, Journal of neurochemistry 98 (2006) 812-823.
[147] S.J. Crocker, A. Pagenstecher, I.L. Campbell, The TIMPs tango with MMPs and
more in the central nervous system, Journal of neuroscience research 75 (2004)
1-11.
[148] K. Brew, D. Dinakarpandian, H. Nagase, Tissue inhibitors of metalloproteinases:
evolution, structure and function, Biochimica et biophysica acta 1477 (2000) 267283.
[149] M.R. Emmert-Buck, H.P. Emonard, M.L. Corcoran, H.C. Krutzsch, J.M. Foidart,
W.G. Stetler-Stevenson, Cell surface binding of TIMP-2 and pro-MMP-2/TIMP-2
complex, FEBS letters 364 (1995) 28-32.
[150] S.M. Wilhelm, I.E. Collier, B.L. Marmer, A.Z. Eisen, G.A. Grant, G.I. Goldberg,
SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase
which is identical to that secreted by normal human macrophages, The Journal of
biological chemistry 264 (1989) 17213-17221.
[151] H.F. Bigg, Y.E. Shi, Y.E. Liu, B. Steffensen, C.M. Overall, Specific, high affinity
binding of tissue inhibitor of metalloproteinases-4 (TIMP-4) to the COOH-terminal
hemopexin-like domain of human gelatinase A. TIMP-4 binds progelatinase A
and the COOH-terminal domain in a similar manner to TIMP-2, The Journal of
biological chemistry 272 (1997) 15496-15500.
[152] J. Gardner, A. Ghorpade, Tissue inhibitor of metalloproteinase (TIMP)-1: the
TIMPed balance of matrix metalloproteinases in the central nervous system,
Journal of neuroscience research 74 (2003) 801-806.
[153] K. Baranger, S. Rivera, F.D. Liechti, D. Grandgirard, J. Bigas, J. Seco, T.
Tarrago, S.L. Leib, M. Khrestchatisky, Endogenous and synthetic MMP inhibitors
in CNS physiopathology, Progress in brain research 214 (2014) 313-351.
[154] S. Rivera, E. Tremblay, S. Timsit, O. Canals, Y. Ben-Ari, M. Khrestchatisky,
Tissue inhibitor of metalloproteinases-1 (TIMP-1) is differentially induced in
neurons and astrocytes after seizures: evidence for developmental, immediate
early gene, and lesion response, The Journal of neuroscience : the official journal
of the Society for Neuroscience 17 (1997) 4223-4235.
[155] A. Pagenstecher, A.K. Stalder, C.L. Kincaid, S.D. Shapiro, I.L. Campbell,
Differential expression of matrix metalloproteinase and tissue inhibitor of matrix
metalloproteinase genes in the mouse central nervous system in normal and
inflammatory states, The American journal of pathology 152 (1998) 729-741.
[156] N. Fager, D.M. Jaworski, Differential spatial distribution and temporal regulation
of tissue inhibitor of metalloproteinase mRNA expression during rat central
nervous system development, Mechanisms of development 98 (2000) 105-109.

174

[157] D.E. Woolley, D.R. Roberts, J.M. Evanson, Inhibition of human collagenase
activity by a small molecular weight serum protein, Biochemical and biophysical
research communications 66 (1975) 747-754.
[158] J. Gardner, K. Borgmann, M.S. Deshpande, A. Dhar, L. Wu, R. Persidsky, A.
Ghorpade, Potential mechanisms for astrocyte-TIMP-1 downregulation in chronic
inflammatory diseases, Journal of neuroscience research 83 (2006) 1281-1292.
[159] D.M. Jaworski, Differential regulation of tissue inhibitor of metalloproteinase
mRNA expression in response to intracranial injury, Glia 30 (2000) 199-208.
[160] T. Ichiyama, M. Kajimoto, N. Suenaga, S. Maeba, T. Matsubara, S. Furukawa,
Serum levels of matrix metalloproteinase-9 and its tissue inhibitor (TIMP-1) in
acute disseminated encephalomyelitis, Journal of neuroimmunology 172 (2006)
182-186.
[161] C. Avolio, M. Ruggieri, F. Giuliani, G.M. Liuzzi, R. Leante, P. Riccio, P. Livrea, M.
Trojano, Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis
subtypes, Journal of neuroimmunology 136 (2003) 46-53.
[162] F.X. Gomis-Ruth, K. Maskos, M. Betz, A. Bergner, R. Huber, K. Suzuki, N.
Yoshida, H. Nagase, K. Brew, G.P. Bourenkov, H. Bartunik, W. Bode,
Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by
TIMP-1, Nature 389 (1997) 77-81.
[163] C.S. Moore, S.J. Crocker, An alternate perspective on the roles of TIMPs and
MMPs in pathology, The American journal of pathology 180 (2012) 12-16.
[164] D.E. Gomez, D.F. Alonso, H. Yoshiji, U.P. Thorgeirsson, Tissue inhibitors of
metalloproteinases: structure, regulation and biological functions, European
journal of cell biology 74 (1997) 111-122.
[165] H.K. Tan, D. Heywood, G.S. Ralph, A. Bienemann, A.H. Baker, J.B. Uney,
Tissue inhibitor of metalloproteinase 1 inhibits excitotoxic cell death in neurons,
Molecular and cellular neurosciences 22 (2003) 98-106.
[166] L.L. Groft, H. Muzik, N.B. Rewcastle, R.N. Johnston, V. Knauper, M.A. Lafleur,
P.A. Forsyth, D.R. Edwards, Differential expression and localization of TIMP-1
and TIMP-4 in human gliomas, British journal of cancer 85 (2001) 55-63.
[167] T.E. VanMeter, H.K. Rooprai, M.M. Kibble, H.L. Fillmore, W.C. Broaddus, G.J.
Pilkington, The role of matrix metalloproteinase genes in glioma invasion: codependent and interactive proteolysis, Journal of neuro-oncology 53 (2001) 213235.
[168] A. Dhar, J. Gardner, K. Borgmann, L. Wu, A. Ghorpade, Novel role of TGF-beta
in differential astrocyte-TIMP-1 regulation: implications for HIV-1-dementia and
neuroinflammation, Journal of neuroscience research 83 (2006) 1271-1280.
[169] C. Avolio, M. Filippi, C. Tortorella, M.A. Rocca, M. Ruggieri, F. Agosta, V.
Tomassini, C. Pozzilli, S. Stecchi, P. Giaquinto, P. Livrea, M. Trojano, Serum
MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with
different magnetic resonance imaging measures of disease activity during IFNbeta-1a treatment, Multiple sclerosis 11 (2005) 441-446.
[170] G.E. Althoff, D.P. Wolfer, N. Timmesfeld, B. Kanzler, H. Schrewe, A.
Pagenstecher,
Long-term
expression
of
tissue-inhibitor
of
matrix
metalloproteinase-1 in the murine central nervous system does not alter the
morphological and behavioral phenotype but alleviates the course of

175

[171]

[172]
[173]
[174]
[175]
[176]
[177]
[178]

[179]
[180]

[181]
[182]
[183]

[184]

experimental allergic encephalomyelitis, The American journal of pathology 177
(2010) 840-853.
J.C. Gasson, D.W. Golde, S.E. Kaufman, C.A. Westbrook, R.M. Hewick, R.J.
Kaufman, G.G. Wong, P.A. Temple, A.C. Leary, E.L. Brown, et al., Molecular
characterization and expression of the gene encoding human erythroidpotentiating activity, Nature 315 (1985) 768-771.
J.C. Gasson, N. Bersch, D.W. Golde, Characterization of purified human
erythroid-potentiating activity, Progress in clinical and biological research 184
(1985) 95-104.
K.K. Jung, X.W. Liu, R. Chirco, R. Fridman, H.R. Kim, Identification of CD63 as a
tissue inhibitor of metalloproteinase-1 interacting cell surface protein, The EMBO
journal 25 (2006) 3934-3942.
R. Chirco, X.W. Liu, K.K. Jung, H.R. Kim, Novel functions of TIMPs in cell
signaling, Cancer metastasis reviews 25 (2006) 99-113.
F. Berditchevski, Complexes of tetraspanins with integrins: more than meets the
eye, Journal of cell science 114 (2001) 4143-4151.
K. Pfistershammer, O. Majdic, J. Stockl, G. Zlabinger, S. Kirchberger, P.
Steinberger, W. Knapp, CD63 as an activation-linked T cell costimulatory
element, Journal of immunology 173 (2004) 6000-6008.
R. Milner, I.L. Campbell, The integrin family of cell adhesion molecules has
multiple functions within the CNS, Journal of neuroscience research 69 (2002)
286-291.
S.Y. Lee, J.M. Kim, S.Y. Cho, H.S. Kim, H.S. Shin, J.Y. Jeon, R. Kausar, S.Y.
Jeong, Y.S. Lee, M.A. Lee, TIMP-1 modulates chemotaxis of human neural stem
cells through CD63 and integrin signalling, The Biochemical journal 459 (2014)
565-576.
W.G. Stetler-Stevenson, Tissue inhibitors of metalloproteinases in cell signaling:
metalloproteinase-independent biological activities, Science signaling 1 (2008)
re6.
L.A. Ridnour, K.M. Barasch, A.N. Windhausen, T.H. Dorsey, M.M. Lizardo, H.G.
Yfantis, D.H. Lee, C.H. Switzer, R.Y. Cheng, J.L. Heinecke, E. Brueggemann,
H.B. Hines, C. Khanna, S.A. Glynn, S. Ambs, D.A. Wink, Nitric oxide synthase
and breast cancer: role of TIMP-1 in NO-mediated Akt activation, PloS one 7
(2012) e44081.
D.D. Sarbassov, D.A. Guertin, S.M. Ali, D.M. Sabatini, Phosphorylation and
regulation of Akt/PKB by the rictor-mTOR complex, Science 307 (2005) 10981101.
J. Liang, J.M. Slingerland, Multiple roles of the PI3K/PKB (Akt) pathway in cell
cycle progression, Cell cycle 2 (2003) 339-345.
S. Fukumoto, C.M. Hsieh, K. Maemura, M.D. Layne, S.F. Yet, K.H. Lee, T.
Matsui, A. Rosenzweig, W.G. Taylor, J.S. Rubin, M.A. Perrella, M.E. Lee, Akt
participation in the Wnt signaling pathway through Dishevelled, The Journal of
biological chemistry 276 (2001) 17479-17483.
R.V. Bhat, S.L. Budd, GSK3beta signalling: casting a wide net in Alzheimer's
disease, Neuro-Signals 11 (2002) 251-261.

176

[185] C. Xie, Z. Li, G.X. Zhang, Y. Guan, Wnt signaling in remyelination in multiple
sclerosis: friend or foe?, Molecular neurobiology 49 (2014) 1117-1125.
[186] L. Zhou, C.Y. Shao, S.M. Xu, J. Ma, Y.J. Xie, L. Zhou, P. Teng, Y. Wang, M. Qiu,
Y. Shen, GSK3beta promotes the differentiation of oligodendrocyte precursor
cells via beta-catenin-mediated transcriptional regulation, Molecular neurobiology
50 (2014) 507-519.
[187] K. Azim, A.M. Butt, GSK3beta negatively regulates oligodendrocyte
differentiation and myelination in vivo, Glia 59 (2011) 540-553.
[188] H. Chen, D. Mo, M. Li, Y. Zhang, L. Chen, X. Zhang, M. Li, X. Zhou, Y. Chen,
miR-709 inhibits 3T3-L1 cell differentiation by targeting GSK3beta of Wnt/betacatenin signaling, Cellular signalling 26 (2014) 2583-2589.
[189] C.M. Fernandez-Martos, C. Gonzalez-Fernandez, P. Gonzalez, A. Maqueda, E.
Arenas, F.J. Rodriguez, Differential expression of Wnts after spinal cord
contusion injury in adult rats, PloS one 6 (2011) e27000.
[190] D. Rodriguez, C.J. Morrison, C.M. Overall, Matrix metalloproteinases: what do
they not do? New substrates and biological roles identified by murine models and
proteomics, Biochimica et biophysica acta 1803 (2010) 39-54.
[191] J. van Horssen, C.D. Dijkstra, H.E. de Vries, The extracellular matrix in multiple
sclerosis pathology, Journal of neurochemistry 103 (2007) 1293-1301.
[192] H. Colognato, I.D. Tzvetanova, Glia unglued: how signals from the extracellular
matrix regulate the development of myelinating glia, Developmental neurobiology
71 (2011) 924-955.
[193] D.R. Zimmermann, M.T. Dours-Zimmermann, Extracellular matrix of the central
nervous system: from neglect to challenge, Histochemistry and cell biology 130
(2008) 635-653.
[194] C.S. Barros, S.J. Franco, U. Muller, Extracellular matrix: functions in the nervous
system, Cold Spring Harbor perspectives in biology 3 (2011) a005108.
[195] P.C. Letourneau, A.M. Madsen, S.L. Palm, L.T. Furcht, Immunoreactivity for
laminin in the developing ventral longitudinal pathway of the brain,
Developmental biology 125 (1988) 135-144.
[196] A. Domogatskaya, S. Rodin, K. Tryggvason, Functional diversity of laminins,
Annual review of cell and developmental biology 28 (2012) 523-553.
[197] T. Nagayoshi, M.G. Mattei, E. Passage, R. Knowlton, M.L. Chu, J. Uitto, Human
laminin A chain (LAMA) gene: chromosomal mapping to locus 18p11.3,
Genomics 5 (1989) 932-935.
[198] L. Pulkkinen, A.M. Christiano, T. Airenne, H. Haakana, K. Tryggvason, J. Uitto,
Mutations in the gamma 2 chain gene (LAMC2) of kalinin/laminin 5 in the
junctional forms of epidermolysis bullosa, Nature genetics 6 (1994) 293-297.
[199] R.T. Libby, M.F. Champliaud, T. Claudepierre, Y. Xu, E.P. Gibbons, M. Koch,
R.E. Burgeson, D.D. Hunter, W.J. Brunken, Laminin expression in adult and
developing retinae: evidence of two novel CNS laminins, The Journal of
neuroscience : the official journal of the Society for Neuroscience 20 (2000)
6517-6528.
[200] P. Liesi, D. Dahl, A. Vaheri, Laminin is produced by early rat astrocytes in
primary culture, The Journal of cell biology 96 (1983) 920-924.

177

[201] J.H. Miner, J. Cunningham, J.R. Sanes, Roles for laminin in embryogenesis:
exencephaly, syndactyly, and placentopathy in mice lacking the laminin alpha5
chain, The Journal of cell biology 143 (1998) 1713-1723.
[202] S.M. Corley, U. Ladiwala, A. Besson, V.W. Yong, Astrocytes attenuate
oligodendrocyte death in vitro through an alpha(6) integrin-laminin-dependent
mechanism, Glia 36 (2001) 281-294.
[203] J. Relucio, I.D. Tzvetanova, W. Ao, S. Lindquist, H. Colognato, Laminin alters fyn
regulatory mechanisms and promotes oligodendrocyte development, The Journal
of neuroscience : the official journal of the Society for Neuroscience 29 (2009)
11794-11806.
[204] G. Gnanaguru, G. Bachay, S. Biswas, G. Pinzon-Duarte, D.D. Hunter, W.J.
Brunken, Laminins containing the beta2 and gamma3 chains regulate astrocyte
migration and angiogenesis in the retina, Development 140 (2013) 2050-2060.
[205] P. Liesi, S. Kaakkola, D. Dahl, A. Vaheri, Laminin is induced in astrocytes of
adult brain by injury, The EMBO journal 3 (1984) 683-686.
[206] T. Nishio, S. Kawaguchi, M. Yamamoto, T. Iseda, T. Kawasaki, T. Hase,
Tenascin-C regulates proliferation and migration of cultured astrocytes in a
scratch wound assay, Neuroscience 132 (2005) 87-102.
[207] H.P. Erickson, J.L. Inglesias, A six-armed oligomer isolated from cell surface
fibronectin preparations, Nature 311 (1984) 267-269.
[208] J.R. Gulcher, M.J. Alexakos, M.M. Le Beau, R.S. Lemons, K. Stefansson,
Chromosomal localization of the human hexabrachion (tenascin) gene and
evidence for recent reduplication within the gene, Genomics 6 (1990) 616-622.
[209] P. Pesheva, R. Probstmeier, The yin and yang of tenascin-R in CNS
development and pathology, Progress in neurobiology 61 (2000) 465-493.
[210] J.E. Holley, D. Gveric, J.L. Whatmore, N.J. Gutowski, Tenascin C induces a
quiescent phenotype in cultured adult human astrocytes, Glia 52 (2005) 53-58.
[211] T. Czopka, A. von Holst, C. ffrench-Constant, A. Faissner, Regulatory
mechanisms that mediate tenascin C-dependent inhibition of oligodendrocyte
precursor differentiation, The Journal of neuroscience : the official journal of the
Society for Neuroscience 30 (2010) 12310-12322.
[212] E. Forsberg, E. Hirsch, L. Frohlich, M. Meyer, P. Ekblom, A. Aszodi, S. Werner,
R. Fassler, Skin wounds and severed nerves heal normally in mice lacking
tenascin-C, Proceedings of the National Academy of Sciences of the United
States of America 93 (1996) 6594-6599.
[213] E. Garcion, A. Faissner, C. ffrench-Constant, Knockout mice reveal a contribution
of the extracellular matrix molecule tenascin-C to neural precursor proliferation
and migration, Development 128 (2001) 2485-2496.
[214] R. Pankov, K.M. Yamada, Fibronectin at a glance, Journal of cell science 115
(2002) 3861-3863.
[215] S.C. Jhanwar, J.T. Jensen, M. Kaelbling, R.S. Chaganti, H.P. Klinger, In situ
localization of human fibronectin (FN) genes to chromosome regions 2p14----p16,
2q34----q36, and 11q12.1----q13.5 in germ line cells, but to chromosome 2 sites
only in somatic cells, Cytogenetics and cell genetics 41 (1986) 47-53.

178

[216] T. Kumazaki, Y. Mitsui, K. Hamada, H. Sumida, M. Nishiyama, Detection of
alternative splicing of fibronectin mRNA in a single cell, Journal of cell science
112 ( Pt 10) (1999) 1449-1453.
[217] T.R. Jones, E. Ruoslahti, S.C. Schold, D.D. Bigner, Fibronectin and glial fibrillary
acidic protein expression in normal human brain and anaplastic human gliomas,
Cancer research 42 (1982) 168-177.
[218] M.N. Meland, M.E. Herndon, C.S. Stipp, Expression of alpha5 integrin rescues
fibronectin responsiveness in NT2N CNS neuronal cells, Journal of neuroscience
research 88 (2010) 222-232.
[219] G.R. Stewart, A.L. Pearlman, Fibronectin-like immunoreactivity in the developing
cerebral cortex, The Journal of neuroscience : the official journal of the Society
for Neuroscience 7 (1987) 3325-3333.
[220] R. Milner, G. Edwards, C. Streuli, C. Ffrench-Constant, A role in migration for the
alpha V beta 1 integrin expressed on oligodendrocyte precursors, The Journal of
neuroscience : the official journal of the Society for Neuroscience 16 (1996)
7240-7252.
[221] F.M. Watt, K.J. Hodivala, Cell adhesion. Fibronectin and integrin knockouts come
unstuck, Current biology : CB 4 (1994) 270-272.
[222] T. Sakai, K.J. Johnson, M. Murozono, K. Sakai, M.A. Magnuson, T. Wieloch, T.
Cronberg, A. Isshiki, H.P. Erickson, R. Fassler, Plasma fibronectin supports
neuronal survival and reduces brain injury following transient focal cerebral
ischemia but is not essential for skin-wound healing and hemostasis, Nature
medicine 7 (2001) 324-330.
[223] J.M. Stoffels, D. Hoekstra, R.J. Franklin, W. Baron, C. Zhao, The EIIIA domain
from astrocyte-derived fibronectin mediates proliferation of oligodendrocyte
progenitor cells following CNS demyelination, Glia 63 (2015) 242-256.
[224] E.G. Hayman, M.D. Pierschbacher, Y. Ohgren, E. Ruoslahti, Serum spreading
factor (vitronectin) is present at the cell surface and in tissues, Proceedings of
the National Academy of Sciences of the United States of America 80 (1983)
4003-4007.
[225] T.M. Fink, D.E. Jenne, P. Lichter, The human vitronectin (complement S-protein)
gene maps to the centromeric region of 17q, Human genetics 88 (1992) 569-572.
[226] D. Seiffert, M.L. Iruela-Arispe, E.H. Sage, D.J. Loskutoff, Distribution of
vitronectin mRNA during murine development, Developmental dynamics : an
official publication of the American Association of Anatomists 203 (1995) 71-79.
[227] R. Milner, S.J. Crocker, S. Hung, X. Wang, R.F. Frausto, G.J. del Zoppo,
Fibronectin- and vitronectin-induced microglial activation and matrix
metalloproteinase-9 expression is mediated by integrins alpha5beta1 and
alphavbeta5, Journal of immunology 178 (2007) 8158-8167.
[228] R.A. Sobel, M. Chen, A. Maeda, J.R. Hinojoza, Vitronectin and integrin
vitronectin receptor localization in multiple sclerosis lesions, Journal of
neuropathology and experimental neurology 54 (1995) 202-213.
[229] X. Zheng, T.L. Saunders, S.A. Camper, L.C. Samuelson, D. Ginsburg,
Vitronectin is not essential for normal mammalian development and fertility,
Proceedings of the National Academy of Sciences of the United States of
America 92 (1995) 12426-12430.

179

[230] J.V. Welser-Alves, A. Boroujerdi, U. Tigges, R. Milner, Microglia use multiple
mechanisms to mediate interactions with vitronectin; non-essential roles for the
highly-expressed alphavbeta3 and alphavbeta5 integrins, Journal of
neuroinflammation 8 (2011) 157.
[231] Y. Takada, X. Ye, S. Simon, The integrins, Genome biology 8 (2007) 215.
[232] R. Milner, I.L. Campbell, Developmental regulation of beta1 integrins during
angiogenesis in the central nervous system, Molecular and cellular
neurosciences 20 (2002) 616-626.
[233] C.S. Barros, T. Nguyen, K.S. Spencer, A. Nishiyama, H. Colognato, U. Muller,
Beta1 integrins are required for normal CNS myelination and promote AKTdependent myelin outgrowth, Development 136 (2009) 2717-2724.
[234] K.L. Blaschuk, E.E. Frost, C. ffrench-Constant, The regulation of proliferation and
differentiation in oligodendrocyte progenitor cells by alphaV integrins,
Development 127 (2000) 1961-1969.
[235] H. Nagase, R. Visse, G. Murphy, Structure and function of matrix
metalloproteinases and TIMPs, Cardiovascular research 69 (2006) 562-573.
[236] J. Skuljec, V. Gudi, R. Ulrich, K. Frichert, O. Yildiz, R. Pul, E.V. Voss, K. Wissel,
W. Baumgartner, M. Stangel, Matrix metalloproteinases and their tissue inhibitors
in cuprizone-induced demyelination and remyelination of brain white and gray
matter, Journal of neuropathology and experimental neurology 70 (2011) 758769.
[237] G.A. Rosenberg, Matrix metalloproteinases and their multiple roles in
neurodegenerative diseases, The Lancet. Neurology 8 (2009) 205-216.
[238] R.L. Lindberg, C.J. De Groot, L. Montagne, P. Freitag, P. van der Valk, L.
Kappos, D. Leppert, The expression profile of matrix metalloproteinases (MMPs)
and their inhibitors (TIMPs) in lesions and normal appearing white matter of
multiple sclerosis, Brain : a journal of neurology 124 (2001) 1743-1753.
[239] M.A. Pizzi, M.J. Crowe, Matrix metalloproteinases and proteoglycans in axonal
regeneration, Experimental neurology 204 (2007) 496-511.
[240] W.C. Parks, C.L. Wilson, Y.S. Lopez-Boado, Matrix metalloproteinases as
modulators of inflammation and innate immunity, Nature reviews. Immunology 4
(2004) 617-629.
[241] A. Mirshafiey, B. Asghari, G. Ghalamfarsa, F. Jadidi-Niaragh, G. Azizi, The
significance of matrix metalloproteinases in the immunopathogenesis and
treatment of multiple sclerosis, Sultan Qaboos University medical journal 14
(2014) e13-25.
[242] R.K. Zabad, L.M. Metz, T.R. Todoruk, Y. Zhang, J.R. Mitchell, M. Yeung, D.G.
Patry, R.B. Bell, V.W. Yong, The clinical response to minocycline in multiple
sclerosis is accompanied by beneficial immune changes: a pilot study, Multiple
sclerosis 13 (2007) 517-526.
[243] D. Muir, Metalloproteinase-dependent neurite outgrowth within a synthetic
extracellular matrix is induced by nerve growth factor, Experimental cell research
210 (1994) 243-252.
[244] L.A. Nordstrom, J. Lochner, W. Yeung, G. Ciment, The metalloproteinase
stromelysin-1 (transin) mediates PC12 cell growth cone invasiveness through
basal laminae, Molecular and cellular neurosciences 6 (1995) 56-68.

180

[245] J.H. Uhm, N.P. Dooley, L.Y. Oh, V.W. Yong, Oligodendrocytes utilize a matrix
metalloproteinase, MMP-9, to extend processes along an astrocyte extracellular
matrix, Glia 22 (1998) 53-63.
[246] P.H. Larsen, A.G. DaSilva, K. Conant, V.W. Yong, Myelin formation during
development of the CNS is delayed in matrix metalloproteinase-9 and -12 null
mice, The Journal of neuroscience : the official journal of the Society for
Neuroscience 26 (2006) 2207-2214.
[247] P.H. Larsen, J.E. Wells, W.B. Stallcup, G. Opdenakker, V.W. Yong, Matrix
metalloproteinase-9 facilitates remyelination in part by processing the inhibitory
NG2 proteoglycan, The Journal of neuroscience : the official journal of the
Society for Neuroscience 23 (2003) 11127-11135.
[248] P.H. Larsen, V.W. Yong, The expression of matrix metalloproteinase-12 by
oligodendrocytes regulates their maturation and morphological differentiation,
The Journal of neuroscience : the official journal of the Society for Neuroscience
24 (2004) 7597-7603.
[249] S.M. Agrawal, L. Lau, V.W. Yong, MMPs in the central nervous system: where
the good guys go bad, Seminars in cell & developmental biology 19 (2008) 42-51.
[250] S.E. Meighan, P.C. Meighan, P. Choudhury, C.J. Davis, M.L. Olson, P.A. Zornes,
J.W. Wright, J.W. Harding, Effects of extracellular matrix-degrading proteases
matrix metalloproteinases 3 and 9 on spatial learning and synaptic plasticity,
Journal of neurochemistry 96 (2006) 1227-1241.
[251] V. Nagy, O. Bozdagi, A. Matynia, M. Balcerzyk, P. Okulski, J. Dzwonek, R.M.
Costa, A.J. Silva, L. Kaczmarek, G.W. Huntley, Matrix metalloproteinase-9 is
required for hippocampal late-phase long-term potentiation and memory, The
Journal of neuroscience : the official journal of the Society for Neuroscience 26
(2006) 1923-1934.
[252] R.A. Sobel, A.S. Ahmed, White matter extracellular matrix chondroitin
sulfate/dermatan sulfate proteoglycans in multiple sclerosis, Journal of
neuropathology and experimental neurology 60 (2001) 1198-1207.
[253] K.S. Fernandes, D.G. Brum, A.C. Palei, V.C. Sandrim, C.T. Guerreiro, J.E.
Tanus-Santos, A.A. Barreira, Functional MMP-9 polymorphisms modulate
plasma MMP-9 levels in multiple sclerosis patients, Journal of neuroimmunology
249 (2012) 56-59.
[254] T. Kanesaka, M. Mori, T. Hattori, T. Oki, S. Kuwabara, Serum matrix
metalloproteinase-3 levels correlate with disease activity in relapsing-remitting
multiple sclerosis, Journal of neurology, neurosurgery, and psychiatry 77 (2006)
185-188.
[255] K. Gijbels, R.E. Galardy, L. Steinman, Reversal of experimental autoimmune
encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases, The
Journal of clinical investigation 94 (1994) 2177-2182.
[256] B. Dubois, S. Masure, U. Hurtenbach, L. Paemen, H. Heremans, J. van den Oord,
R. Sciot, T. Meinhardt, G. Hammerling, G. Opdenakker, B. Arnold, Resistance of
young
gelatinase
B-deficient
mice
to
experimental
autoimmune
encephalomyelitis and necrotizing tail lesions, The Journal of clinical
investigation 104 (1999) 1507-1515.

181

[257] A. Goncalves DaSilva, V.W. Yong, Matrix metalloproteinase-12 deficiency
worsens relapsing-remitting experimental autoimmune encephalomyelitis in
association with cytokine and chemokine dysregulation, The American journal of
pathology 174 (2009) 898-909.
[258] Y. Benesova, A. Vasku, H. Novotna, J. Litzman, P. Stourac, M. Beranek, Z.
Kadanka, J. Bednarik, Matrix metalloproteinase-9 and matrix metalloproteinase-2
as biomarkers of various courses in multiple sclerosis, Multiple sclerosis 15
(2009) 316-322.
[259] Y.S. Kim, S.S. Kim, J.J. Cho, D.H. Choi, O. Hwang, D.H. Shin, H.S. Chun, M.F.
Beal, T.H. Joh, Matrix metalloproteinase-3: a novel signaling proteinase from
apoptotic neuronal cells that activates microglia, The Journal of neuroscience :
the official journal of the Society for Neuroscience 25 (2005) 3701-3711.
[260] Y. Ogata, J.J. Enghild, H. Nagase, Matrix metalloproteinase 3 (stromelysin)
activates the precursor for the human matrix metalloproteinase 9, The Journal of
biological chemistry 267 (1992) 3581-3584.
[261] M.E. Muroski, M.D. Roycik, R.G. Newcomer, P.E. Van den Steen, G.
Opdenakker, H.R. Monroe, Z.J. Sahab, Q.X. Sang, Matrix metalloproteinase9/gelatinase B is a putative therapeutic target of chronic obstructive pulmonary
disease and multiple sclerosis, Current pharmaceutical biotechnology 9 (2008)
34-46.
[262] B. Dubois, S.M. Leary, I. Nelissen, G. Opdenakker, G. Giovannoni, A.J.
Thompson, Serum gelatinase B/MMP-9 in primary progressive multiple sclerosis
patients treated with interferon-beta-1a, Journal of neurology 250 (2003) 10371043.
[263] C.M. Vos, E.S. van Haastert, C.J. de Groot, P. van der Valk, H.E. de Vries,
Matrix metalloproteinase-12 is expressed in phagocytotic macrophages in active
multiple sclerosis lesions, Journal of neuroimmunology 138 (2003) 106-114.
[264] F. Hansmann, V. Herder, A. Kalkuhl, V. Haist, N. Zhang, D. Schaudien, U.
Deschl, W. Baumgartner, R. Ulrich, Matrix metalloproteinase-12 deficiency
ameliorates the clinical course and demyelination in Theiler's murine
encephalomyelitis, Acta neuropathologica 124 (2012) 127-142.
[265] B. Kornek, M.K. Storch, R. Weissert, E. Wallstroem, A. Stefferl, T. Olsson, C.
Linington, M. Schmidbauer, H. Lassmann, Multiple sclerosis and chronic
autoimmune encephalomyelitis: a comparative quantitative study of axonal injury
in active, inactive, and remyelinated lesions, The American journal of pathology
157 (2000) 267-276.
[266] N.J. Gutowski, J. Newcombe, M.L. Cuzner, Tenascin-R and C in multiple
sclerosis lesions: relevance to extracellular matrix remodelling, Neuropathology
and applied neurobiology 25 (1999) 207-214.
[267] R.A. Sobel, M.E. Mitchell, Fibronectin in multiple sclerosis lesions, The American
journal of pathology 135 (1989) 161-168.
[268] J. van Horssen, B.P. Brink, H.E. de Vries, P. van der Valk, L. Bo, The blood-brain
barrier in cortical multiple sclerosis lesions, Journal of neuropathology and
experimental neurology 66 (2007) 321-328.

182

[269] J. van Horssen, L. Bo, C.D. Dijkstra, H.E. de Vries, Extensive extracellular matrix
depositions in active multiple sclerosis lesions, Neurobiology of disease 24
(2006) 484-491.
[270] L.W. Lau, R. Cua, M.B. Keough, S. Haylock-Jacobs, V.W. Yong,
Pathophysiology of the brain extracellular matrix: a new target for remyelination,
Nature reviews. Neuroscience 14 (2013) 722-729.
[271] R. Frischknecht, K.J. Chang, M.N. Rasband, C.I. Seidenbecher, Neural ECM
molecules in axonal and synaptic homeostatic plasticity, Progress in brain
research 214 (2014) 81-100.
[272] A.D. Gaudet, P.G. Popovich, Extracellular matrix regulation of inflammation in the
healthy and injured spinal cord, Experimental neurology 258 (2014) 24-34.
[273] K. Xie, Y. Liu, W. Hao, S. Walter, B. Penke, T. Hartmann, M. Schachner, K.
Fassbender, Tenascin-C deficiency ameliorates Alzheimer's disease-related
pathology in mice, Neurobiology of aging 34 (2013) 2389-2398.
[274] D.E. Harlow, W.B. Macklin, Inhibitors of myelination: ECM changes, CSPGs and
PTPs, Experimental neurology 251 (2014) 39-46.
[275] M.V. Sofroniew, Molecular dissection of reactive astrogliosis and glial scar
formation, Trends in neurosciences 32 (2009) 638-647.
[276] D.R. Alessi, L.R. Pearce, J.M. Garcia-Martinez, New insights into mTOR
signaling: mTORC2 and beyond, Science signaling 2 (2009) pe27.
[277] C. Dello Russo, L. Lisi, D.L. Feinstein, P. Navarra, mTOR kinase, a key player in
the regulation of glial functions: relevance for the therapy of multiple sclerosis,
Glia 61 (2013) 301-311.
[278] C.Y. Li, X. Li, S.F. Liu, W.S. Qu, W. Wang, D.S. Tian, Inhibition of mTOR
pathway restrains astrocyte proliferation, migration and production of
inflammatory mediators after oxygen-glucose deprivation and reoxygenation,
Neurochemistry international (2015).
[279] E. Norsted Gregory, A. Delaney, S. Abdelmoaty, D.B. Bas, S. Codeluppi, G.
Wigerblad, C.I. Svensson, Pentoxifylline and propentofylline prevent proliferation
and activation of the mammalian target of rapamycin and mitogen activated
protein kinase in cultured spinal astrocytes, Journal of neuroscience research 91
(2013) 300-312.
[280] A. Faber-Elman, V. Lavie, I. Schvartz, S. Shaltiel, M. Schwartz, Vitronectin
overrides a negative effect of TNF-alpha on astrocyte migration, FASEB journal :
official publication of the Federation of American Societies for Experimental
Biology 9 (1995) 1605-1613.
[281] S. Chakraborty, D.K. Kaushik, M. Gupta, A. Basu, Inflammasome signaling at the
heart of central nervous system pathology, Journal of neuroscience research 88
(2010) 1615-1631.
[282] S.J. Crocker, R.F. Frausto, J.L. Whitton, R. Milner, A novel method to establish
microglia-free astrocyte cultures: comparison of matrix metalloproteinase
expression profiles in pure cultures of astrocytes and microglia, Glia 56 (2008)
1187-1198.
[283] S. Robel, S. Bardehle, A. Lepier, C. Brakebusch, M. Gotz, Genetic deletion of
cdc42 reveals a crucial role for astrocyte recruitment to the injury site in vitro and

183

[284]

[285]

[286]

[287]

[288]
[289]
[290]
[291]

[292]
[293]

[294]
[295]

in vivo, The Journal of neuroscience : the official journal of the Society for
Neuroscience 31 (2011) 12471-12482.
G.R. John, L. Chen, M.A. Rivieccio, C.V. Melendez-Vasquez, A. Hartley, C.F.
Brosnan, Interleukin-1beta induces a reactive astroglial phenotype via
deactivation of the Rho GTPase-Rock axis, The Journal of neuroscience : the
official journal of the Society for Neuroscience 24 (2004) 2837-2845.
G.R. John, J.E. Simpson, M.N. Woodroofe, S.C. Lee, C.F. Brosnan, Extracellular
nucleotides differentially regulate interleukin-1beta signaling in primary human
astrocytes: implications for inflammatory gene expression, The Journal of
neuroscience : the official journal of the Society for Neuroscience 21 (2001)
4134-4142.
R. Milner, I.L. Campbell, Increased expression of the beta4 and alpha5 integrin
subunits in cerebral blood vessels of transgenic mice chronically producing the
pro-inflammatory cytokines IL-6 or IFN-alpha in the central nervous system,
Molecular and cellular neurosciences 33 (2006) 429-440.
M. Penkowa, M. Giralt, N. Lago, J. Camats, J. Carrasco, J. Hernandez, A.
Molinero, I.L. Campbell, J. Hidalgo, Astrocyte-targeted expression of IL-6
protects the CNS against a focal brain injury, Experimental neurology 181 (2003)
130-148.
R.W. O'Meara, J.P. Michalski, R. Kothary, Integrin signaling in oligodendrocytes
and its importance in CNS myelination, Journal of signal transduction 2011
(2011) 354091.
A. Thalhammer, L.A. Cingolani, Cell adhesion and homeostatic synaptic plasticity,
Neuropharmacology 78 (2014) 23-30.
K.I. Claycomb, K.M. Johnson, P.N. Winokur, A.V. Sacino, S.J. Crocker, Astrocyte
regulation of CNS inflammation and remyelination, Brain sciences 3 (2013) 11091127.
C. Sticozzi, G. Belmonte, A. Meini, P. Carbotti, G. Grasso, M. Palmi, IL-1beta
induces GFAP expression in vitro and in vivo and protects neurons from
traumatic
injury-associated
apoptosis
in
rat
brain
striatum
via
NFkappaB/Ca(2)(+)-calmodulin/ERK mitogen-activated protein kinase signaling
pathway, Neuroscience 252 (2013) 367-383.
G.R. John, S.C. Lee, C.F. Brosnan, Cytokines: powerful regulators of glial cell
activation, The Neuroscientist : a review journal bringing neurobiology, neurology
and psychiatry 9 (2003) 10-22.
L. Summers, K. Kangwantas, L. Nguyen, C. Kielty, E. Pinteaux, Adhesion to the
extracellular matrix is required for interleukin-1 beta actions leading to reactive
phenotype in rat astrocytes, Molecular and cellular neurosciences 44 (2010) 272281.
T. Kubo, A. Yamaguchi, N. Iwata, T. Yamashita, The therapeutic effects of RhoROCK inhibitors on CNS disorders, Therapeutics and clinical risk management 4
(2008) 605-615.
K.M. Johnson, R. Milner, S.J. Crocker, Extracellular matrix composition
determines astrocyte responses to mechanical and inflammatory stimuli,
Neuroscience letters (2015).

184

[296] S.D. Keene, T.M. Greco, I. Parastatidis, S.H. Lee, E.G. Hughes, R.J. BaliceGordon, D.W. Speicher, H. Ischiropoulos, Mass spectrometric and computational
analysis of cytokine-induced alterations in the astrocyte secretome, Proteomics 9
(2009) 768-782.
[297] J.V. Welser-Alves, S.J. Crocker, R. Milner, A dual role for microglia in promoting
tissue inhibitor of metalloproteinase (TIMP) expression in glial cells in response
to neuroinflammatory stimuli, Journal of neuroinflammation 8 (2011) 61.
[298] K.I. Claycomb, P.N. Winokur, K.M. Johnson, A.M. Nicaise, A.W. Giampetruzzi,
A.V. Sacino, E.Y. Snyder, E. Barbarese, E.R. Bongarzone, S.J. Crocker,
Aberrant production of tenascin-C in globoid cell leukodystrophy alters
psychosine-induced microglial functions, Journal of neuropathology and
experimental neurology 73 (2014) 964-974.
[299] C. Barcia, C.M. Ros, V. Annese, M.A. Carrillo-de Sauvage, F. Ros-Bernal, A.
Gomez, J.E. Yuste, C.M. Campuzano, V. de Pablos, E. Fernandez-Villalba, M.T.
Herrero, ROCK/Cdc42-mediated microglial motility and gliapse formation lead to
phagocytosis of degenerating dopaminergic neurons in vivo, Scientific reports 2
(2012) 809.
[300] A.A. Schmitz, E.E. Govek, B. Bottner, L. Van Aelst, Rho GTPases: signaling,
migration, and invasion, Experimental cell research 261 (2000) 1-12.
[301] C.J. De Groot, C.H. Langeveld, C.A. Jongenelen, L. Montagne, P. Van Der Valk,
C.D. Dijkstra, Establishment of human adult astrocyte cultures derived from
postmortem multiple sclerosis and control brain and spinal cord regions:
immunophenotypical and functional characterization, Journal of neuroscience
research 49 (1997) 342-354.
[302] Z. Kornyei, A. Czirok, T. Vicsek, E. Madarasz, Proliferative and migratory
responses of astrocytes to in vitro injury, Journal of neuroscience research 61
(2000) 421-429.
[303] M. Amano, M. Nakayama, K. Kaibuchi, Rho-kinase/ROCK: A key regulator of the
cytoskeleton and cell polarity, Cytoskeleton 67 (2010) 545-554.
[304] S. Lee, J.Y. Park, W.H. Lee, H. Kim, H.C. Park, K. Mori, K. Suk, Lipocalin-2 is an
autocrine mediator of reactive astrocytosis, The Journal of neuroscience : the
official journal of the Society for Neuroscience 29 (2009) 234-249.
[305] E. Jang, J.H. Kim, S. Lee, J.H. Kim, J.W. Seo, M. Jin, M.G. Lee, I.S. Jang, W.H.
Lee, K. Suk, Phenotypic polarization of activated astrocytes: the critical role of
lipocalin-2 in the classical inflammatory activation of astrocytes, Journal of
immunology 191 (2013) 5204-5219.
[306] N. Morimoto, M. Nagai, Y. Ohta, K. Miyazaki, T. Kurata, M. Morimoto, T.
Murakami, Y. Takehisa, Y. Ikeda, T. Kamiya, K. Abe, Increased autophagy in
transgenic mice with a G93A mutant SOD1 gene, Brain research 1167 (2007)
112-117.
[307] A.I. Flores, S.P. Narayanan, E.N. Morse, H.E. Shick, X. Yin, G. Kidd, R.L. Avila,
D.A. Kirschner, W.B. Macklin, Constitutively active Akt induces enhanced
myelination in the CNS, The Journal of neuroscience : the official journal of the
Society for Neuroscience 28 (2008) 7174-7183.
[308] J.C. Gensel, D.L. Schonberg, J.K. Alexander, D.M. McTigue, P.G. Popovich,
Semi-automated Sholl analysis for quantifying changes in growth and

185

[309]
[310]

[311]

[312]
[313]

[314]

[315]
[316]
[317]
[318]

[319]
[320]

differentiation of neurons and glia, Journal of neuroscience methods 190 (2010)
71-79.
H. Zhang, A.A. Jarjour, A. Boyd, A. Williams, Central nervous system
remyelination in culture--a tool for multiple sclerosis research, Experimental
neurology 230 (2011) 138-148.
F. Ye, Y. Chen, T. Hoang, R.L. Montgomery, X.H. Zhao, H. Bu, T. Hu, M.M.
Taketo, J.H. van Es, H. Clevers, J. Hsieh, R. Bassel-Duby, E.N. Olson, Q.R. Lu,
HDAC1 and HDAC2 regulate oligodendrocyte differentiation by disrupting the
beta-catenin-TCF interaction, Nature neuroscience 12 (2009) 829-838.
S.P. Fancy, S.E. Baranzini, C. Zhao, D.I. Yuk, K.A. Irvine, S. Kaing, N. Sanai, R.J.
Franklin, D.H. Rowitch, Dysregulation of the Wnt pathway inhibits timely
myelination and remyelination in the mammalian CNS, Genes & development 23
(2009) 1571-1585.
K. Feigenson, M. Reid, J. See, E.B. Crenshaw, 3rd, J.B. Grinspan, Wnt signaling
is sufficient to perturb oligodendrocyte maturation, Molecular and cellular
neurosciences 42 (2009) 255-265.
C. Lock, G. Hermans, R. Pedotti, A. Brendolan, E. Schadt, H. Garren, A. LangerGould, S. Strober, B. Cannella, J. Allard, P. Klonowski, A. Austin, N. Lad, N.
Kaminski, S.J. Galli, J.R. Oksenberg, C.S. Raine, R. Heller, L. Steinman, Genemicroarray analysis of multiple sclerosis lesions yields new targets validated in
autoimmune encephalomyelitis, Nature medicine 8 (2002) 500-508.
G. Wolswijk, Chronic stage multiple sclerosis lesions contain a relatively
quiescent population of oligodendrocyte precursor cells, The Journal of
neuroscience : the official journal of the Society for Neuroscience 18 (1998) 601609.
R.J. Franklin, C. Zhao, F.J. Sim, Ageing and CNS remyelination, Neuroreport 13
(2002) 923-928.
P. Ye, Q. Hu, H. Liu, Y. Yan, J. D'Ercole A, beta-catenin mediates insulin-like
growth factor-I actions to promote cyclin D1 mRNA expression, cell proliferation
and survival in oligodendroglial cultures, Glia 58 (2010) 1031-1041.
L. Magri, M. Gacias, M. Wu, V.A. Swiss, W.G. Janssen, P. Casaccia, c-Mycdependent transcriptional regulation of cell cycle and nucleosomal histones
during oligodendrocyte differentiation, Neuroscience 276 (2014) 72-86.
E. Hammond, J. Lang, Y. Maeda, D. Pleasure, M. Angus-Hill, J. Xu, M. Horiuchi,
W. Deng, F. Guo, The Wnt effector transcription factor 7-like 2 positively
regulates oligodendrocyte differentiation in a manner independent of Wnt/betacatenin signaling, The Journal of neuroscience : the official journal of the Society
for Neuroscience 35 (2015) 5007-5022.
A. Menoret, S. Kumar, A.T. Vella, Cytochrome b5 and cytokeratin 17 are
biomarkers in bronchoalveolar fluid signifying onset of acute lung injury, PloS one
7 (2012) e40184.
T. Ohashi, H.P. Erickson, Fibronectin aggregation and assembly: the unfolding of
the second fibronectin type III domain, The Journal of biological chemistry 286
(2011) 39188-39199.

186

[321] A. Ambesi, P.J. McKeown-Longo, Anastellin, the angiostatic fibronectin peptide,
is a selective inhibitor of lysophospholipid signaling, Molecular cancer research :
MCR 7 (2009) 255-265.
[322] J.W. Choi, S.E. Gardell, D.R. Herr, R. Rivera, C.W. Lee, K. Noguchi, S.T. Teo,
Y.C. Yung, M. Lu, G. Kennedy, J. Chun, FTY720 (fingolimod) efficacy in an
animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate
receptor 1 (S1P1) modulation, Proceedings of the National Academy of Sciences
of the United States of America 108 (2011) 751-756.
[323] R. Milner, I.L. Campbell, The extracellular matrix and cytokines regulate
microglial integrin expression and activation, Journal of immunology 170 (2003)
3850-3858.
[324] A. Giampetruzzi, J.H. Carson, E. Barbarese, FMRP and myelin protein
expression in oligodendrocytes, Molecular and cellular neurosciences 56 (2013)
333-341.
[325] M. Bsibsi, R. Ravid, D. Gveric, J.M. van Noort, Broad expression of Toll-like
receptors in the human central nervous system, Journal of neuropathology and
experimental neurology 61 (2002) 1013-1021.
[326] J.A. Ellison, J.J. Velier, P. Spera, Z.L. Jonak, X. Wang, F.C. Barone, G.Z.
Feuerstein, Osteopontin and its integrin receptor alpha(v)beta3 are upregulated
during formation of the glial scar after focal stroke, Stroke; a journal of cerebral
circulation 29 (1998) 1698-1706; discussion 1707.
[327] B. Rocamonde, S. Paradells, J.M. Barcia, C. Barcia, J.M. Garcia Verdugo, M.
Miranda, F.J. Romero Gomez, J.M. Soria, Neuroprotection of lipoic acid
treatment promotes angiogenesis and reduces the glial scar formation after brain
injury, Neuroscience 224 (2012) 102-115.
[328] J.R. Wujek, R.A. Akeson, Extracellular matrix derived from astrocytes stimulates
neuritic outgrowth from PC12 cells in vitro, Brain research 431 (1987) 87-97.
[329] A.Y. Chiu, A. Espinosa de los Monteros, R.A. Cole, S. Loera, J. de Vellis,
Laminin and s-laminin are produced and released by astrocytes, Schwann cells,
and schwannomas in culture, Glia 4 (1991) 11-24.
[330] J. Relucio, M.J. Menezes, Y. Miyagoe-Suzuki, S. Takeda, H. Colognato, Laminin
regulates postnatal oligodendrocyte production by promoting oligodendrocyte
progenitor survival in the subventricular zone, Glia 60 (2012) 1451-1467.
[331] K. Matsumoto, N. Hiraiwa, A. Yoshiki, M. Ohnishi, M. Kusakabe, PDGF receptoralpha deficiency in glomerular mesangial cells of tenascin-C knockout mice,
Biochemical and biophysical research communications 290 (2002) 1220-1227.
[332] K. Liu, L. Cheng, A. Flesken-Nikitin, L. Huang, A.Y. Nikitin, B.U. Pauli,
Conditional knockout of fibronectin abrogates mouse mammary gland
lobuloalveolar differentiation, Developmental biology 346 (2010) 11-24.
[333] Y.C. Jang, R. Tsou, N.S. Gibran, F.F. Isik, Vitronectin deficiency is associated
with increased wound fibrinolysis and decreased microvascular angiogenesis in
mice, Surgery 127 (2000) 696-704.
[334] M.A. Sussman, S. Welch, A. Walker, R. Klevitsky, T.E. Hewett, R.L. Price, E.
Schaefer, K. Yager, Altered focal adhesion regulation correlates with
cardiomyopathy in mice expressing constitutively active rac1, The Journal of
clinical investigation 105 (2000) 875-886.

187

[335] V. Egea, S. Zahler, N. Rieth, P. Neth, T. Popp, K. Kehe, M. Jochum, C. Ries,
Tissue inhibitor of metalloproteinase-1 (TIMP-1) regulates mesenchymal stem
cells through let-7f microRNA and Wnt/beta-catenin signaling, Proceedings of the
National Academy of Sciences of the United States of America 109 (2012) E309316.
[336] X. Zhang, C.T. Chen, M. Bhargava, P.A. Torzilli, A Comparative Study of
Fibronectin Cleavage by MMP-1, -3, -13, and -14, Cartilage 3 (2012) 267-277.
[337] W.J. van Geel, H.P. de Reus, H. Nijzing, M.M. Verbeek, P.E. Vos, K.J. Lamers,
Measurement of glial fibrillary acidic protein in blood: an analytical method,
Clinica chimica acta; international journal of clinical chemistry 326 (2002) 151154.

188

